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ABSTRACT 
 
Relapse after tumor dormancy is one of the leading causes of cancer recurrence that ultimately 
leads to patient mortality. Upon relapse, cancer manifests as metastases that are linked to almost 
90% cancer related deaths. Capture of the dormant and relapsed tumor phenotypes in high-
throughput will allow for rapid targeted drug discovery, development and validation. Ablation of 
dormant cancer will not only completely remove the cancer disease, but also will prevent any 
future recurrence. A novel hydrogel, Amikagel, was developed by crosslinking of aminoglycoside 
amikacin with a polyethylene glycol crosslinker. Aminoglycosides contain abundant amount of 
easily conjugable groups such as amino and hydroxyl moieties that were crosslinked to generate 
the hydrogel. Cancer cells formed 3D spheroidal structures that underwent near complete 
dormancy on Amikagel high-throughput drug discovery platform. Due to their dormant status, 
conventional anticancer drugs such as mitoxantrone and docetaxel that target the actively 
dividing tumor phenotype were found to be ineffective. Hypothesis driven rational drug discovery 
approaches  were used to identify novel pathways that could sensitize dormant cancer cells to 
death. Strategies were used to further accelerate the dormant cancer cell death to save time 
required for the therapeutic outcome. 
Amikagel’s properties were chemo-mechanically tunable and directly impacted the outcome of 
tumor dormancy or relapse. Exposure of dormant spheroids to weakly stiff and adhesive 
formulation of Amikagel resulted in significant relapse, mimicking the response to changes in 
extracellular matrix around dormant tumors. Relapsed cells showed significant differences in their 
metastatic potential compared to the cells that remained dormant after the induction of relapse.  
Further, the dissertation discusses the use of Amikagels as novel pDNA binding resins in 
microbead and monolithic formats for potential use in chromatographic purifications. High 
abundance of amino groups allowed their utilization as novel anion-exchange pDNA binding 
resins. This dissertation discusses Amikagel formulations for pDNA binding, metastatic cancer 
cell separation and novel drug discovery against tumor dormancy and relapse.   
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CHAPTER 1: INTRODUCTION 
AMINOGLYCOSIDE-DERIVED POLYMERIC MATERIALS FOR BIOMEDICAL APPLICATIONS 
Aminoglycosides are anti-bacterial therapeutic agents composed of amino-modified glycosides or 
any organic molecule that contains aminosugar substructures. These aminoglycosides inhibit the 
gram-negative bacterium by broadly inhibiting their protein synthesis 1. Aminoglycosides such as 
streptomycin, neomycin, irreversibly bind to the bacterial ribosomal RNA and cause improper 
translation. Alternately, other aminoglycosides such as amikacin bind to the 30S sub-unit of the 
bacterial ribosomes and inhibit their proper functioning by blocking active translation 2-6. 
Aminoglycosides have multiple easily conjugable hydrophilic functional groups such amino and 
hydroxyl groups. These groups can be actively linked together to generate small to medium chain 
polymers (molecular weight 3-5 kDa) and other crosslinked polymeric hydrogels 5. These 
polymers are not only biocompatible and hydrophilic, but also contain amino and hydroxyls for 
further conjugation or desired cargo delivery 5. In the studies presented in this dissertation, 
crosslinked aminoglycoside hydrogels have been used for generating high-throughput 3D tumor 
microenvironment models (3DTMs), high-throughput models of tumor dormancy, relapse and 
micrometastases etc. These high-throughput models of tumor dormancy and relapse have been 
used for rational drug discovery and development. Also presented are the studies on utilizing the 
aminoglycoside hydrogels in form of microbeads and macroporous gels as novel 
chromatographic resins for plasmid DNA binding and recovery and micellar delivery of anticancer 
drug mitoxantrone towards TRAIL sensitization.  
 
1.1. HIGH-THROUGHPUT 3D CANCER CELL CULTURE PLATFORMS  
 
High-throughput cell culture platforms are extremely useful in resource intensive processes of 
drug discovery, development and validation. These platforms provide rapid and cost-effective 
alternatives to conventional animal testing methodologies for drug discovery 7-8. Often, these 
platforms are used for drug discovery and validation prior to small and large animal testing 9-11. 
These platforms allow for initial confirmation and validation of the drug/biologic activity, thereby 
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reducing the risk associated with its future. These platforms are currently being used to discover 
novel drugs against diseases such as cancer 7, 12-13, Alzheimer’s 14, cystic fibrosis 15 etc. Unlike 
2D cancer cell culture platforms, 3D cancer spheroid cell models capture multiple complexities 
such as extensive cell-cell contacts, cell-ECM contacts (tumor-stoma interactions), zones of 
differential cell proliferation, zones of hypoxia, nutrient gradients, necrosis, different gene and 
protein expression profiles that closely represent the tumor in-vivo 16-17. As cells are surrounded 
by either other cells or ECM in the in-vivo environment, flat 2D cell culture surfaces do not 
adequately take into account those interactions. Thus, these 2D cell culture platforms can often 
result in misleading and non-predictive data for in-vivo responses 18-19.  
It is however important that the 3D cancer cell culture models closely mimic the disease 
or tissue in-vivo. Extensive research work continues to develop robust 3D cell culture models that 
closely mimic the tumor in-vivo. Conventionally, 3D cell cultures have been generated on non-
adhesive gels such as agarose, PEG gels, hanging drop cultures, low adhesion-corning plates 
etc 13, 20-21. Low substrate adhesivity prompts the cells to attach to one another generating a 3D 
spheroidal mass. Techniques such as hanging drop cultures pose certain challenges in high-
throughput culture due to the low volume of liquid that can be used for such cultures. They also 
require special low evaporation platforms to avoid significant loss of media 13, 20. 3D spheroids 
have also been generated using spinner flasks and suspension techniques. A significant limitation 
of suspension cultures is the generation of spheroids with different sizes that require further 
filtration and separation to isolate the right size.  22.  
Other gels such as Matrigel, collagen gel, laminin or fibronectin-coated gels have also 
been used to generate 3D cancer cell culture platforms 23. Unlike the previously described non-
adhesive gels, these gels present surfaces rich in adhesive ligands that closely mimic the in-vivo 
microenvironment. However, these specialized gels also require advanced temperature control 
strategies in order for proper gelation. Pickl et al. 24 showed that human epidermal growth factor 
receptor (HER2) overexpressing cancer cells show considerable differences towards trastuzumab 
in 2D versus the 3D cell culture platforms. 2D cell culture surfaces largely induce HER2 and 
HER3 heterodimers whereas 3D culture largely generates homodimers. Presence of homodimers 
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also shows enhanced response to trastuzumab. Birgersdotter et al. 19 showed large global gene 
expression differences between solid tumors and immortal cell lines used to study them and 
showed that inclusion of stromal cells into the co-culture significantly improved the outcome.    
We used the aminoglycoside hydrogels (‘Amikagels’) as novel substrates for high-
throughput cell culture. Crosslinking units of adhesive aminoglycoside amikacin and non-
adhesive PEGDE resulted in the novel hydrogel (‘Amikagel’). By varying the mole ratios of the 
two monomers (Amikacin and PEGDE), different hydrogels could be prepared with varied chemo-
mechanical properties. Unlike other contemporary hydrogels for 3D cell-culture like agarose or 
Matrigel that instantly gel upon temperature modulation, amikagel preparation and gelation was 
tunable by temperature variation. Amikagels with high mechanical stiffness and low adhesivity 
generated hydrogels that were non-adhesive and conducive for 3D spheroid formation. We 
generated multiple singular as well as co-culture spheroids of bladder, prostate, breast and 
pancreatic cancer cell types using the amikagels. This dissertation will delve in-depth into the 
physico-chemical and mechanical properties of amikagels and their influence on spheroid 
formation and its phenotype.  
 
1.2. TUMOR DORMANCY AND RELAPSE 
Primary treatments after a cancer diagnosis include chemotherapy, radiotherapy, biologic 
therapy, surgery or a combination of the above 25. Often, these treatments cause reduction in the 
primary tumor size and the cancer is said to be in treatment-induced remission once it is not 
detectable by conventional imaging techniques. However, a number of times, cancer relapses 
from remission, causing tumor metastases in the primary or distant secondary sites leading to 
patient death 26-27. In fact, 90% of cancer deaths are due to metastases to distant sites such as 
bone, liver and lungs etc 28.  Deaths due to breast and prostate cancer metastases account for 
majority of deaths in patients with those diseases 29. It is now widely believed that cancer cells 
undergo prolonged periods of dormancy before relapse. In this dormant state, these cancer cells 
exhibit low cell proliferation profiles, low metabolic consumption and are highly resistant to 
conventional chemotherapeutics that exclusively target the actively dividing phenotype (Figure 
4 
1.2) 30. Increasing evidence points towards a definitive phase of prolonged G0/G1 arrest (‘cellular 
dormancy’) of micrometastatic nodules rather than balanced proliferation to support prolonged 
viability before relapse 27. Upon relapse, these cancer cells give rise to highly aggressive forms of 
tumor metastases, often causing death as a result. Research has shown that cancer cells from 
primary tumor shed and migrate to the distant secondary sites (bone, liver and lung) even before 
the detection of the primary tumor 26, 30. Dormancy at distant disseminated sites has been shown 
to be induced by the local microenvironment, which is foreign to the invading cancer cells 31. 
These populations of non-dividing G0/G1 arrested cancer cells that evade traditional 
chemotherapy regimens indicate poor prognosis for the patient 32. Ablation of these cancer cell 
systems in their dormant state can not only completely eliminate the disease, but also reduce the 
risk of tumor relapse. There is a need to develop high-throughput in-vitro systems (HTS) that can 
capture the tumor dormancy in a 96 well plate format 33-34. These high-throughput systems (HTS) 
could allow the rapid discovery, development and validation of dormancy-specific drugs, their 
combinations and novel formulations towards drug delivery etc (Fig. 1-1) 13. 
 
 
Figure 1-1. Tumor dormancy and relapse timeline. Tumor dormancy is the phase between the 
cancer remission to relapse characterized by cancer cells with low rates of cell division and high 
chemotherapeutic resistance. 
 
Wenzel et al. 35 developed an 384 well agarose gel (1.5% wt/vol) based breast cancer 
T47D multicellular tumor spheroid culture in high-throughput. The T47D multicellular tumor 
spheroid consisted of regions of active growth towards the exterior and internal low-growth 
regions with low cell division rates. While the exterior regions were susceptible to paclitaxel and 
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cisplatin, cells in the inner regions with intermediate oxygen supply were resistant to those drugs. 
Utilizing the high-throughput system, the authors identified compounds that not only ablate the 
actively dividing cells, but also the dormant cancer cells. Authors identified respiratory inhibitors 
as compounds that work to ablate the dormant regions in the MCTS. While respiratory inhibitors 
can effectively ablate the dormant tumors, it is important to note that these could also 
indiscriminately kill the normal dividing cells, making delivery of these drugs specifically to target 
cells equally important. In addition, agarose substrate might not be suitable for large-scale 
platforms without sophisticated temperature control technologies.  We developed a novel 
aminoglycoside based hydrogel that is highly temperature controllable and induced spheroid 
formation with high viability and complete dormancy. In our comparative studies, Amikagel fared 
better than agarose gel in inducing complete tumor dormancy in bladder cancer cells. In fact, 
bladder cancer cells were almost completely arrested in the G0/G1 phase of cell cycle on 
Amikagels. These results are of significance since very few methods have been developed for 
generating high-throughput 3D models of total tumor cell dormancy; most methods using 3D 
models have demonstrated only ~70% cells in the G0/G1 phase of the cell cycle for cancer cells 
at best 36.  
Previous research has closely linked upregulation of p38, p27 and p16 proteins with the 
induction of tumor dormancy and cell cycle arrest in the G0/G1 phase 37-39. Ghiso et al. 40 
reported that the ratio of ERK/MAPK and p38 proteins regulate the entry or exit of cells from 
tumor dormancy in many cell types. Higher p38 protein was associated with dormant state of cells 
in-vivo whereas higher ERK/MAPK was associated with proliferation. Further, Ranganathan et 
al.37 showed that p38 induced dormancy, initiated by microenvironmental changes (loss of 
integrin adhesion to fibronectin rich surfaces 41) induced PERK activation that reduced translation 
and phosphorylated eukaryotic translation initiator factor 2α (eIF2α), arresting cells in the G0/G1 
state. Some cell types can also induce dormancy independent of p38, by directly upregulating 
several CDK inhibitors such as p21, p27 and p16 42. In fact, p38 protein has also been shown to 
modulate several downstream CDK inhibitors such as p21, p27 and p16 that work to induce cell 
cycle arrest and dormancy 43-44. Barkan et al. 42 showed that dormant breast cancer D2.0R 
6 
tumors have high expression of p27 (~77% of cell nuclei) and lower amounts (~50%) of p16 CDK 
inhibitors. These dormant D2.0R breast cancer cells when injected into mice invaded distant 
metastatic sites and remained as single quiescent cells for prolonged periods of time before 
metastases. Near complete total dormancy achieved on Amikagel platform allows its usage as a 
clinically relevant model for high-throughput drug discovery. Not only can we study the induction 
and maintenance of tumor dormancy on this platform, but also study the incidences of relapse 
from the dormant phenotype.  
Our cellular model of tumor dormancy involves transitional cell carcinoma T24 bladder 
cancer and UMUC3 bladder cancer cell lines. Bladder cancer is one of the leading urothelial 
cancers, the 7th leading cause of new cancers each year in USA and is the 4th leading cause of 
cancer deaths 45-46. Most of the bladder cancer deaths are associated with the metastases of the 
cancer cells to the lymph nodes, lungs, liver and bone areas 46. Previous research has shown that 
T24 cells undergo cell-cycle G0/G1 arrest upon cell-cell contact mediated by p27Kip1 expression 
and subsequent CDK inhibition 39, 47. We hypothesized that a 3D cell culture platform that 
effectively induces robust cell-cell adhesions would likely induce dormancy in these cancer cells. 
Upon doing so, a high-throughput model platform to accurately study the dormancy phase of 
cancer cells can be established. Such a high-throughput model of cellular dormancy will allow for 
rational drug discovery, development, validation and delivery. Not only can the model of cellular 
dormancy be established, a subsequent high-throughput model of relapse from tumor dormancy 
can also be established. Our research centered on developing amikagel hydrogel formulations 
that can rapidly induce dormancy behavior and relapse in the cancer cells.  
Previous works have also shown significant heterogeneity in the T24 cell line and its 
metastatic potential 48. While some reports describe T24 cell line as non-tumorigenic due to poor 
growth rate and poor tumor formation in mice, several reports state the cell line as highly 
metastatic 48-50. Makridakis et al. 51 reported that injection of T24 cells into mice resulted in tumor 
formation only in 33% of the mice. Gildea et al. 47 isolated the T24 metastatic cell fractions from 
the heterogeneous T24 cell population and showed significant differences in HRAS expression, 
beta-catenin levels in the metastatic T24M cells. It is now believed that the T24 cell line consists 
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of a heterogeneous mix of cells with different phenotypes within the same population. While 
decades worth of research has progressed into isolating and understanding the metastatic 
version of the bladder cancer cell line and strategies to ablate them, almost no research has been 
performed in trying to understand and ablate the dormancy in these cancer cell lines. We use 
these bladder cancer cells as a model to understand tumor dormancy in general. In our work, we 
have worked to understand and ablate the dormant bladder cancer 3D tumor microenvironments 
(3DTMs) by targeting the cellular adaptations in tumor dormancy.  
Relapse and reawakening from tumor dormancy is almost always associated with 
significant mortality 52. Relapse from tumor dormancy has been shown to be associated with 
changes in the extracellular environment around the dormant tumor 38. Barkan et al.42 showed a 
switch from dormant to relapse behavior in breast cancer cells via fibronectin – β-integrin 
mediated signaling. Addition of fibronectin to growth factor reduced gels resulted in significant 
proliferation and migration of dormant D2.0R breast cancer cells 42. In bladder cancer, changes in 
extracellular matrix have been associated with metastasis and migration of the cancer cells 53. 
Incidentally, the cells that tend to migrate and metastasize are the ones with lower expression of 
beta-catenin levels, higher MMP expressing cells etc 47. Aberrant expression of N-cadherin has 
also been associated with poor prognosis of bladder cancer 54. N-cadherin protein expression 
along with E-cadherin modulation is a hallmark of epithelial to mesenchymal transition (EMT) 
event and has been linked to poor prognosis for the bladder cancer patient 55. However, reduction 
or complete absence of N-cadherin has been associated with increased migration, metastases in 
multiple cancer cell types including bladder cancer. Reduction of N-cadherin or complete absence 
of N-cadherin has been connected to extremely poor prognosis for bladder cancer patients 55-57. 
In a study of bladder cancer patient samples by Jager et al. 58, N-cadherin reduction and absence 
was identified to be an extremely poorer prognostic indicator than expression of N-cadherin 
(which was also a significant prognostic indicator of invasive cancer disease). 
We hypothesized that transferring the dormant T24 3DTMs from non-adhesive and 
mechanically stiff Amikagel formulations to a more adhesive, mechanically pliant Amikagel 
formulations could result in relapse and migration of metastatic populations of the cells. We 
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hypothesized that cells with differential expression of N-cadherin could be isolated from within the 
population of T24 cells by modulating the chemo-mechanics and adhesivity of the substrate 
matrix. In order to do so we varied the ratio of the input monomers amikacin and PEGDE to 
generate different formulations of Amikagel with varying adhesivities and studied the relapse of 
the cancer cells from tumor dormancy. Our goal for this work has been to develop a novel high-
throughput platform that not only captures complete tumor dormancy, but also relapse and further 
metastatic cell migration and micrometastases formation for rapid drug discovery, validation, 
delivery and development (Fig. 1-2). 
 
Figure 1-2. T24-3DTM Amikagels as a proposed drug screening platform against multiple 
cancer phenotypes. T24 3D-DTM Amikagel system as high-throughput drug screening platform 
against tumor specific phenotypes of a) total dormancy, b) relapse from dormancy and c) cell 
escape and micrometastases captured within a 96 well plate. 
 
1.3. TARGETING CELLULAR ADAPTATIONS IN TUMOR DORMANCY AND RELAPSE 
Dormant cells utilize a number of pathways to adapt to their dormant state. Targeting these 
adaptations could allow us to selectively ablate the dormant cancer cells, sparing the other non-
dividing healthy cells. Ranganathan et al. 37 revealed significant ER stress response in the 
dormant human epidermoid-carcinoma cell line HEp3 cells. In their proteomic analysis, several 
key ER stress markers such as BiP/GRP78, XBP-1, HSP47 and PERK were activated in dormant 
cancer cells. Ranganathan et al. 37 associated the upregulation of ER stress markers as an 
adaptation of the dormant state. The authors suggested that dormant cells might be chronically 
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under ER stress and utilize the adaptations to survive. In our studies, we found that the total 
protein content per cell in the dormant state was slightly but significantly upregulated, indicating 
strategies to target the ER and the protein production pathway could be beneficial. We focused 
on ways to induce and accelerate the ER stress in the dormant cells as a strategy to ablate them. 
Our strategy has been to induce and overwhelm the dormant cancer cell with chronic ER stress.  
Endoplasmic Reticulum (ER) is an organelle that is responsible for ensuring proper 
folding of the nascent peptides into 3D protein structures 59. Ribosomes associated with the 
endoplasmic reticulum deposit nascent linear peptides into the ER after mRNA translation 60. In 
the ER, the nascent peptides are properly folded into 3D structures via the help of multiple 
chaperones such as calcium dependent chaperones calnexin and calreticulin and other assistive 
proteins etc 61-62. Any disturbance in the chaperone assisted folding of the nascent peptides or 
otherwise results in protein misfolding and accumulation. Accumulation of misfolded or unfolded 
proteins results in activation of cellular adaptation cascade known as unfolded protein response 
(Fig. 1-3) 63. The cascade activates multiple pathways focused on initially trying to restore 
balance to the ER and relieve the ER stress 64. In an event of chronic ER stress, the pathway 
focuses on inducing apoptotic cell death in the stressed cell 65-66.  
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Figure 1-3. ER stress adaptation pathways during protein unfolding or misfolding. Cellular 
adaptation under protein misfolding or ER stress results in a cascade of cell signalling events 
collectively referred to as unfolded protein response (UPR). HSP90, Calnexin – Chaperones 
required for proper folding of nascent proteins, IP3R-VDAC-MCU – Pores that direct calcium 
entry from ER to mitochondrial matrix, SERCA – Scarcoplasmic/Endoplasmic Reticulum Ca2+-
ATPase calcium channel for maintaining ER calcium levels, ATF6 – Activating Transcription 
factor 6, Ire1 – Ionositol requiring enzyme 1, PERK – protein kinase RNA-like endoplasmic 
reticulum kinase, BiP – Binding Immunoglobulin protein 
 
Accumulation of misfolded/unfolded proteins sequesters the adaptor protein BiP/GRP78 
that causes the activation of significant number of downstream effectors 67-68. Under normal 
conditions, binding of BiP/GRP78 adaptor protein to a number of downstream effectors such as 
ATF6, IRE1, PERK and IP3R keeps them under check. But sequestration of the adaptor by the 
misfolded proteins activates the cascade. In a well-elucidated pathway (Fig. 1-3), accumulation of 
misfolded proteins in ER causes the activation of two main pathways, the Ire1/XBP-1 and ATF6-
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dependent pathway and PERK/eIF-2alpha phosphorylation-dependent pathway 69-70. Dimerization 
of Ire1 causes autophosphorylation and intronic splicing of XBP-1 mRNA and spliced XBP-1 
protein production which causes transcriptional activation of multiple chaperone proteins to repair 
the misfolded/unfolded proteins 70. Phosphorylation of PERK via oligomerization tends to reduce 
the ribosomal translation in order to reduce the load of nascent proteins being deposited into the 
ER 71. PERK and ATF6 also cause transcriptional activation of multiple pro-apoptotic factors such 
as CHOP 65. Spliced XBP-1 protein also causes transcriptional activation of lipid synthesis, 
foldases and ERAD (ER associated protein degradation), which ubiquitinylates the 
misfolded/unfolded proteins for their removal via proteasome 72. The aim of these responses is to 
remove misfolded/unfolded proteins from the ER and relive the ER stress.  
If the cellular adaptation pathways are unable to relieve the ER stress, the cell enters a 
phase towards apoptotic death under chronic ER stress. Under chronic ER stress, the pro-
apoptotic proteins CHOP and Bax, Bak are produced which puncture the outer mitochondrial 
membrane. CHOP is a multifunctional transcriptional activator that is closely linked with chronic 
ER stress associated apoptosis. CHOP is responsible for transcriptional activation of multiple pro-
apoptotic proteins such as Bax and Bak, which work to puncture the outer mitochondrial 
membrane. Further, the intra-ER and cytoplasmic calcium is pumped into mitochondrial matrix via 
specialized IP3R-VDAC-MCU set of channels during prolonged ER stress (Fig. 1.4). Pumping of 
calcium ions into the mitochondrial matrix results in erosion of the mitochondrial potential 
difference between the matrix and the outer mitochondrial membrane space resulting in 
mitochondrial swelling, and eventual lysis 66, 73-76. Mitochondrial depolarization releases pro-
apoptotic proteins cytochrome c and SMAC/DIABLO into the cytoplasm 77. Cytochrome c 
stimulates the formation of multi-protein apoptosome complex along with pro-caspase 9. 
Apoptosome complex causes self-catalytic event and activation of caspase 9 78. Activated 
caspase 9 cleaves and activates multiple other pro-caspases such as pro-caspase 3,6 and 7 
resulting in apoptosis 75-76. The mitochondrial depolarization and lysis represent a "point of no 
return" in the apoptosis-signaling cascade. In addition, permeabilization of single mitochondria 
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results in release of reactive oxygen species into the cytoplasm that act to depolarize more 
mitochondria, thus amplifying the effect and accelerating apoptosis 79.  
Our approach has been to identify novel drug combinations that not only sensitize the 
dormant cancer cells to apoptotic death, but also accelerate the process towards apoptotic death. 
By identifying strategies that work to accelerate the cell death, we were able to speed up the 
dormant cancer cell death process. Relapse from tumor dormancy is often associated with 
changes in the local microenvironment. Barkan et al. 42 showed that the relapse and metastases 
of the dormant cancer cells could be avoided by targeting the cytoskeleton of the relapsed cells. 
Barkan et al. targeted phosphorylation of myosin light chain by myosin light chain kinase that is 
required for actin stress fiber formation and subsequent cell migration during the relapse. Our 
strategies have focused on targeting the cellular mechanisms that allow relapsed cells to bind 
and interact with the substrate during cell migration and relapse. In this dissertation, using the 
high-throughput dormancy relapse platform, we explored and identified strategies that work to 
inhibit or accelerate the relapse from dormant tumors.  
 
1.4. Cross-Linked Aminoglycoside Polymers For Nucleic Acid Biotechnology 
Aminoglycoside based polymers have also been used to deliver important therapeutic cargoes 
into the mammalian cells. Potta and Zhen et al.80 hypothesized that the cationic charge of 
aminoglycosides at physiological pH and their natural affinity towards nucleic acids could be 
exploited to bind and deliver anionic plasmid DNA if aminoglycosides could be assembled into 
polymeric structures. Delivery of plasmid DNA encoding therapeutic proteins to cells that lack 
them could benefit patients with deadly diseases such as cancer, cystic fibrosis and AIDS. Potta 
and Zhen et al.80 developed a library of 56 aminoglycoside-based polymers by crosslinking 7 
different aminoglycosides (neomycin sulfate, kanamycin sulfate, streptomycin sulfate, apramycin 
sulfate, paromomycin sulfate, sisomicin sulfate and amikacin hydrate) with 8 different cross-
linkers (1,4-cyclohexanedimethanol diglycidyl ether (CDDE), neopentylglycol diglycidyl ether 
(NPGDE), 1,4-butanediol diglycidyl ether (BGDE), ethyleneglycol diglycidyl ether (EGDE), poly 
(ethyleneglycol) diglycidyl ether (PEGDE), poly(propyleneglycol) diglycidyl ether (PPGDE), 
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resorcinol diglycidyl ether (RDE) and glycerol diglycidyl ether (GDE)). pGL3 plasmid coding for 
luciferase protein was delivered to the cells to quantify the transfection efficacy of the polymers. 
Nanoscale aminoglycoside polymer-pGL3 polyplexes were delivered to PC3 and 22Rv1 human 
prostate cancer cells, MiaPaCa2 human pancreatic cancer cells and MB49 bladder cancer cells. 
Aminoglycoside polymers prepared using apramycin, paromomycin and sisomicin crosslinked 
with RDE and GDE respectively were identified as lead polymers that generated highest 
transfection efficacy. Almost all the lead polymers showed higher transfection efficacy compared 
to pEI at the best N/P ratio. Potta and Zhen et al. also showed robust transfection efficacy of the 
lead aminoglycoside-based polymers in presence of fetal bovine serum, indicating their stability in 
binding and delivering plasmid cargo to the cells in high serum concentrations (transfection 
efficacy dropped under 2 fold). 
In order to understand the quantitative structure-property relationship of the polymer and 
its transgene efficacy, authors employed support vector machine (SVM) based algorithms to build 
both classification (SVM) and regression models (SVR). A total of 139 molecular descriptors were 
employed to accurately capture the quantitative information of the aminoglycoside-based 
polymers. Output variable of transfection efficacy was regressed against 139 input molecular 
descriptor variables to identify key independent variables that impact transfection efficacy (log10 
(RLU/mg)). The training model had a squared Pearsons’ correlation coefficient (r2) of 0.78 and a 
coefficient of determination (R2) of 0.78. Cross-validated model generated using part of training 
set which used other remaining data as validation set gave r2 and R2 values of 0.65 each, 
indicating the robust predictive power. Five descriptors, PEOE_VSA_PPOS, logP (o/w), 
RECON_SIEPMax, BCUT_PEOE_3, and RECON_PIPMax were seen to significantly explain the 
transfection efficacy of the aminoglycoside-based polymers and were used to generate the QSAR 
model. These descriptors describe the 2D electrostatic map (total polar surface area), molecular 
hydrophobicity, electrostatic potential, partial molecular charges and electron density at van der 
Waals surface of the molecule respectively. QSAR model indicated that balance between 
hydrophobic and hydrophilic moieties, basicity of the amine groups largely influence the 
transfection efficacy of the aminoglycoside-based polymers.  
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Miryala et al.81 reported further improvement in the transfection efficacy of the lead 
polymers via quaternization. Miryala and her co-authors conjugated glycidyl trimethyl ammonium 
chloride groups to the amino groups in the aminoglycoside polymers. These GTMAC groups 
provided the lead polymers with a permanent positive charge due to the quaternary ammonium 
groups. These quaternary ammonium modified lead polymers were better transfection agents 
compared to their parental polymers. Miryala et al.81 reported that their lead polymers performed 
2-4 times better than the comparison lipofectamine 3000. Miryala et al. 82 also developed lipid-
conjugated aminoglycoside polymers to prepare nanoparticles for transgene delivery. Alkanoyl 
conjugations were achieved by reacting alkanoyl chloride to the aminoglycoside polymers 
resulting in lipopolymers. In most cases transgene delivery using lipopolymers was found to be 
better than the polymers alone. Long chain stearoyl (C18) groups conjugated to lead polymers 
(neomycin-glycerol diglycidyl ether (NG) and apramycin-glycerol diglycigylether (AG)) were noted 
to generate higher transgene expression compared to hexanoyl (C6) and myristoyl (C14) groups. 
QSAR cheminformatic SVR-based model indicated that high number of amines on polymers, 
hydrophobic chain length, smaller lipid-polymer conjugation ratios collectively contribute to 
enhance the transgene delivery efficacy of the lipopolymers. 
In our work 83, we exploited the binding affinity of aminoglycosides to nucleic acids for 
plasmid DNA (‘pDNA’) binding and desorption in a chromatographic setting. We developed a 
novel aminoglycoside (‘Amikacin’) based hydrogel microbeads/microresins (‘Amikabeads’) to 
adsorb and desorb pDNA for its potential usage as chromatographic resins. Conversion of freely 
soluble aminoglycosides into hydrogel microbeads via crosslinking allowed their usage as 
chromatographic resins. These aminoglycoside microbeads were prepared using emulsion based 
polymerization (Fig. 1-4). No other conventional pDNA chromatographic resins utilize the natural 
affinity of aminoglycosides towards pDNA chromatography 84. Presence of abundant conjugable 
groups such as hydroxyls and amines will also allow for conjugation of multiple other pDNA 
specific groups on the surface of amikagel microbeads towards its use in one-step pDNA isolation 
from bacterial broths.  
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Figure 1-4. Formulation of Amikagels as chromatographic resins. Novel aminoglycoside 
based microbeads (‘Amikabeads’) were prepared using the emulsion-polymerization method.  
 
Binding of plasmid DNA was significantly improved by converting the primary amines to 
quaternary ammonium groups via GTMAC conjugation, thus giving them a permanent positive 
charge. Conversion of the amine groups of Amikabeads to quaternary ammonium groups caused 
significantly higher plasmid DNA binding to the resins at pH 8.5, 25OC and 10 mM Tris-Cl buffer 
similar to that observed by Miryala et al 81. The binding capacity of the quaternized Amikabeads 
was comparable to the commercially existing alternatives such as gigaporous rigid ceramic 
HyperD-Q polymerized hydrogel resins 84. This dissertation describes the development of suitable 
buffer systems to elute maximal plasmid DNA from the parental and quaternized amikagel based 
chromatographic resins. In the end, we show that the novel Amikabeads can also be used to 
extract mammalian cell DNA from whole cell systems for applications into on-site PCR etc.  
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1.5. THESIS CONTRIBUTIONS 
This dissertation describes multiple inventions regarding design and development of 
aminoglycoside based hydrogels for applications in high-throughput cell culture models of tumor 
dormancy, relapse (for drug discovery and development) and novel chromatographic resins for 
plasmid DNA biotechnology: 
1. The first demonstration and development of amikacin aminoglycoside based 
hydrogel with tunable chemo-mechanical properties of mechanical stiffness and 
adhesivity. 
2. Aminoglycoside based hydrogels for high-throughput 3D cell culture platforms of 
prostate, bladder, breast and pancreatic cancer cell types.  
3. High-throughput in-vitro platform of tumor dormancy, relapse and 
micrometastases in a 96 well plate format  
4. Identification of chronic ER stress as a novel pathway to induce apoptosis in 
dormant bladder cancer tumors. 
5. Acceleration of chronic ER stress induced apoptosis by exogenous delivery of 
calcium to the cell cytoplasm. 
6. Identification of material strategies for rapid isolation and separation of metastatic 
cell fractions from a heterogeneous cancer cell population. 
7. Design and development of novel aminoglycoside based microbeads and 
macroporous gels for pDNA binding and recovery. 
 
In addition, this dissertation also describes generation of novel acrylic devices for high-
throughput generation of user desired polymeric scaffolds and micellar mitoxantrone drug delivery 
of TRAIL sensitizer to sensitize multiple cancer cell lines to TRAIL mediated cell death: 
 
1. Micellar delivery of anticancer drug mitoxantrone towards TRAIL sensitization of 
bladder, prostate and breast cancer cell lines in-vitro.  
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2. Design and development of high-throughput acrylic based devices for rapid and 
high-throughput generation of user desired macroporous and non-macroporous 
polymeric scaffolds.  
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CHAPTER 2: AMINOGLYCOSIDE-DERIVED HYDROGEL (‘AMIKAGEL’) AS A NOVEL 
SUBSTRATE FOR HIGH-THROUGHPUT GENERATION OF 3D TUMOR 
MICROENVIRONMENTS (3DTMS) 
 
2.1. INTRODUCTION 
Two dimensional (2D) monolayer cultures are ubiquitous in cell-based molecular investigations. 
However, 2D cultures often fail to capture the complexity inherent in three dimensional tissues 85. 
Significant disadvantages of these systems include inability to achieve in vivo-like extensive cell-
cell adhesions 86, considerable differences in cellular morphologies 87, minimal nutrient and 
metabolite gradients 34, differences in gene expression profiles 88 and absence of cell-ECM 
interactions 89 and absence of vascularization etc. In order to circumvent these problems, three 
dimensional (3D) cellular models 21 have been proposed and developed in diverse fields of 
developmental/embryonic biology 90, cancer biology 91, drug discovery 92, and regenerative 
medicine 93. Of these, developments of multicellular three-dimensional tumor spheroids that 
closely mimic the native tumor microenvironmental intricacies are of critical importance. These 
three dimensional tumor microenvironment (3DTM) models can capture the cellular and 
metabolic profiles of tumors, and demonstrate defined regions of outer proliferating cells, 
intermediate quiescent cells and innermost necrosis, generated due to limitations in nutrient, 
oxygen and metabolic transport. In particular, 3DTMs generated by co-culturing epithelial cancer 
cells with their stromal/stellate counterparts can provide insights into tumor-stroma interactions, 
and cell-ECM interactions, in addition to shedding light on their roles in carcinogenesis and 
metastasis 94. High throughput generation of 3DTMs can lead to fundamental advancements in 
tumor biology and facilitate realistic drug screening in the context of tumor complexity, reduced 
drug and metabolite transport, drug and radiation resistance, and induced hypoxia due to the 
three dimensional architecture. 
The ability to chemically or biologically engineer the substrates supporting the 3DTMs 
can provide exquisite control over important spheroid properties such as metastasis 95, growth 
and proliferation 96, angiogenic ability 97-98 etc. These properties if captured in-vitro, can serve as 
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important models to study the disease. Liang et al. 95 showed that fine tuning the matrix stiffness 
of PEG-collagen gel can dictate metastatic properties into 3D liver tumor spheroids.  Also, 
synthetic hydrogels have been created with growth factors attached to mimic native tissues to 
probe cell-ECM interactions during tumor growth, metastasis and resistance 96.  
Generation of 3D cell spheroids can be facilitated by methods such as hanging drop 
cultures, rotary suspension cultures, and culture on non adherent substrates (agarose) and 
Matrigel®  20, 99-102. In principle, the hanging drop technique allows high throughput generation of 
spheroids under gravity via cell-cell adhesion, but is tedious and can accommodate only small 
amount of media, thereby requiring frequent refreshing of the media. This system can also lead to 
poor yields. Conventional suspension cultures generated using spinner flasks for spheroid growth 
often result in a heterogenous population of spheroids, making the isolation of spheroids with 
desired sizes difficult. Existing gels including agarose and Matrigel can undergo undesired gelling 
during experimentation, making their use without temperature controlled robotic liquid handling 
systems quite stressful during high-throughput assays.  In addition, Matrigel is expensive 
compared to other alternatives, needs maintenance of cold temperatures whilst transferring and 
has batch-to-batch variations, thus reducing the flexibility of operating protocols. Low adherent 
cell culture plates provide a non-adhesive surface that cannot be tuned to provide differential 
mechanical input to the 3DTM if desired by the user. In addition, some of these substrates also 
lack optical transparency leading to considerable challenges in live bioimaging in a confocal 
microscopy experimental setting.  
This chapter describes the discovery and detailed characterization of a new, highly 
versatile, optically transparent aminoglycoside antibiotic-based polymeric hydrogel material 
(Amikagel), whose chemo-mechanical properties could be heavily engineered. Important 
properties such as hydrogel mechanical stiffness, hydrogel adhesivity, gelation kinetics etc were 
easily controlled by temperature modulation and by varying the input monomer mole ratios. 
Amikagel thus formed, supported formation and maintenance of high-throughput cultures of 
three-dimensional tumor microenvironments (3DTMs) across multiple cancer cell lines of breast, 
bladder and pancreatic cancer. 
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2.2. MATERIALS AND METHODS 
Materials  
Amikacin hydrate (AH) (referred to as amikacin henceforth), docetaxel, wortmannin, chloroquine, 
propidium iodide, ribonuclease-A, poly (ethyleneglycol) diglycidyl ether (PEGDE), sodium 
orthovanadate and sodium fluoride were purchased from Sigma-Aldrich (St. Louis, MO), and 
used without further purification. Bortezomib was obtained from Selleck Chem (Houston, TX). 
Mitoxantrone was obtained from Ontario Chemicals (Guelph, ON). Thapsigargin and ROCK 
inhibitor Y-27632 dihydrochloride were obtained from Santa Cruz Biotech (Dallas, TX). Calcein 
AM/ethidium homodimer Live/Dead stain®, AlexaFluor 568-Phalloidin (actin-binding), 4', 6-
diamidino-2-phenylindole (DAPI) and Collagenase Type-2 were purchased from Life 
Technologies, (Carlsbad, CA). T24 and UMUC3 human bladder cancer cells were obtained from 
Professor Christina Voekel-Johnson at Medical University of South Carolina, Charleston, SC as 
part of an existing collaboration. These cell lines were verified for their authenticity through Bio-
Synthesis Inc (Lewisville, TX). PC3-eGFP prostate cancer cells were obtained as a gift from Anne 
Cress' lab and Experimental Mouse Shared Service (EMSS)/ Cancer Center Support Grant 
(CCSG), University of Arizona Cancer Center. MTT and XTT cell proliferation kit, prostate stromal 
cells (WPMY-1) and PC3 prostate carcinoma cells were purchased from American Type Culture 
Collection (ATCC) (Manassas, VA) 103. Bj5ta human foreskin fibroblasts were obtained from 
Center for Biosignatures Discovery Automation (CBDA), Biodesign Institute, ASU as part of an 
existing collaboration. NIH3T3 murine fibroblasts were obtained from Professor David Capco, 
School of Life Sciences, Arizona State University, Tempe, AZ as part of an existing collaboration. 
Cell culture media – RPMI media, DMEM with L-glutamine, Pen-Strep solution: 10000-units/mL 
penicillin and 10000-µg/mL streptomycin in 0.85% NaCl were purchased from Hyclone (Logan, 
UT). Premium heat inactivated fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Flowery Branch, GA). Cell culture-treated 24 and 96 well plates were purchased from Corning 
Life Sciences (Corning, NY). Growth Factor reduced (Basement membrane) Matrigel matrix was 
obtained from Corning (Bedford, MA) and molecular biology grade agarose was obtained from 
Fisher Scientific (Pittsburgh, PA). Nanopure water was used in all preparations.   
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Amikagel synthesis 
Ring-opening polymerization between amine groups of amikacin hydrate and epoxide groups of 
poly (ethylene glycol) diglycidyl ether (PEGDE) resulted in the formation of a novel hydrogel 
henceforth called ‘Amikagel’. Different stoichiometric ratios of amikacin and the cross-linker 
PEGDE were dissolved in Nanopure® water, mixed and incubated at 40°C for 7.5 h, in order to 
obtain Amikagels AM1, AM2, and AM3 of different compositions (Table 1). The final concentration 
of amikacin was 10 wt% in all gels. All experiments were carried out in triplicate unless otherwise 
mentioned.   
 
Optical transparency measurements 
40 µL of amikagel pregel solution was added to wells of a 96 well plate. After gelation of the gel 
as described above, an absorbance sweep was performed from the wavelength 400 nm to 700 
nm and was compared to a well with no gel as control. Any absorption peaks measured were 
considered as reduction in transparency of the hydrogel.  
 
Rheological Measurements  
Rheological measurements were carried out at 25°C with an AR-G2 rheometer (TA Instruments) 
using parallel-plate configuration in the oscillatory mode. Amikagel samples of different mole 
ratios were prepared in a high-throughput device to yield gel discs of diameter 8 mm and 3 mm 
thickness. 8 mm was chosen to match the dimension of the upper parallel plate. These Amikagel 
discs were loaded between the plates till the samples were in contact with the upper and lower 
plates (normal force applied 1N). Once in contact, a time sweep of 180 seconds was performed 
at an angular frequency of 0.1 rad/sec was conducted at a fixed strain of 0.1%. Storage (G’) and 
loss (G”) moduli were experimentally determined as a function of applied frequency and absolute 
shear modulus (|G*|) was estimated. The storage modulus (G') gives information about material 
elastic properties and its mechanical stiffness, while loss modulus (G") provides information about 
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the viscous/liquid properties of the material. Absolute shear modulus representing the stiffness of 
the hydrogel was calculated as |G*| = (G’2 + G”2) 0.5.  
 
High throughput device design  
A novel acrylic device was designed to rapidly generate Amikagel discs of desired dimensions in 
high-throughput for the rheological studies. In any experiment on a parallel plate AR-G2 
rheometer, it is recommended that the diameter of the sample gel disc match the diameter of 
upper parallel plate. As the gelation of the hydrogel takes a considerable time on the device, it 
was prepared in an external high-throughput device and the rheological properties of the 
Amikagel disc were then measured. A novel design for the high-throughput device was conceived 
and created on the AutoCAD software. These designs were then produced on 0.17 inch thick 
acrylic sheet using a CO2 laser cutter (Universal laser systems) at ~100% power and 5% speed. 
The designs were tested and modified to achieve high satisfaction for easy high-throughput 
generation of hydrogel discs. 
 
FT-IR Spectroscopy of Amikagels 
Extent of Chemical cross-linking developed between the epoxide and amine groups upon 
Amikagel gelation was studied using FT-IR.Amikagel FT-IR measurements were made with 
Perkin-Elmer FT-IR system (Spectrum GX). In a typical example, 0.2 gm of Amikacin Hydrate 
was allowed to react with 0.45 ml of PEGDE, incubated 7.5 h at 40°C for gel formation. After 
incubation, the sample was immediately freeze dried and pressed into pellet with potassium 
bromide for infra-red spectroscopy measurements. Amikagel sample before gelation was used as 
control in the experiment.  
 
Swelling studies 
Different Amikagels were prepared as stated above. Amikagel discs of diameter ~ 10mm and 
thickness ~ 1mm were cut, placed on a glass slide and immersed into Nanopure® water (ca. 40 
ml, 37oC, 48 hours). After removal of excess water, the samples were weighed to determine the 
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wet weight (Wwet). The discs were then freeze dried and weighed again to determine (Wdry).  
Amikagel 
The degree of swelling (DS) was calculated as follows: 
                                    
 
 
Scanning electron microscopy of fractured Amikagels  
The inner network morphology of cross-linked Amikagel was studied using FE-SEM (Field 
Emission Scanning Electron Microscopy). Amikagels were prepared as described in section 2.4, 
frozen, fractured and mounted onto an aluminum stud. The samples were lyophilized, and the 
freeze-dried sample was fractured and sputter-coated with gold for 240 s (E1030 Ion sputter). 
The interior of the Amikagel sample was visualized using a Field Emission Scanning Electron 
Microscope (FE-SEM; PHILIPS FEI XL-30 SEM) at 25kV. The thickness of the sample was 3 mm 
in these experiments.  
 
Scanning electron microscopy of wet Amikagel surface 
Constituent components of Amikagel were reacted as described in section 2.4 and hydrated with 
Nanopure® water at 37°C for 12 hours.  The water in hydrated Amikagels was exchanged with 
acetone by incubating specimens for 15 minutes each in a graded acetone series.  The gels were 
subsequently dried through the critical point of CO2 and sputter coated with Pt-Au using the 
instruments Balzer CPD 020 and a Technics sputter coater respectively.  Images were scanned 
with a JOEL JSM scanning electron microscope operating at 15 keV housed in the W.M. Keck 
Bioimaging facility at Arizona State University.  
 
Generation of 3D Tumor Microenvironment models (3DTMs)  
Cell culture 
3DTMs were generated using single cell lines or co-cultures of cancer cells with stromal cells on 
AM3 (Table 1). Different cancer cell lines including, T24 and UMUC-3 bladder cancer, PC3 and 
W dry
Wwet Wdry
DS =
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PC3-eGFP prostate cancer and MDA-MB-231 breast cancer were employed in the generation of 
3DTMs. Stromal cells including NIH3T3 murine fibroblasts, BJ-5ta human foreskin fibroblasts, 
WPMY-1 human prostate stromal cells were also used. T24, MDA-MB-231, WPMY-1 and Bj-5ta 
cells were propagated in DMEM supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) 
penicillin and streptomycin (Pen-Strep solution: 10000 units/mL penicillin and 10000 µg/mL 
streptomycin in 0.85% NaCl). For NIH3T3 cell propagation, 1% (v/v) sodium pyruvate was added 
and fetal bovine serum was replaced with calf serum in the media. For all the remaining cell lines, 
RPMI media supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin and 
streptomycin was used. 
 
Generation of 3D-DTMs using Amikagels 
1 ml of amikagel AM1, AM2 and AM3 pre-gel solutions were filtered through a 0.20 µm filter and 
40 µL of the filtrate was added to each well of a 96 well plate.  The plates were sealed with 
paraffin tape (Parafilm, Menasha, WI) and incubated in an oven maintained at 40oC for 7.5 hours. 
After gelation, the surfaces of Amikagels were washed with 150 µL of Nanopure® water for 12 
hours, in order to remove traces of unreacted monomers. All 3D-DTM experiments were set up 
by liquid overlay culture 104 of cells on top of Amikagel surface in a total volume of 150 mL media 
/well; either 100,000 cancer cells alone (single culture) or 50,000 stromal cells followed by 50,000 
cancer cells (co-culture) were incubated, unless indicated otherwise in specific cases.  After 48 
hours of incubation, 50% of the media in the wells was replaced with fresh media i.e. 
DMEM/RPMI + 10% (v/v) FBS + 1% (v/v) Pen-Strep at regular intervals of 48 hours. Care was 
taken to withdraw and add the media slowly so as to not perturb 3D-DTM formation. Fresh media 
was added every 48 hours following cell plating. For 3D-DTM generation on 24 well plates, 400 
µL of pre-gel volume was used instead of 40µl. Different co-culture 3D-DTM systems are 
represented as fibroblast/stromal cells-epithelial cells (e.g. NIH3T3-T24, WPMY-1-T24) to 
accurately indicate the sequence of their addition. In most cases, 3D-DTMs were formed 5-7 days 
following culture on Amikagels.  
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Scanning electron microscopy (SEM) of 3D-DTMs 
Unless otherwise stated, all materials were purchased from Electron Microscopy Sciences (EMS; 
Hatfield, PA) and used when fresh. 3D-DTMs, approximately ~1 mm in diameter, were manually 
manipulated with a fire-polished glass Pasteur pipet and washed three times using phosphate-
buffered saline (PBS) in wells of a 96-well plate. 3D-DTMs were cytologically preserved with 0.1 
M cacodylate buffer made fresh with 2% glutaraldehyde and 1% formaldehyde at room 
temperature for 1 hour.  Specimens were washed 5 times with 0.1 M cacodylate buffer, and 
subsequently post-fixed in 1% OsO4 for 2 hours at room temperature in the dark. After extensive 
washes in nanopure deionized (DI) water, the samples were dehydrated through a graded 
ethanol series, and dried through the critical point of CO2 using Blazer CPD 020. Spheroids were 
immobilized on aluminum stubs and sputter coated with Pt-Au using a Technics sputter coater. 
Images were collected according to the conditions described in section above. 
 
Actin staining 
Unless otherwise stated, all reagents used for immunocytochemistry were purchased from Sigma 
Aldrich (St. Louis, MO). Different 3D-DTMs were fixed in 4% formaldehyde in 1X PBS for 12 
hours before their transfer to 30% sucrose solution (w/v) for another 12 hours. Fixed spheroids 
were collected in Tissue Tek and flash frozen in liquid nitrogen. Following this, 3D-DTMs were cut 
into thin sections of ~40 µm thickness using a cryotome maintained at -14oC.  The cut sections 
were placed on a positively charged glass slide and dried at 37oC to facilitate the attachment of 
the cryosection to the charged slide. Once dried, the 3D-DTM sections were thawed in 100 mM 
PBS with 2% formaldehyde (v/v) added to it.  Cells were permeabilized with an intracellular buffer 
(ICB) (ICB contained the following ingredients: 100 mM KCl, 5 mM MgCl2, and 20 mM HEPES 
(pH 6.8)) with 2% formaldehyde and 0.1% Triton X-100 for 10 minutes at room temperature in the 
dark. Cells were washed 3 times for 15 minutes per wash in ICB containing 1% bovine serum 
albumin (ICB-BSA) with gentle agitation. Fluorophore-conjugated actin-binding drug, Alexa Fluor 
568 Phalloidin was used in this study to label filamentous actin.  Phalloidin was diluted from the 
stock at a 1:200 µL dilution in antibody dilution buffer (ICB modified to contain 0.01% Tween-20 
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and 1% non-fat dry milk) and allowed to incubate on the sections over night in a humidified 
chamber protected from light at room temperature. The sections were washed 3 x 15 minutes 
with ICB-BSA the following morning, and the nuclear probe 4', 6-diamidino-2-phenylindole (DAPI) 
was challenged at 1:100 dilution in ICB for 15 minutes at room temperature. The sections were 
subsequently mounted in Vectashield (Vector Labs) and the cover slips were sealed at the edges 
with optically clear nail polish.  All images were collected on a Leica SP5 laser scanning confocal 
microscope housed in the WM Keck Bioimaging Facility at ASU.  The images shown represent 
maximum projection overlays with the z-axis set to scan at intervals of 0.4 µm. Images were 
adjusted linearly for contrast and brightness. 
 
Hematoxylin & Eosin (H&E) staining of 3D-DTMs 
Spheroidal 3D-DTMs, approximately 1 mm in the longest dimension, were collected by manual 
manipulation of a fire-polished glass pipette and subjected to several washes with PBS. The 
specimens were subsequently fixed overnight in freshly prepared Bouin’s fluid (75% saturated 
solution of picric acid, 5% glacial acetic acid in neutral-buffered formalin (pH 7.0) at 4°C with 
gentle agitation. Fixed specimens were dehydrated through graded ethanol series and embedded 
in Paraplast+. Serial 10 µm thick sections were collected on glass slides and incubated at 42°C 
overnight. Paraffin was removed with histology-grade toluene, and the slides were rehydrated 
through an ethanol series in Coplin jars, and washed for 5 minutes in Barnstead Nanopure filtered 
water (resistance of 18.2 MΩ). Basophilic elements (e.g. nuclei) of the cells were stained using 
Mayer’s hematoxylin for 15 minutes at room temperature followed by 20 minutes in running tap 
water. The samples were counterstained with eosin for 5 minutes and incubated through 
increasing graded ethanol series. Slides were briefly transitioned from ethanol to toluene and 
incubated in 100% toluene for 2 minutes. Drops (approximately 15 µL) of Permount served to 
mount glass cover slips permanently. The slides were dried in a chemical hood overnight and 
imaged with a Nikon inverted microscope fitted with an Olympus DP26 color camera housed in 
the W.M. Keck Bioimaging Facility at ASU. 
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Cell cycle analyses 
Following five days of incubation on AM3, 3D-DTMs of T24 cells with NIH3T3 murine fibroblast 
cells were harvested for cell cycle analysis. Four or five individual 3D-DTMs of T24 cells alone or 
UMUC3 cells alone were harvested on the 7th day after seeding on Amikagels, collected in an 
eppendorf tube. 50 µL of 5 mg/ml collagenase was added to 3D-DTMs prepared using fibroblast 
helper cells for 30 minutes at 37°C in order to facilitate their disassembly by gentle pipetting. 
Single cell 3D-DTMs were disassembled using manual pipetting. Disassembled 3D-DTM cells 
were then centrifuged at 200 r.c.f. in order to collect the cell pellet. The pellet was resuspended in 
a solution of 1% v/v 1X Triton-X, 5% (v/v) fetal bovine serum (FBS), 50 µg/mL propidium iodide, 
and 0.006-0.01 units/mL ribonuclease A. After incubation for 30 minutes on ice, cells were 
analyzed for their cell cycle profiles using flow cytometry; the propidum iodide (PI) signal was 
detected using an excitation at 535 nm and emission at 617 nm. Voltages of the FL2-A, SSC and 
FSC channels were adjusted in order to obtain best representative peaks for alignment of 2n 
(diploidy – G0/G1) peak to 200 intensity units during flow cytometry. FL2A (FL2-Area) provides 
the information regarding the pulse area of the emitted fluorescence signal (total cell 
fluorescence) whereas SSC and FSC provide the information regarding the forward scatter and 
the side scatter light from the sample. FSC is a measure of diffracted light from the sample 
proportional to cell surface area or size and SSC is proportional to cell granularity or internal 
complexity.  
 
Investigation of Chemotherapeutic Drug Efficacy on 3D-DTM Viability 
Different concentrations (12.5, 25, 50 and 100 µM) of the anticancer drugs docetaxel, (10-40 µM) 
mitoxantrone, or (250-500 µM) thioTEPA were added to 3D-DTMs formed after 5-7 days of initial 
cell seeding on Amikagel. Drugs were added to 3D-DTMs of T24 cells co-cultured with NIH3T3 
murine fibroblasts on day 5, but added to 3D-DTMs of T24 cells alone on day 7 due to the 
different times required for their formation. After 96 hours of drug exposure, T24 3D-DTMs were 
disassembled using manual pipetting. Co-culture 3D-DTMs were disassembled using 50 µl of 5 
mg/ml collagenase for 20 minutes and cell viability was assessed by Live/Dead® staining followed 
28 
by flow cytometry. 3D-DTM viability was also measured using MTT/XTT assay as described 
previously 105.  
 
Statistical Analyses 
Averages have been expressed as mean ± SD. Two-tailed t-test with 95% CI was used analyze 
and compare the percent cell death data of individual drugs. One-way ANOVA has been used to 
study the differences between the effectiveness of multiple drugs and their combinations. Tukey’s 
multiple comparisons test was used during multiple pairwise comparisons whereas Dunnett’s 
multiple comparisons test was used while comparing multiple means to a single one (control). 
p<0.05 indicated significance in the analyses. All analyses were performed using the Prism 
GraphPad software. All experiments have been performed at least n=2 independent experiments 
with three replicates each unless specified. 
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2.3. RESULTS AND DISCUSSION 
Amikagel formation and characterization 
Reaction of amines, present in the aminoglycoside amikacin, with epoxides in the PEGDE cross-
linker resulted in the formation of a new hydrogel, ‘Amikagel’ (Fig. 2-1 (i)) that underwent a sol-
gel transition upon incubation at 40oC (Fig. 2-1 (ii), A-B). Of particular interest was the presence 
of an aliphatic primary amine in amikacin which can be cross-linked rapidly. In addition, the 
presence of multiple sugar groups in Amikacin along with the cross-linker poly (ethylene glycol) 
(PEG) was hypothesized to yield biocompatible hydrogels. The epoxide groups of PEGDE upon 
reaction with amines of amikacin formed covalent bonds among adjacent aminoglycoside 
molecules,  thus generating a cross-linked hydrogel network that underwent a sol-gel transition at 
40oC (Fig. 2-1 (ii), A-B). Three chemo-mechanically different Amikagels (AM1, AM2 and AM3) 
were prepared by varying the mole ratios of the monomers; amikacin and PEGDE. Fig. 2-1 
shows the synthesis procedure, and Table 2-1 shows different hydrogel compositions, AM1, 
AM2, and AM3, generated. 
 
Table 2-1. Stoichiometric amounts of Amikacin Hydrate (AH) and Poly (ethylene glycol) 
diglycidyl ether (PEGDE) used in preparation of different Amikagels. 
Amikagel Composition 
Amikagel Mole Ratio (AH: PEGDE) 
AM1 1:1.5 
AM2 1:2 
AM3 1:3 
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Figure 2-1. Schematic of Amikagel formation. (i) Amikacin hydrate and poly (ethylene glycol) 
diglycidyl ether (PEGDE) were reacted in nanopure water at room temperature. (ii). Characteristic 
(A) sol to (B) gel transition of Amikagel at 40° C after 7.5 h of incubation. (C) Amikagel held 
between fingers.  
 
Fig. 2-2 shows the time required for formation of Amikagels AM1, AM2 and AM3 as a 
function of temperature. The time required for gelation at a given temperature, decreases as the 
amount of PEGDE increases (i.e. AM 3 ~ AM 2 < AM 1). In addition, as the gelation temperature 
was increased, the time required for gelation reduced indicating a temperature controllable 
Amikagel formation process. At the highest temperature tested of 75oC, complete gelation was 
achieved within 20 minutes for all the three gels. As the temperature increases, the rate of 
reaction between the epoxide groups of PEGDE and amine groups of amikacin moieties are likely 
to react rapidly leading to faster gelation. Similarly, higher amount of the crosslinker will allow for 
faster crosslinking between the PEGDE and the amikacin groups leading to faster gelation.   
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Figure 2-2. Temperature dependent kinetics of Amikagel gelation.  At higher temperatures 
(60oC and 75oC) there was no significant difference recorded for the time required for gelation 
between AM1, 2 and 3 Amikagels. At 37oC, AM2 and AM3 amikagels were found to gel before 
AM1 gel (p-value < 0.01). 
 
FT-IR spectra of Amikagel AM3 was recorded immediately after mixing the monomers 
(t=0) and after completion of cross-linking (t=7.5 hours) of the monomers at 40°C (Fig. 2-3). 
Epoxide specific stretch peaks were seen in the range of 860-950 cm-1 in the spectra at t=0, 
measured immediately after mixing the monomers. However, the epoxide peaks largely 
disappeared in the Amikagel hydrogel (t=7.5h), indicating the consumption of epoxide groups 
during hydrogel formation.  In addition, a large number of secondary amines formed due to the 
ring-opening reaction between amines and epoxides, were seen at t=7.5h (secondary amine 
specific stretch peaks at 2873 cm-1). The hydrogel also showed a broad absorption band from 
3024-3756 cm-1, indicating presence of a large number of hydroxyl groups (3552 cm-1) and 
primary amines NH2 (3336 cm-1). A strong twin peak at 1351 cm-1 confirmed the presence of 
ether links in the hydrogel, while the band at 1103 cm-1 was indicative of the glycosidic linkage 
(C-O-C) present in amikacin. Carbonyl group stretching is indicated by the peak at 1656 cm-1 and 
the absorption band indicative of the -CH2-CH2-O- moiety of PEG was seen around 2956 cm-1. 
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Taken together, FT-IR studies show consumption of epoxides and generation of secondary 
amines during hydrogel formation, thus confirming the formation of cross-linked network between 
amikacin and PEGDE. 
 
 
Figure 2-3. FT-IR spectrum of freeze-dried Amikagel (AM3). FT-IR spectrum at (A) initial (t=0) 
and (B) after (t=7.5 hr) incubation at 40° C temperature.  
 
Optical transparency to visible light (wavelengths – 400-700 nm) of Amikagel AM3 was 
investigated to identify the wavelengths of light that may not be used in for bio-imaging studies on 
the gel. The absorbance profiles of amikagels show these hydrogels were as optically transparent 
as empty plastic well of 2D tissue culture 96 well plate (Fig. 2-4). Absorbance peaks of both 
amikacin and PEGDE lie majorly in UV regions of 250-400 nm, with minimal absorbance in the 
visible light region, making the gel optically transparent for bio-imaging applications such as 
confocal microscopy, fluorescence imaging, live cell imaging etc 106-107.  
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Figure 2-4. Absorbance of AM3 Amikagel. AM3 Amikagel showed minimal absorbance in the 
visible light region indicating its easy use in multiple fluorescent bioimaging applications.  
 
Amikagel Material Properties 
Amikagels AM1, AM2 and AM3 were characterized for complex modulus (rheological 
characterization), swelling ratios, hydrophilicity, inner crosslinking, surface morphology and 
adhesivity to elucidate different properties of the novel material. 
 
High Throughput Device for Amikagel Generation For Parallel Plate Rheological 
Measurements 
The storage modulus (G') and loss modulus (G") of chemically cross-linked Amikagels were 
determined using oscillatory rheology experiments at room temperature using the parallel plate 
AR-G2 rheometer. In order to create circular gel discs in high-throughput that match the 
dimension of upper parallel plate (8 mm) (recommended), a novel high-throughput device was 
designed. Traditional techniques using cylindrical wells castings, test tubes or syringes etc to 
generate the discs largely suffer from non-reproducibility and are not high-throughput. 
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We developed three generations of acrylic devices that housed gaps within them for 
gelation. The first and second generation devices did not generate easy recoverable gel discs 
(Fig. 2-5A). For example, the second-generation device contained cavities could be filled up with 
pre-gel solution, leading to in-situ gelation (Fig. 2-5B). Although the gelation was satisfactory, the 
recovery of columns from the device proved tricky. Second-generation acrylic design was 
plagued with issues of less recovery of fully formed Amikagel discs. Learning from the previous 
two generations, we designed the third generation of acrylic geometry (Fig. 2-5 C-F), which 
showed very high success in high throughput Amikagel generation.  
Third generation acrylic designs consisted of two mirror pieces with semi-circular teeth 
(diameter - 0.8 cm) that could be linked to each other to generate one unit (Fig. 2-5 C-F). Both 
cylindrical pieces were wrapped with a layer of paraffin film for easy assembly and disassembly. 
One of the flat sides of the device was covered with paraffin film to prevent any leakage.  The 
cylindrical gap created by assembling the unit was filled with Amikagel pre-gel solution for 
gelation. After gelation, the recovery of gels was found to be very easy. One of the greatest 
strengths of this device was the incorporation of the central break-line that can dissociate the 
pieces of the device after the gel is formed very easily. Usage of parafilm also ensured minimal 
adhesion of the gel with the film. The gels tended to stay unbroken during their recovery and were 
directly used for rheological studies. This third generation acrylic design was found to be far 
superior compared to other two previous generations in its ease of use and the reproducibility for 
Amikagel production. The entire method was tested by at least two/three independent operators 
across more than 50 independent experiments (n>50). 
Additional design insets were created to increase the throughput of the device (Fig. 2-5 
E-F). As shown in (Fig. 2-5 E-F), multiple additional insets were developed to add to the existing 
device. The insets have semi-circular teeth on both sides and can be joined in between the two 
end pieces of the existing device. These insets were greatly able to increase the throughput of 
the device.  
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Figure 2-5. High throughput device for Amikagel generation. (A) First (B) Second (C-D) Third 
generation acrylic designs for high-throughput Amikagel generation. Third generation of the 
acrylic was found to be the ideal for the gel recovery after gelation. Mirror pieces of acrylic 
geometries with semicircular teeth were combined to form a central circular gap to allow for pre-
gel to gel formation. (E-F) Insets to increase the throughput of the device are shown. These 
insets have semi-circular teeth on both sides and attach to the end pieces to increase the 
throughput/device. 
 
 
Rheological Analysis Of Amikagels 
|G*| values of Amikagels (AM1, AM2 and AM3) depended on the mole ratio of Amikacin: PEGDE 
added to form the hydrogel. Amikagels AM1, AM2 and AM3 possessed material stiffness (|G*|) of 
17 kPa, 84 kPa, and 135 kPa when dehydrated, and 36 kPa, 140 kPa and 215 kPa, when fully 
hydrated (Fig. 2-6). In all cases, the absolute shear modulus was noted to significantly increase 
after complete hydration of the gels (p<0.05, two-sided student’s t-test). It is likely that the water 
forms additional bonds within the crosslinked hydrogel structure, thus introducing new nodes to 
store elastic energy. This could lead to increase in the absolute shear modulus of the gel after 
hydration.  
Amikagels showed higher values of G' (storage modulus) compared to G′′ (loss modulus) 
and exhibited a loss angle (δ) ~ 1, indicating that Amikagels are predominantly elastic (δ ~ 0o) 
A.    B.      C. 
 
D.         E.          F. 
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and not viscous (δ ~ 90o) in nature. As the amount of PEGDE relative to Amikacin increased, the 
absolute shear modulus (|G*|) of the gels increased (AM3>AM2>AM1). Higher amounts of 
PEGDE likely resulted in higher cross-linked gels, increase in degree of cross-linking, which, in 
turn, caused the increase in their mechanical stiffness due to increase in the nodes available for 
storage of elastic energy.   
 
Fig. 2-6.  Absolute shear modulus measurement of wet and dry Amikagels. |G*| absolute 
shear modulus (material mechanical stiffness) of AM1, AM2 and AM3 amikagels before (dry) and 
after (wet) hydration respectively. 
 
 
Other Structural Properties Of Amikagels 
Macroscopic surface morphology and microscopic inner cross-linked networks of Amikagels were 
studied using Field Emission Scanning Electron Microscopy (FE-SEM). As expected, the PEGDE 
content and degree of cross-linking had a significant impact on both surface and interior 
morphology of Amikagels. The folding on the hydrogel surface, as shown in Fig. 2-7A, increased 
with increase in the degree of cross-linking. AM1 Amikagel had a predominantly smooth surface, 
which increasingly turned into grooves and ridges as the PEGDE content increased. Internally, as 
the PEGDE content and degree of cross-linking increased, the pore sizes of the fractured 
Amikagels decreased (Fig. 2-7B) (AM3>AM2>AM1). Increase in degree of cross-linking between 
adjacent aminoglycoside molecules could have directly led to the reduced pore sizes and a stiffer 
hydrogel.  
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Figure 2-7: Characterization of Amikagels using electron microscopy and swelling studies. 
Scanning Electron Microscopy (SEM) images of (A) different Amikagel surfaces, and (B) 
fractured Amikagels. (C) Swelling ratios of Amikagels after 48 h incubation at room temperature 
in Nanopure water. Lower crosslinking ratios led to higher swelling of the Amikagels, likely due to 
porous crosslinks, which could absorb water to swell up.  
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Amikagels 1, 2 and 3 exhibited swelling ratios of 16.7, 6.4, and 3.7, respectively (Fig. 2-
7C) which is similar to other PEG crosslinked hydrogels 108. Swelling ratios depended on the 
degree of cross-linking in the hydrogel network; as the degree of cross-linking increased, the 
swelling ratios decreased. It is likely that as the degree of cross-linking increases, gel strength 
increases due to the extensive crosslinks and rigidity of the network, which, in turn, prevents the 
gel from swelling. Increased porosity of AM1 hydrogel could have aided in increased water 
absorption and retention after hydration, thus increasing its swelling ratio.  
Next, we carried out contact angle measurements on dehydrated Amikagels in order to 
investigate the hydrophilicity and wettability of the surface. Contact angles (θ) of Amikagels AM1, 
AM2 and AM3 were found to be 52.2 ± 1.1o, 54.4 ± 2.9o and 48.01 ± 4.0o respectively, indicating 
an overall hydrophilic gel surface. Contact angle (θ) of less than 90o is considered a hydrophilic 
surface whereas beyond 90o constitutes a hydrophobic one 109. Hydrophilicity of the surface did 
not change with respect to the amount of PEGDE crosslinker used. As amines, hydroxyls and the 
glycol units together contribute to the hydrophilicity, lowering the amount of one of them could be 
compensated by another.  
Presence of poly(ethylene glycol) as a cross-linker imparted Amikagels with 
hydrophilicity, biocompatibility and was hypothesized to provide a non-adherent surface too. 
Polyethylene glycol rich surfaces are known to be non-adhesive 110. The surface adhesivity of  
Amikagels were observed by introducing bladder cancer and prostate stromal cells on to the 
surface. Upon introduction of cells to AM3 Amikagel surface, cells attained a rounded morphology 
and self-assembled into 3D spheroidal tumor microenvironments (3DTMs), indicative of minimal 
attachment to the surface. Cell spreading was noticed on AM1 and 2 amikagels (Fig. 2-8 A and 
B). Increased PEG content along with higher mechanical stiffness in AM3 hydrogels could be 
attributed to the non-adhesivity of AM3’s surface. Cell spreading on AM1 and AM2 hydrogels 
could be attributed to their higher number of unreacted surface primary amines along with lower 
PEG content (Fig. 2-8 A and B). Non-attachment of cells to AM3 surface was hypothesized to 
promote and generate self-assembled cellular masses that could capture tumor micro-
environmental intricacies useful in multiple biological studies. 
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Figure. 2-8. Adhesion of mammalian cells on chemo-mechanically tuned Amikagels. (A) 
T24 bladder cancer cells and (B) WPMY-1 prostate stromal fibroblasts were cultured on 
Amikagels of different compositions with varied surface adhesive properties.  Notice the 
elongated cellular appendages on AM1 and AM2 Amikagels that seem absent on cells cultured 
on AM3 Amikagel imaged after 24 hours of culture. Scale Bar: 100 µm. 
 
Formation of Three-Dimensional Tumor Microenvironments (3DTMs) on Amikagels 
Prostate, bladder, breast, or pancreatic cancer cells, when cultured either alone or together with 
stromal / stellate / fibroblast cells on AM3 resulted in the formation of a single spheroidal 3DTM in 
every well (Fig. 2-9 A-C), likely facilitated by the high mechanical stiffness and non-adhesivity of 
the hydrogel.  
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A. 
    
B.  
 
C.  
 
Figure 2-9. High-throughput generation of 3D tumor microenvironments on Amikagel.  (A) 
High-throughput generation of 3D tumor microenvironments (3DTMs) on AM3 Amikagel; the 
3DTM (0.8-1mm diameter) can be visualized using the naked eye. (B) Phase-contrast and 
fluorescence (Live-Dead®) images of breast, and bladder cancer 3DTMs. Scale bar = 100 µm. (C) 
Representative phase-contrast image of high-throughput generation of T24 3DTMs in 24 wells 
coated with AM3. Formation of ‘one well-one 3DTM’, with near-uniform sized 3DTMs, can be 
seen after 7 days of initial seeding. Scale bar = 100 µm.  
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Live/dead® staining of the 3DTMs generated using NIH3T3 murine fibroblasts / Bj5ta 
human foreskin fibroblasts indicated an outer green (viable) ‘ring’ with an inner red (dead / dying) 
core, indicating a metabolically active and viable outer shell of cells, along with a stressed inner 
core of cells (Fig. 2-9B i, iii and v). Co-cultures of cancer cells with helper fibroblast cells often 
resulted in a live outer shell (intracellular calcein fluorescence) with a stressed core (red staining 
due to ethidium homodimer binding the extracellular DNA), likely due to hypoxia and necrosis in 
the core of the 3DTMs (Fig. 2-9B i, iii and v). Big size of the 3DTMs (<400 µm diameter) with 
dense ECM production due to presence of fibroblast cells could lead to difficulties in nutrient and 
metabolite entry and gas exchange resulting in a necrotic phenotype in the center of the 
spheroids 7, 111. However, 3DTMs generated using T24 cells/WPMY-1 cells alone did not show 
prominent red-staining in the core, indicating differential biochemical consequences depending on 
the cells employed (Fig. 2-9B ii and iv). Single cell 3DTMs generated using T24 bladder cancer 
cells also did not show any signs of stressed interior (Fig. 2-9B ii) absence of NIH3T3 fibroblasts 
and dense accompanying ECM. The size of 3DTMs was modulated by seeding different cell 
densities on AM3; the longest dimension of the 3DTMs could be tailored from ~300 µm to ~1200 
µm with increasing cell density (Fig. 2-10).  
 
 
Figure 2-10. 3D-DTM characterization. Control of 3DTM size by using different cell seeding 
densities per well in a 96-well plate coated with AM3. Scale bar = 100 µm. 
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Co-culture of PC3-EGFP (PC3 human prostate cancer cells constitutively expressing 
GFP) along with red-fluorescent quantum dot loaded NIH3T3 fibroblasts indicated that both, 
cancer cells and stromal cells were present throughout the 3DTM after proper mixing (Fig. 2-11).  
 
 
Figure 2-11. Distribution of cells in a co-culture system. Quantum Dot (QD)-loaded NIH3T3 
fibroblasts and PC3-EGFP (EGFP expressing prostate cancer cells) co-culture 3DTM on AM3. 
(A) Phase contrast image, (B) GFP emission of PC3-EGFP prostate cancer cells, (C) dsRED 
emission from QD-loaded fibroblastss (D) Overlay. Scale =100 µm.  
 
The simplicity and fidelity of the Amikagel platform are significant advantages over other 
more complicated methods including suspension cultures using microcarrier beads in rotating 
wall bioreactors 112 or shaker systems 22 which typically result in the formation of heterogeneous 
spheroid populations. 
 
Effect of Amikagel chemo-mechanical properties on 3DTM formation  
Mechanical strength, non-adhesivity and surface functionalization can have significant impact on 
the formation and fate of in vitro tumor models 113. As shown Fig. 2-9B, T24 cells and NIH3T3-
T24 co-culture systems formed single 3DTMs when cultured on Amikagel AM3. Of the three 
Amikagels, AM3 possesses the highest mechanical stiffness and lowest cell adhesivity (Table 2-
1) due to the highest degree of cross-linking. Kinetics of 3DTM formation on Amikagels was 
studied by imaging cells at regular intervals following seeding. T24 bladder cancer cells first 
formed a freely floating cell sheet, approximately 1-2 cells thick, within the first two days of culture 
on AM3 Amikagel. The cell sheet subsequently folded upon itself resulting in the formation of a 
single 3DTM in an individual well (Fig. 2-12 and 2-13). It is likely that the shape of the meniscus 
affects the shape of 3DTM formation leading to differences in the final 3DTM shape. Mechanical 
stiffness of the hydrogel and the shape of the hydrogel groove have been shown to influence the 
spheroid shape 113-114.  
	 a b c d
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Figure 2-12. Kinetics of formation of T24 3DTMs on AM3 Amikagel. T24 cells formed a cell-
sheet, which slowly folded upon itself to give rise to a condensed 3DTM.  
 
Stromal cells significantly enhanced the kinetics of 3DTM formation; for example, the 
NIH3T3 murine fibroblast cells -T24 co-culture system formed 3DTMs in 3 days while T24 cells 
formed 3DTMs over 7 days in absence of stromal cells (Fig. 2-13). It is likely that stromal cell-
epithelial cell interactions, in presence of the non-adhesive AM3 Amikagel, facilitate faster 
formation of 3DTMs compared to T24 cells by themselves. The lower mechanical strengths and 
higher cellular adhesivities of AM1 Amikagels (Fig. 2-13) resulted in the formation of multiple 
smaller 3DTMs in contrast to 3DTM formation on AM3 Amikagels under conditions of equal cell 
seeding densities (Fig. 2-13). T24 cells assembled into micro-colonies (~100 µm diameter) on 
day 4-5 (Fig. 2-13). Addition of NIH3T3-cells to the mixture also formed small micro-clusters, 
which were noted to merge on day 4 (Fig. 2-13I). Gildea et al. found that metastatic fraction of 
T24 cells formed small microcolonies on soft agar gels and hypothesized a role of paracrine 
signaling inducing the microcolony formation 47. It is likely that a similar mechanism could be 
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involved in the microcolonies observed in the AM1 gel where the metastatic fraction of cell 
population induces the formation of the microcolonies on the AM1 gel.  
 
Figure 2-13. Effect of Amikagel chemo-mechanical properties on T24 and NIH3T3-T24 co-
culture 3DTM formation. Scale bar = 100 µm. On AM1 Amikagel, T24 cells (A-C) and NIH3T3-
T24 cells (G-I) formed micro-clusters (Average longest dimension: 112 ± 34 µm) whereas larger 
3DTMs can be seen on AM3 Amikagel in both cases. Micro-clusters of NIH3T3-T24 cells were 
noted to merge on day 4, unlike T24 cells alone. 
 
Cell Cycle Profile of 3DTMs 
Arrest of cells in the G0/G1 phase of the cell cycle is a key characteristic feature of tumor 
dormancy 32, and is responsible for resistance to chemotherapeutics that are typically effective 
against rapidly dividing cells. Cell cycle analyses indicated the formation of viable fully dormant 
3D T24 bladder cancer microenvironments (called ‘3D-DTMs’ hereafter) on AM3; ~95% of the cell 
population was arrested in the G0/G1 phase of the cell cycle (Table 2-2 and Fig. 2-14 A-B).  
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Table 2-2. Cell cycle analysis of 2D cell cultures vs. 3D-DTMs (3D dormant tumor 
microenvironments) for different bladder cancer cell lines as individual and co-cultures.  
 
 
**  Indicates p<0.0001 for cell population in the G0/G1 phase of the cell cycle for T24 and 
UMUC3 3D-DTMs compared to their corresponding 2D cultures, respectively. Statistical 
significance determined using Student’s t-test of at least n=3 independent experiments. 
 
 
This is in stark contrast to the cell cycle profile of 2D culture of T24 cells in which ~54% 
cells were in the G0/G1 phase of the cell cycle (Table 2-2 and Fig. 2-14 A-B). T24 cells 
transitional cell carcinoma of bladder origin 48. Transitional cells line the outer epithelium of the 
bladder and serve as the outermost layer of cells that are directly in contact with the urine 115. 
Being epithelial in origin, the healthy non-cancerous transitional cells are terminally differentiated, 
epithelial in origin and express E-cadherin as a intercellular marker 116-117. The switch of these 
outer bladder epithelial cells into bladder transitional cancer cell phenotype is very often 
associated switch and transition from epithelial to mesenchymal phenotype (EMT). Specifically,  
EMT of bladder is associated with downregulation of epithelial marker E-cadherin and 
upregulation of mesenchymal marker N-cadherin 54-55, 58, 118. N-cadherin is a widely accepted 
intercellular marker that represents the EMT, metastases from primary cancer site and is usually 
constitutes poor prognosis for the patient 58. T24 cells are known to be E-cadherin null with high 
Cell line Cell cycle 
phase 
2D culture 3D-DTMs 
T24 bladder  
3D-DTMs 
M1 (G1/G0) 54 ± 2 % 95 ± 3 % (**) 
M2 (S) 17 ± 2 % 2 ± 1 % 
M3 (G2/M) 28 ± 3 % 3 ± 2 % 
UMUC3 bladder 
3D-DTMs 
M1 (G1/G0) 57 ± 1 % 68 ± 4 % (**) 
M2 (S) 15 ± 1 % 2 ± 1 % 
M3 (G2/M) 19 ± 1 % 10 ± 3 % 
NIH3T3-T24  
Co-culture  
3D-DTMs 
M1 (G1/G0) -- 82 ± 2 % 
M2 (S) -- 11 ± 4 % 
M3 (G2/M) -- 4 ± 1 % 
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expression of N-cadherin cell surface marker 54, 118.  However, they have been shown to be very 
heterogenous in their metastatic ability 48, 50. Multiple researchers have shown T24 cells to 
contain heterogenous population of metastatic and non-metastatic cell fractions 47-48. T24 cells 
are known to be contact inhibited 39, and aggregation of cells within the 3DTM likely mimics this. 
Previous research has shown presence of p27 CDK inhibitor in the T24 cells, that reduces it 
tumorigenicity in mice 39. Separately, dense surface expression of N-cadherin has been directly 
linked to increase in hypophosphorylated pRb levels leading to accumulation of p27 CDK inhibitor 
via lower ubiquitination and cell cycle arrest in G1 phase in confluent cultures of CHO cells. It is 
likely that a very similar mechanism of cell cycle arrest is active in N-cadherin rich T24 cells 119. 
Capturing tumor dormancy in high-throughput is very significant as it can allow for large scale 
rational drug discovery, delivery and further development.  
UMUC3 human bladder cancer cells also demonstrated the formation of 3D-DTMs that 
were arrested in the G0/G1 phase, although the extent was not as high as in T24 cells (Table 2-2 
and Fig. 2-14 C-D). Co-culture of NIH3T3 and T24 cells formed 3DTMs with a majority of the cell 
population arrested in G0/G1 and S phases of the cell cycle indicating dormancy (Table 2-2). A 
modest amount of cell apoptosis was seen in the case of UMUC3 cells, which is likely possible 
since high mechanical stress and non adhesivity of the substrate promote have been shown to 
lead to cell cycle arrest 42 and death in some cases 113. Consistent with cell cycle arrest, T24 3D-
DTMs also demonstrated significantly reduced media (nutrient) consumption compared to actively 
dividing T24 cells, further indicating their dormant nature (Fig. 2-14E).  
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E. Reduced metabolite consumption of T24 3D-DTMs compared to actively dividing T24 
cells.  
 
Figure 2-14. Cell cycle distribution - Cell cycle analysis of (A) 2D culture vs. (B) 3D-DTM for 
T24 human bladder cancer cells and (C) 2D culture vs. (D) 3D-DTM for UMUC3 human bladder 
cancer cells. ** indicates p<0.0001 for cell population in the G0/G1 phase of the cell cycle for T24 
and UMUC3 3D-DTMs compared to their corresponding 2D cultures, respectively. (n=3, 
independent experiments). Statistical significance determined using Student’s t-test. (E) Reduced 
metabolic (media) consumption was observed in case of T24 3D-DTMs compared to that in case 
of actively proliferating 2D culture. Cell culture media on the 3D-DTMs did not significantly 
change color or pH after 48 hours of cell seeding. 
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The propensity for 3D-DTM formation on agarose and Matrigel® was investigated since 
these substrates are commonly used in 3D cell culture. The mechanical properties of 1% and 
10% agarose gels were comparable to those of AM1 and AM3, respectively (Fig. 2-15A).  
 
A.      B. 
  
C.   1% agarose gels      10% agarose gels D. 
     
 
Figure 2-15. T24 cells on Agarose (comparison with Amikagels). (A) Absolute shear modulus 
of 1% and 10% agarose gel was determined to be similar to that of AM1 and AM3 gels 
respectively. (B) T24 spheroid formation was seen to occur only on AM3 and 1% agarose gels. 
(C) Phase contrast image of T24 cells on 1% and 10% agarose gels respectively after 7 days of 
culture. Scale = 100 µm (D) Cell cycle distribution of T24 cells on agarose gels (1% and 10% 
gels) after 7 days of culture. AM3 was better in inducing complete dormancy in T24 cells 
compared to 10% agarose.  
 
Extensive cell death was seen on 10% agarose gels which demonstrate high mechanical 
stiffness, while a single spheroid was seen on 1% agarose gels whose mechanical stiffness was 
similar to that of AM1 Amikagels (Fig. 2-15 B-C). However, in contrast to the extensive (~95%) 
arrest of T24 cells in the G0/G1 phase of the cell cycle on AM3, only ~70% T24 cells were seen 
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in the G0/G1 phase on 1% agarose gels (Fig. 2-15 D). Other 3D culture methods have shown 
~70% cells in the G0/G1 phase of the cell cycle, which is not representative of complete arrest 36. 
T24 cells cultured on formed multiple clusters with invasive protrusions on Matrigel®, and induced 
a change in media color which was indicative of active growth and proliferation (Fig. 2-16) and 
not arrest. Increasing evidence points towards a definitive phase of quiescence (prolonged G0/G1 
arrest) rather than balanced proliferation to support prolonged viability before relapse 27.  To our 
knowledge, the Amikagel platform is the first of its kind that results in a single, near-total dormant 
3D-DTMs in vitro.  
 
 
Figure 2-16. T24 cells on Matrigel (comparison with Amikagels). 25,000 T24 cells on Matrigel 
after 7 days of seeding were seen attached to the surface. Scale = 100 µm. Cell culture media 
after 48 hours of 25,000 T24 cell culture on Matrigel was seen to be yellowish indicating active 
consumption and metabolism unlike T24 3D-DTMs.  
 
Morphological and Biochemical Characterization of 3D-DTMs. Scanning electron 
microscopy (SEM) of fibroblast-cancer cell co-culture 3D-DTMs showed a compact 3D-DTM 
which contained fibrous structures, which are formed likely due to deposition of extracellular 
matrix (ECM) by the fibroblasts (Fig. 2-17 A-B) 120-121.  
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Figure 2-17. NIH3T3-T24 3D-DTM characterization - SEM and H&E staining  (A) Scanning 
Electron Microscopy (SEM) images of (i-v) NIH3T3-T24 co-culture 3D-DTMs. Images ii-v show 
NIH3T3-T24 3D-DTM at higher magnifications, with most cells showing a rounded morphology. 
NIH3T3-T24 3D-DTMs were covered with fibrous material indicative of extracellular matrix (ECM) 
formation (red arrows). (B) Hematoxylin and Eosin (H&E) staining of 3DTMs: NIH3T3-T24 3D-
DTM.  Scale = 100 µm and insets (i- central necrotic core, ii-middle densely packed cells and iii-
outer loosely packed cells) Scale = 20 µm. Yellow pointers indicate condensed nuclei indicative of 
pyknosis.  
 
In contrast, 3D-DTMs of T24 cells alone did not show presence of significant amounts of 
fibrous structures (Fig. 2-18 A(i-iii)). The ability to generate ECM in 3D cell systems is important 
since cancer cell-stromal cell interactions are known to play a critical role in the local tumor 
microenvironment 122. 
A.        B. 
 
Figure 2-18. T24 3D-DTM characterization - SEM and H&E staining  (A) Scanning Electron 
Microscopy (SEM) images of (i-iii) T24 3D-DTMs. Images ii, iii and iv show rounded cell 
morphology of T24 3D-DTM. (B) Hematoxylin and Eosin (H&E) staining of T24 3D-DTM, 
indicated minimal to no necrotic areas unlike NIH3T3-T24 3D-DTMs. Scale bar =  (i) 100 µm and 
(ii and iii) 50 µm. 
 
Hematoxylin and eosin (H&E) staining of NIH3T3-T24 3D-DTMs indicated the presence 
of three distinct regions: loosely packed cells in the periphery, densely packed cells in the middle, 
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and a necrotic region in the middle that showed prominent nuclear blebbing and absence of 
distinct cellular boundaries (Fig. 2-14B, i-iv). Presence of a necrotic core due to hypoxia and 
nutrient deprivation is common in tumors, and has been reported in spheroids greater than 400-
500 µm in diameter 7. Presence of a necrotic core in NIH3T3-T24 3D-DTM could also be a result 
of the dense ECM  formed (Fig. 2-17 A-B (i-iv)) 123. Unlike NIH3T3-T24 3D-DTMs, T24 3D-DTMs 
by themselves did not demonstrate significant ECM like fibres and a distinct necrotic core region 
(Fig. 2-18A-B (i-iii)). It is likely that lower ECM deposition in T24 3D-DTMs is responsible for 
easier access of nutrients throughout the spheroid. H&E staining results also were consistent with 
Live/Dead® staining of 3D-DTMs which indicated that the outer cell layers were actively 
proliferating while inner cell layers were metabolically inactive / stressed in co-culture 3D-DTMs 
(Fig. 2-9B); however, T24 3D-DTMs without fibroblasts did not show predominant dead regions in 
the core. (Fig. 2-9B). Actin staining of 40 µm thick T24 3D-DTM cryosections (Fig. 2-19) 
indicated that F-actin (red stain) localized along the intracellular cortical regions. Unlike 2D cell 
cultures, where cellular F-actin stress fibers support strong cell-substratum interactions 124, 
localization of F-actin filaments in the cellular cortex in T24 3D-DTMs indicate increased cell-cell 
interactions, rather than cell-substratum interactions, leading to cell cycle arrest. 
 
 
Figure 2-19. Actin staining of T24 3D-DTMs - Actin staining on sections of T24 3D-DTM. Red: 
Phalloidin-Alexa 548 stained actin, Blue: DAPI. Scale = 20 µm.  Note: The distribution of actin is 
cortical in T24 3D-DTMs. 
 
T24 3D-DTM 
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We also tested the presence of cell-cell intercellular contacts in T24 3D-DTMs using 
EDTA calcium chelation and removal. Integrins and cadherins require calcium for their effective 
functioning and calcium removal from media would cause these integrins and cadherins to fail, 
leading to instant cell dissociation. Upon addition of 4 mM EDTA for 12 hours, we noticed a 
complete disassembly of the 3D-DTM, without any significant loss to the cell viability (Fig. 2-20 A-
C). T24 cells are known to be E-cadherin null, positive for N-cadherin and are known to contain  
β1 integrins. Our results using EDTA based calcium removal indicate that there are cell-cell 
interactions present (likely cadherin and integrin based) in T24 3D-DTMs and cortical presence of 
actin likely supports those interactions (Fig. 2-20).  
 
  A.    B. 
 
C. 
 
 
Figure 2-20. EDTA treatment of T24 3D-DTMs – Treatment with (A) 0 mM (representative 
image) and (B) 4 mM EDTA (representative image) for 12 hours followed by slight shaking. 
Removal of calcium by EDTA completely disassociated the T24 3D-DTM but did not change its 
viability to a large extent (C). Scale = 100 µm.  
 
	
0 mM EDTA   4 mM EDTA   
0 mM EDTA 1 mM EDTA 2 mM EDTA 4 mM EDTA
0
50
100
C
el
l v
ia
bi
lit
y 
(%
)
53 
Chemoresistance of 3D-DTMs 
T24 and NIH3T3-T24 co-culture 3D-DTMs were treated with different doses of the DNA-
damaging drug mitoxantrone 125 or microtubule-stabilizing drug docetaxel in order to investigate 
their response to conventional anticancer therapeutics 25. NIH3T3-T24 3D-DTMs were resistant 
for up to 80 µM mitoxantrone even after 96 h of treatment (Fig. 2-21 A-C).  
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Figure 2-21. Mitoxantrone delivery to NIH3T3-T24 3D-DTMs: 3D-DTM drug resistance. (A-C) 
Chemotherapeutic treatment of NIH3T3-T24 3D-DTMs using mitoxantrone. (A) Cell viability (%; 
determined using the MTT assay) after exposure of NIH3T3-T24 3D-DTM to the drug for 96 
hours. 3D-DTMs were treated with collagenase (50 µl of 5 mg/ml) prior to MTT assay to allow for 
disassembly. (B) Visualization of mitoxantrone (40 µM; false red colour; excitation: 637 nm; 
emission: 670 nm) penetration into NIH3T3-T24 3D-DTM after 24 hours of drug administration. All 
3D-DTM sections were counterstained with DAPI (false blue colour; excitation: 350 nm, emission: 
470 nm) in order to visualize cell nuclei.  Scale = 20 µm. (C) Representative image of cell cycle 
distribution of NIH3T3-T24 3D-DTMs cultured on AM3 for 5 days. Most cells were arrested in 
G0/G1 and S phase of the cell cycle, indicating probable dormancy. Table showing the percent 
distribution of cells of NIH3T3-T24 3D-DTM in different phases of the cell cycle. (D). Visualization 
of mitoxantrone (40 µM; false red colour; excitation: 637 nm; emission: 670 nm) penetration into 
NIH3T3-T24 3D-DTM after 24 hours indicates extensive penetration of the drug into the 3D-DTM. 
Scale =100 µm (E). Blank control, i.e. NIH3T3-T24 3D-DTMs not treated with mitoxantrone; 
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absence of far-red fluorescence after 24 hours is due to lack of presence of the drug. Scale =100 
µm.  
This is in striking contrast to the LC50 (dose of drug which induces loss in 50% cells) of 
mitoxantrone (9 µM) in 2D cultures of T24 cells 125. We verified that lack of cell death was not due 
to poor drug penetration into the 3D-DTM; fluorescence micrscopy indicated mitoxantrone 
localization throughout the NIH3T3-T24 3DTM in 24 hours (Fig. 2-21D), which was not seen in 
the control (Fig. 2-21E). T24 3D-DTMs were also resistant to mitoxantrone and docetaxel (Fig. 2-
22 and 2-23); treatments as high as 100 µM docetaxel induced only 10% cell death in T24 3D-
DTMs, even though LC50 values for 2D proliferating cultures were substantially lower (Fig. 2-24).  
 
Figure 2-22. Treatment of T24 3D-DTMs with mitoxantrone (A). Live/dead® staining of 
disassembled T24 3D-DTMs after 96 hours of exposure with different doses of mitoxantrone. 
Increasing the concentration of mitoxantrone did not have significant impact on the cell viability of 
T24 cells in the 3D-DTMs. Scale = 100 µm. 
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 Figure 2-23. Treatment of T24 3D-DTMs with docetaxel. Live/dead® staining of disassembled 
T24 3D-DTMs after 96 hours of exposure to different doses of docetaxel. Increasing the 
concentration of docetaxel did not have any impact on the cell viability of T24 cells in the 3D-
DTMs. Scale = 100 µm. 
 
This low sensitivity to conventional anti-proliferative chemotherapeutic drugs is a key 
hallmark of cancer dormancy. Due to the arrest of these cancer cells in the non-mitotic phases of 
cell division, the effect of docetaxel and other conventional drugs is likely minimal. Docetaxel, 
prevent cell mitosis and division by stabilizing the microtubules. Docetaxel treated microtubules 
are unable to depolymerize and hence do not  
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Figure 2-24. Docetaxel dose response on T24 3D-DTMs. Comparison of cell death (%) 
following treatment of 2D proliferating (circles) and 3D dormant (3D-DTMs) T24 cells with 
docetaxel for 96 hours. LC50 for 2D culture was ~10 µM, while T24 3D-DTMs showed very high 
resistance to docetaxel.  
 
Arrest of cells in the G0/G1 phase and negligible presence of cells in the dividing G2/M 
phase contribute significantly to the observed chemotherapeutic resistance in 3D-DTMs (Table 2-
2).  Taken together, 3D-DTMs formed on Amikagels demonstrate key hallmarks of tumor cell 
dormancy including arrest in the G0/G1 phase of the cell cycle and high resistance to anti-
proliferative chemotherapeutics. Thus, the Amikagel platform is an attractive technology for 
fundamental studies as well as identification of drugs against dormancy. 
 
2.4. CONCLUSION 
Novel aminoglycoside hydrogel (Amikagel) was prepared by crosslinking amikacin with 
crosslinker polyethylene glycol diglycidyl ether. Physico-chemical properties of Amikagel such as 
cell-substrate adhesivity, mechanical stiffness, pore size and gelation kinetics were tunable based 
on the mole ratios of the monomers used. Increasing the ratio of PEGDE to amikacin reduced the 
adhesivity of the substrate and increased its mechanical stiffness. At a ratio of 1:3, the Amikagel 
was found most suitable to generate a high-throughput spheroidal cell culture platform. Multiple 
cancer cells of prostate, pancreas, breast and bladder cancer were seen to form spheroidal 
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3DTMs with or without the help of additional helper fibroblast or stellate or stromal cells. T24 
bladder cancer cells generated dormant 3DTMs, were completely arrested in G0/G1 phase of cell 
cycle, were highly viable and were produced in high-throughput on Amikagels with high-fidelity. 
NIH3T3-T24 co-culture 3D-DTM generated on Amikagels were seen to produce abundant fibrous 
like structures likely ECM with necrotic core due to limitations in nutrient transfer and metabolite 
transfer. Due to their dormant phenotype, the 3D-DTMs generated on Amikagels were seen to be 
very resistant to conventional anticancer drugs such as mitoxantrone and docetaxel. Our platform 
provides a novel chemo-mechanically tunable hydrogel platform that can capture important 
cancer phenotypes of tumor dormancy and drug resistance allowing for further rational drug 
discovery approaches.  
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CHAPTER 3: ACCELERATION OF ER STRESS INDUCED DORMANT CANCER CELL 
DEATH BY EXOGENOUS CALCIUM SUPPLEMENTATION  
 
3.1. INTRODUCTION 
Interventions including surgery, chemotherapy and radiotherapy constitute standard 
treatment options for patients with primary cancer 126. However, a significant proportion of 
patients experience cancer metastasis to distant secondary disease sites such as bone, liver and 
lymph nodes 127-129. Cancer metastasis represents the single largest contributor of patient 
mortality and it still remains technically incurable 130.  
Studies have shown that cancer cells can disseminate from primary tumor to secondary 
sites such as bone even before its detection and treatment 30. Often in these cases of metastasis, 
tumor cells initially undergo prolonged periods of dormancy, which are followed by relapse 30. 
Increasing evidence points towards a definitive phase of prolonged G0/G1 arrest (‘cellular 
dormancy’) of micrometastatic nodules rather than balanced proliferation to support prolonged 
viability before relapse 27. Upon relapse, these cancer cells give rise to highly aggressive forms of 
tumor metastases, often causing death as a result. Dormancy at distant disseminated sites has 
been shown to be induced by the local microenvironment, which is foreign to the invading cancer 
cells 31. These populations of non-dividing G0/G1 arrested cancer cells evade traditional 
chemotherapy regimens that rely on actively dividing cells for their activity and thus indicate poor 
prognosis for the patient 32.  
Tumor resistance to drugs severely limits the success of modern chemotherapy in 
eliminating cancer diseases 131. Sensitive cancer cells are eliminated following exposure to 
chemotherapeutic drugs, while resistant and dormant cells survive the treatment. Ultimately, 
these dormant and resistant cells repopulate, causing a relapse of the disease at the primary 
location, as well as at distant metastatic sites. Dormant cells can exist either as minimal residual 
disease in which, cells are present at the site of primary tumor after surgical resection, or as 
distant disseminated cells in metastatic sites such as bone, liver and lymph nodes 52. At a 
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molecular level, proteins p38, p27 and p21 have all been implicated in inducing dormancy and 
cell cycle arrest in cancer cells. In studies by Ranganathan et al. 37 Higher p38 protein was 
associated with dormant state of cells in-vivo whereas higher ERK/MAPK was associated with 
proliferation. Further, Ranganathan et al. 37 showed that p38 induced dormancy, initiated by 
microenvironmental changes (loss of integrin adhesion to fibronectin rich surfaces 41) induced 
PERK activation that reduced translation and phosphorylated eukaryotic translation initiator factor 
2α (eIF2α), arresting cells in the G0/G1 state. Some cell types can also induce dormancy 
independent of p38, by directly upregulating several CDK inhibitors such as p21, p27 and p16 42. 
In fact, p38 protein has also been shown to modulate several downstream CDK inhibitors such as 
p21, p27 and p16 that work to induce cell cycle arrest and dormancy 43-44. 
Ablation of these cancer cell systems in their dormant state can not only eliminate the 
disease, but also reduce the risk of tumor relapse. We have previously developed novel high-
throughput amikagel platform that induced total bladder cancer 3D viable spheroid formation and 
complete tumor dormancy (almost 95% of the cells were arrested in G0/G1 phase of the cell 
cycle). Bladder cancer 3D-DTMs also showed very high resistance to conventional 
chemotherapeutics such as microtubule stabilizing docetaxel and DNA intercalating drug 
mitoxantrone.  
This chapter describes the bioengineered high-throughput approaches to develop an in-
vitro completely dormant drug discovery platform. Utilizing the amikagel based high-throughput 
dormant platform, we discovered novel drugs and drug combinations that work to ablate the 
dormant cancer phenotype. Bioengineered high-throughput, in vitro systems of tumor dormancy 
and relapse can allow for large-scale rational screening of lead drugs and their combinations, 
thus aiding cancer drug discovery and delivery 12. Taken together, we describe a versatile high-
throughput, in vitro platform for phenotype-specific drug screening, and for investigating 
fundamental biochemical and cellular phenomena in tumor dormancy and relapse. 
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3.2. MATERIALS AND METHODS 
Materials  
Amikacin hydrate (AH) (referred to as amikacin henceforth), docetaxel, wortmannin, chloroquine, 
propidium iodide, ribonuclease-A, poly (ethyleneglycol) diglycidyl ether (PEGDE), sodium 
orthovanadate and sodium fluoride were purchased from Sigma-Aldrich (St. Louis, MO), and 
used without further purification. Bortezomib was obtained from Selleck Chem (Houston, TX). 
Thapsigargin and ROCK inhibitor Y-27632 dihydrochloride were obtained from Santa Cruz 
Biotech (Dallas, TX). Caclimycin ionophore was obtained from RPI Corp (Mount Prospect, IL). 
16:0 PC (DPPC) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine was obtained from Avanti Lipids 
(Alabaster, Alabama) to prepare the liposomes. Calcium chloride dihydrate was obtained EMD 
millipore (Billerica, MA). Calcein AM/ethidium homodimer Live/Dead stain®, JC-1 Dye—
Mitochondrial Membrane Potential Probe were purchased from Life Technologies, (Carlsbad, 
CA). T24 human bladder cancer cells were obtained from Professor Christina Voekel-Johnson at 
Medical University of South Carolina, Charleston, SC as part of an existing collaboration. These 
cell lines were verified for their authenticity through Bio-Synthesis Inc (Lewisville, TX). MTT and 
XTT cell proliferation kit were purchased from American Type Culture Collection (ATCC) 
(Manassas, VA) 103. Cell culture media – RPMI media, DMEM with L-glutamine, Pen-Strep 
solution: 10000-units/mL penicillin and 10000-µg/mL streptomycin in 0.85% NaCl were purchased 
from Hyclone (Logan, UT). Premium heat inactivated fetal bovine serum (FBS) was purchased 
from Atlanta Biologicals (Flowery Branch, GA). Cell culture-treated 24 and 96 well plates were 
purchased from Corning Life Sciences (Corning, NY). RIPA buffer, Halt protease inhibitor cocktail 
(100X), Super Signal West Femto Maximum sensitivity substrate, and Fluo-4 DirectTM Calcium 
Assay kit were obtained from ThermoScientific (Waltham, MA). Tris, glycine, SDS, Blotting-Grade 
Blocker, 2X Laemmli Sample Buffer, Mini Precast PROTEAN gels and precision plus protein 
standards (Dual color) were obtained from BioRad (Hercules, CA). Growth Factor reduced 
(Basement membrane) Matrigel matrix was obtained from Corning (Bedford, MA) and molecular 
biology grade agarose was obtained from Fisher Scientific (Pittsburgh, PA). Amersham Hybond P 
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0.45 PVDF membrane was purchased from GE healthcare (Buckinghamshire, UK). CHOP D46F1 
Rabbit mAb primary antibody, β-actin Rabbit Ab primary antibody and anti-rabbit IgG HRP-linked 
secondary antibodies were obtained from Cell Signaling (Boston, MA). Nanopure water was used 
in all preparations.   
 
Amikagel synthesis 
Ring-opening polymerization between amine groups of amikacin hydrate and epoxide groups of 
poly (ethylene glycol) diglycidyl ether (PEGDE) resulted in the formation of a novel hydrogel 
henceforth called ‘Amikagel’. Different stoichiometric ratios of amikacin and the cross-linker 
PEGDE were dissolved in Nanopure® water, mixed and incubated at 40°C for 7.5 h, in order to 
obtain Amikagels AM1, AM2, and AM3 of different compositions (Table 1). The final 
concentration of amikacin was 10 wt% in all gels. All experiments were carried out in triplicate 
unless otherwise mentioned.   
 
Preparation of calcium liposomes  
16:0 PC (DPPC) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine was dissolved in chloroform at a 
concentration of 20 mg/mL. 1 mL of the lipid solution in chloroform was dried under a constant 
stream of filtered air. The lipid crust was desiccated for 24 hours under vacuum to remove all 
traces of chloroform. The lipid crust was hydrated in 1 mL of sterile filtered 200 mM calcium 
chloride solution. The mixture was vortexed for 30 seconds followed by heating at 55oC for 60 
minutes with vortexing every 15 minutes. Next, the liposomes were sonication for 45 minutes in a 
bath sonicator at a temperature of 55oC. The loading percent was increased inside the vesicles 
using repeated freeze thaw method. Lipid –calcium chloride solution was heated to 55oC (above 
the transition temperature of the DPPC) for one minute and rapidly cooled to -60oC. 10 cycles of 
repeated freeze thaw were performed. The unencapsulated calcium was removed via ion 
exchange using Amberlite IR-120+, H+ form activated by incubating the resin in 1M HCl for 24 
hours prior to the exchange. After the exchange, the solvent around liposomes was brought to 10 
mM HEPES buffer, pH 7.4, adjusted using 10M NaOH. Encapsulated calcium content was 
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determined using the atomic absorption spectroscopy at the range of 1-5 ug/mL (detection range 
of the instrument). Size and the zeta potential of the liposomes were measured using Malvern 
Zetasizer Nano (Malvern Instruments, MA). Calcium liposomes were always freshly prepared 
before use. 
 
Generation of 3D Dormant Bladder Tumor Microenvironment model (3DTMs)  
Cell culture 
T24 bladder cancer cells were propagated in DMEM supplemented with 10% (v/v) fetal bovine 
serum and 1% (v/v) penicillin and streptomycin (Pen-Strep solution: 10000 units/mL penicillin and 
10000 µg/mL streptomycin in 0.85% NaCl). For NIH3T3 cell propagation, 1% (v/v) sodium 
pyruvate was added and fetal bovine serum was replaced with calf serum in the media. For all the 
remaining cell lines, RPMI media supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) 
penicillin and streptomycin was used. 
 
Generation of 3D-DTMs using Amikagels 
1 ml of amikagel AM1, AM2 and AM3 pre-gel solutions were filtered through a 0.20 µm filter and 
40 µL of the filtrate was added to each well of a 96 well plate.  The plates were sealed with 
paraffin tape (Parafilm, Menasha, WI) and incubated in an oven maintained at 40oC for 7.5 hours. 
After gelation, the surfaces of Amikagels were washed with 150 µL of Nanopure® water for 12 
hours, in order to remove traces of unreacted monomers. All 3D-DTM experiments were set up 
by liquid overlay culture 104 of cells on top of Amikagel AM3 surface in a total volume of 150 mL 
media /well; 100,000 cancer cells alone (single culture) were incubated, unless indicated 
otherwise in specific cases.  After 48 hours of incubation, 50% of the media in the wells was 
replaced with fresh media i.e. DMEM/RPMI + 10% (v/v) FBS + 1% (v/v) Pen-Strep at regular 
intervals of 48 hours. Care was taken to withdraw and add the media slowly so as to not perturb 
3D-DTM formations. Fresh media was added every 48 hours following cell plating. For 3D-DTM 
generation on 24 well plates, 400 µL of pre-gel volume was used instead of 40µl. 3D-DTMs were 
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formed 5-7 days following culture on AM3 Amikagels and were studied for drug treatments after 7 
days.  
 
Quantification of total cell protein content and mitochondrial activity of 3D-DTMs and 2D 
cells  
100,000 T24 cells seeded on AM3 Amikagels were disassembled via manual pipetting followed 
by trypsinization. Cells plated on 2D cell culture plates were disassembled via trypsinization. 
Trypsin was deactivated using serum containing media after cellular disassembly from 3D-DTMs, 
pelleted by centrifugation at 800 rpm for 10 minutes and washed thoroughly in 1X PBS before 
lysis to avoid any contamination from the serum proteins. The washed cells were counted and 
lysed using 5X promega cell lysis buffer diluted to 1X lysis buffer concentration in 1xPBS. 
100,000 cells from 3D-DTMs were collected after 7 days of seeding on AM3 Amikagels.  The total 
protein content in the cells was measured by BCA assay. BSA standards were used to generate 
a standard curve of absorbance vs. protein concentration. The total protein content was 
expressed as a ratio to the total cell number. 
100,000 disassembled cells (by manual pipetting) collected from 3D-DTMs on AM3 
Amikagels and actively dividing 2D cultures were incubated with 1:2 ratio (v/v) of Activated XTT 
regent: cell culture media for 3.5 hours as per vendor’s protocol. After 3.5 hours, the absorbance 
of the orange color indicative of mitochondrial activity was measured at 475 nm and background 
was measured at 660 nm. The mitochondrial activity of the 2D and 3D-DTM cell sample were 
measured and expressed in absorbance units.  
 
Investigation of Chemotherapeutic Drug Efficacy on 3D-DTM Viability 
Bortezomib, thapsigargin and wortmannin drugs were added at different concentrations  (0.5, 1, 
5, 10 and 20 µM) to T24 3D-DTMs after 7 days of seeding on AM3 Amikagel. After 96 hours of 
exposure, the 3D-DTMs were disassembled by manual pipetting followed by XTT assay to 
estimate cell viability. Cell death (%) was estimated from the cell viability data and used for 
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analyses. Cell viability was also assessed by Live/Dead® staining. For combination studies, drug 
concentrations inducing ~10% death were chosen.  
For single agent calcimycin ionophore studies, calcium concentration of 1.8 and 5 mM 
was used with ionophore of different concentrations (0.1, 0.5, 1, 5 and 10 µM) for 24 hours 
followed by XTT assay to estimate remaining cell viability. Calcium liposomes were also added at 
a concentration of 175, 350 and 700 µM to the dormant cells to 24 hours followed by XTT assay. 
In all cases, concentrations of drugs that induced ~10% cell death as single agents were used for 
combination studies.   
0.5-µM calcimycin was treated together with either 1.8-mM calcium (present in cell 
culture media) or 5 mM calcium (additional 3.2 mM calcium chloride added to media). These 
concentrations were chosen since they induced ~10% single agent cell death in 24 hours (Fig. 
3G).  Higher concentrations of calcimycin (5 µM and 10 µM) with or without calcium induced 
significantly higher cell death in 24 hours, and were therefore not used (Fig. 3G).   
 
Fluorescence microscopy and Flow Cytometry of 3D-DTMs  
Mitochondrial membrane potential detection 
Mitochondrial membrane potential after treatment with bortezomib, thapsigargin, calcimycin and 
calcium was identified using JC-1 dye. 100,000 T24 cells seeded on AM3 gels for a week were 
treated with bortezomib (0.5 µM) and thapsigargin (0.5 µM), calcimycin (5 µM), calcium (5 mM) 
and their respective combinations for 24 and 48 hours. They were resuspended in DMEM media 
supplemented with 100X dilution of the JC-1 dye and distributed into 24 well plates for 
fluorescence measurements. After incubation for one hour at 37oC, the cells were imaged using 
the biotek plate at an excitation of 485 nm and emission of 528 nm (green) and 590 nm (red). 
Green fluorescence indicated presence of mitochondrial depolarization whereas red emission 
indicated intact mitochondria.  
 
 
 
66 
Intracellular Calcium Imaging 
T24 3D-DTMs grown on AM3 were treated with calcimycin (0.5 and 5 µM) with calcium (5 mM) 
and calcium liposomes (175 µM) for 3 hours. Following 3 hours, the 3D-DTMs were 
disassembled using rapid pipetting and cells were collected by centrifugation. The cells were 
washed with 1X PBS and resuspended in 50 µL cell culture media + 50 µL Fluo-4-AM dye 
solution (prepared as per vendor’s recommendation). After incubation for 60 minutes, the cells 
were imaged at excitation: 494 nm, emission: 516 nm. Green color fluorescence was used as an 
indicator of intracellular calcium concentration.  Intracellular calcium fluorescence was quantified 
using imageJ. 
 
Western Blotting  
100,000 cells seeded on AM3 were treated with bortezomib (0.5 µM) and Thapsigargin (0.5 µM), 
Calcimycin (5 µM), Calcium (5 mM) and their respective combinations for 24 hours, following 
which the cells were collected, washed with ice-cold 1X PBS, and lysed in 500 µL of RIPA buffer 
(25mM Tris.HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
supplemented with sodium orthovanadate (1 mM), sodium fluoride (1 mM), and 100 µL of 100X 
Halt protease inhibitor cocktail at 4oC. The lysates were then sonicated thrice for 10-15 seconds 
on ice and collected by centrifugation (16,000 rpm, 20 minutes, 4oC). Supernatants containing the 
whole cell protein were stored at -20oC for subsequent use.   
BCA assay was used to quantify the total protein content of the cell lysates. Equivalent 
quantities of whole cell proteins (4 µg) were combined with 2x Laemmli buffer containing 5% β-
mercaptoethanol, and were heat denatured for 5 minutes at 95oC. Equal amounts of protein (4 
µg) were then loaded into to the wells of pre-cast gels and run for 35 minutes at 200 V in running 
buffer (25 mM Tris, 190 nM glycine, and 0.1% SDS, pH = 8.3). The proteins were transferred to a 
methanol-activated Hybond PVDF membrane for 30 minutes at 20 V in the transfer buffer (25 mM 
Tris, 190 mM glycine, and 20% methanol, pH = 8.3). The Hybond PVDF membrane was rinsed 
with 1X PBST and blocked with 3% blocking buffer 3x for 5 minutes each. The membrane was 
then incubated with the primary antibody for 12 hours at 4oC (1:1000 CHOP D46F1 Rabbit mAb 
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primary antibody) and (1:5000 β-actin Rabbit Ab primary antibody). After three washes with 3% 
blocking buffer, the membrane was incubated in the secondary antibody (Anti-rabbit IgG HRP-
linked Antibody) at 1:2000 dilution in the dark for 2.5 hours at 25oC. Following three washes with 
1X PBST, the membrane was developed using Super Signal West Femto Maximum sensitivity 
substrate and viewed under chemiluminescence.  
Areas of the proteins actin and CHOP on the nitrocellulose membranes were measured 
using image-J software. The CHOP proteins from treatment samples were then normalized to 
their actin content and expressed, which was further expressed as a percentage of the live 
control.  
 
Statistical Analyses 
Averages have been expressed as mean ± SD. The effectiveness of the drug combinations were 
quantified using the combination index (CI) by Chou-Talalay method. Two-tailed t-test with 95% 
CI was used analyze and compare the percent cell death data of individual drugs. One-way 
ANOVA has been used to study the differences between the effectiveness of multiple drugs and 
their combinations. Tukey’s multiple comparisons test was used during multiple pairwise 
comparisons whereas Dunnett’s multiple comparisons test was used while comparing multiple 
means to a single one (control). p<0.05 indicated significance in the analyses. All analyses were 
performed using the Prism GraphPad software. All experiments have been performed at least 
n=2 independent experiments with three replicates each unless specified. 
 
3.3. RESULTS AND DISCUSSION 
Dormant cells show high mitochondrial activity and total per cell protein content  
Drugs against dormant tumors are an unmet biomedical need, which is borne by the poor efficacy 
of conventional chemotherapeutics against this phenotype. Several treatments are effective at 
addressing primary cancer disease, but relapse from prolonged states of dormancy after 
remission presents a significant challenge for improving patient outcomes. It is now widely 
believed that some cancer cells undergo a period of dormancy and escape chemotherapy due to 
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their differential phenotype 27. Ablation of cancer cells in their dormant state, either as part of 
primary chemotherapy or as maintenance treatment, can likely lead to an increase in 
progression-free survival. Capture of these dormant phenotypes on a high-throughput in vitro 
platform can facilitate discovery and development of novel drugs targeted to the dormant tumor 
phenotype.   
We focused our attention to mechanisms other than DNA and microtubule damage, 
which are default approaches for anticancer therapeutics 132-133. G0/G1 phase of cell cycle is 
largely associated with RNA synthesis via transcription and protein production via translation. 
Cellular arrest in the G0/G1 phase of cell cycle has been associated with increased protein 
content in cells 134. T24 3D-DTMs showed marginally higher per cell protein content compared to 
the 2D actively dividing cells (approximately 1.3 fold higher) (Fig. 3-1A). The 3D-DTMs showed a 
per cell protein content of approximately 0.30 ± 0.10 ng/cell whereas 2D actively dividing cells 
showed a total per cell protein content of 0.22 ± 0.09 ng/cell.  Previous work has found the total 
cell protein content to be in a similar range of approximately 0.3-0.5 ng/cell 135. The increase in 
total protein content in 3D-DTMs is also consistent with previous results showing arrest in G0/G1 
phase leads to higher per cell protein content 134.  
The dormant 3D-DTMs also showed a mildly lower mitochondrial activity compared to the 
actively dividing 2D cells (Fig. 3-1B). Both T24 and actively dividing 2D T24 cancer cells showed 
approximately similar absorbance values after exposure to XTT assay for 3.5 hours. T24 3D-
DTMs showed a mild reduction in the mitochondrial activity (0.85 fold) compared to the actively 
dividing 2D T24 cells. It is likely that the spheroidal shape of the 3D-DTM could limit oxygen 
diffusion into the core of the 3D-DTM leading to reduced mitochondrial activity 94. However, we 
did not see any signs of necrosis in the T24 3D-DTM core after H&E staining (Fig. 2-18). These 
results indicate that targeting mitochondria and protein production pathway could lead to 
development of novel therapeutics that targets the dormant tumors. While T24 3D-DTMs show 
very high resistance to conventional chemotherapeutics such as docetaxel and mitoxantrone due 
to its non-dividing status, it is likely that these drugs could sensitize T24 3D-DTMs to cell death 
(Fig. 2-23 and 2-24).  
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B. 
 
Figure 3-1. Total protein content and mitochondrial activity in dormant cancer cells vs. 
actively dividing cells. (A) Total protein content in T24 3D-DTMs is higher than that in actively 
dividing cells on a per-cell basis. (n=3, p<0.05, 1.3 fold higher, Student’s t-test). (B) Mitochondrial 
activity measured using XTT assay showed higher activity in 2D cells compared to T24 3D-DTMs. 
(n=3, p<0.05, 1.3 fold higher, Student’s t-test). The numbers of cells were equal in both the 
groups tested.  
 
Ablation of 3D-DTMs by targeting the Cellular Protein Production Machinery and 
Mitochondria 
We found that protein production in T24 3D-DTMs was modestly, but significantly, higher than in 
2D cells (Fig. 3-1 A). We hypothesized that small molecules can be used to inhibit key molecular 
targets in the active protein production machinery, leading to induction of chronic ER stress and 
subsequent ablation of dormant cancer cells (Fig. 3-2 A-B). It has been previously shown that 
microenvironment induced p38-mediated tumor dormancy leads to upregulation of ER stress and 
promotes an unfolded protein response (UPR), which confers a pro-survival mechanism in 
dormant cells 37. Proteomic analysis of p38-mediated dormant HEp3 squamous carcinoma cells 
showed an upregulation of UPR (ER stress chaperone BiP and PERK) resulting in resistance to 
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doxorubicin 67. Although ER stress is a pro-survival adaptive mechanism adopted by cancer cells, 
chronic ER stress eventually leads to cell death.  
Thapsigargin, an ER-specific calcium channel blocker, is known to reduce calcium 
concentration in the ER lumen, causing malfunctioning of calcium-dependent ER chaperones 136, 
and concomitant elevation in the cytoplasmic and mitochondrial concentration of calcium. 
Improperly functioning calcium dependent chaperones such as calnexin and calreticulin, cause 
production of misfolded or unfolded proteins. Thapsigargin has also been implicated to induce ER 
stress by inhibiting autophagic autophagosome-lysosome fusion 137. 
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A.  
 
B. 
 
 
Figure 3-2 Hypothesis driven rational drug discovery against tumor dormancy. (A) 
Mechanism-based combination treatment in which ER stress inducers (SERCA inhibitor 
thapsigargin or T) that cause protein misfolding are treated in concert with autophagy or 
proteasome inhibitors wortmannin (W) or bortezomib (B), respectively. (B) Chronic ER stress due 
to accumulation of misfolded proteins in the ER leads to activation of multiple pro-apoptotic 
proteins leading to mitochondrial depolarization.  
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Thapsigargin treatment (15 µM) resulted in a loss of viability in ~50% T24 3D-DTMs after 
96 hours of treatment (Fig. 3-3 A). This is a significantly improved response compared to 
docetaxel, or mitoxantrone. Under chronic ER stress, cells can utilize protein degradation 
pathways including proteasome degradation and / or autophagy to remove misfolded / unfolded 
proteins 63, 138 promoting cell survival. We therefore hypothesized that a combination of ER stress 
inducers and proteasome / autophagy inhibitors would demonstrate synergistic activity for the 
ablation of 3D-DTMs (Fig. 3-2 A). Bortezomib is a highly selective, reversible inhibitor of 26S 
proteasome. The boron atom of the bortezomib drug binds to the catalytic site of the 26S 
proteasome with high affinity and selectivity, thereby inhibiting it. Under this inhibition, the 
proteasome cannot perform its regular functions of degrading ubiquitinylated proteins, and 
peptides. The proteasome also cannot degrade ubiquitinylated misfolded or unfolded proteins 
and therefore acts to amplify the ER stress under inhibition by bortezomib 63, 139-141. Bortezomib is 
FDA approved for treatment of relapsed multiple myeloma and mantle cell lymphoma 142-144. Due 
to its reversible nature, resistance against bortezomib has been documented leading to the 
development of second-generation proteasome inhibitor drugs such as carfilzomib, ONX 0912 
and NPI-0052 that bind proteasome irreversibly 145-146. Wortmannin is a potent, selective and 
reversible PI3 kinase inhibitor that inhibits organelle sequestration in autophagy 147. Prevention of 
organelle sequestration leads to malfunctioning and inhibition of autophagic processes. Under ER 
stress, cell uses autophagy to sequester and degrade misfolded proteins in the ER, which fails to 
occur under wortmannin mediated PI3-kinase inhibition 148. 
Single-agent toxicity of 0.5 µM wortmannin (W) (autophagy inhibitor) and bortezomib (B) 
(proteasome inhibitor) were minimal (<10% cell death; Fig. 3-3 B). Similar results were observed 
with 0.5-µM thapsigargin (T) that induced death in only 5% 3D-DTM cells at this low dose of the 
drug. The LC50 value of single-agent bortezomib (2-µM) was significantly lower than that of 
thapsigargin (15 µM) indicating high dependence of dormant cancer cells on functional 
proteasome activity for survival (Fig. 3-3 A). It is likely that these 3D-DTMs recycle folded 
proteins generated in the ER under the dormant status to survive. Hence, bortezomib inhibition 
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effectively sensitizes these cancer cells compared to the other drugs used. All three drugs (B, T 
and W) showed dose dependent toxicity (Fig. 3-3 A). 
A.             B.                        
 
 
 
 
 
 
 
 
 
 
 
 
C. 
 
 
 
Figure 3-3. ER stress induces death in dormant cancer cells. (A) Cell viability following 
treatment of T24 3D-DTMs with single-agent thapsigargin (T), bortezomib (B) or wortmannin (W). 
(B) Treatment of T24 3D-DTMs with 0.5 µM B or W resulted in death of <10% cells in either case. 
(C) T24 3D-DTMs were treated with autophagy inhibitor wortmannin and proteasome inhibitor 
bortezomib (0.5-20 µM) as shown after treating with Live-Dead® stain (Calcein AM-EthD-1). 
Bortezomib was very effective in inducing cell death on the dormant T24 3D-DTMs. Spheroid 
morphology was completely lost during the wash steps during the treatments with bortezomib. 
Scale = 100 µm in all cases. Live-Dead staining revealed similar results to that of XTT data. 
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Single agent drug concentrations inducing under 10% cell death in 96 hours were chosen 
for the combination studies. Proteasome inhibitor and autophagy inhibitor drugs bortezomib (B), 
and wortmannin (W) induced ~10% death as single agents at a concentration of 0.5 µM and were 
chosen in the combination studies with different concentrations of thapsigargin (0.5 – 20 µM) 
(Fig. 3-3 A-B). Combination of 0.5 µM W and 0.5 µM T did not result in increase in cell death 
even at higher doses of thapsigargin (Fig. 3-4 A and C). A combination of 0.5 µM B + 0.5 µM T 
however, resulted in near-total ablation of 3D-DTM in 96 hours (Fig. 3-4 B and C). The 
combination index (CI) for the B+T treatment was 0.1 ± 0.03 (Chou-Talalay method), which 
indicates very strong synergy between the two drugs for ablation of the dormant cancer cell 
phenotype. These results indicate the heavy dependence of T24 3D-DTMs on functional 
proteasome activity for their survival. Treatment with low concentrations of thapsigargin caused a 
depletion of calcium ions in the ER, which affects the activity of several calcium-dependent ER 
chaperones. This, in turn causes generation and accumulation of misfolded proteins leading to 
ER stress and unfolded protein response 66, 149. Inhibition of the proteasome degradation 
machinery using bortezomib likely causes an accumulation of unfolded proteins leading to 
induction of chronic ER stress) which ultimately induces death of dormant cells. The relatively low 
concentrations of the individual drugs required for complete ablation of dormant tumor cells is 
promising since this can help minimize side-effects in eventual treatments 150. 
 
 
 
 
 
 
 
 
 
 
75 
A.      B. 
  
C.      D.  
    
Figure 3-4. Chronic ER stress induces death in dormant cancer cells. (A) Wortmannin (0.5 
µM) with thapsigargin did not induce significant synergistic cell death in T24 3D-DTMs.  (B) 
Bortezomib (0.5 µM) with thapsigargin induced significant synergistic cell death in T24 3D-DTMs.  
(C) Combination of thapsigargin with bortezomib induces synergistic increase in cell death in 3D-
DTMs (96 hours) leading to near-total ablation of the dormant phenotype. A combination index 
(CIB+T) = 0.1 ± 0.025 indicates strong synergy between the two drugs. Reversal of cell death upon 
pan-caspase inhibition using the inhibitor zVAD-fmk indicated that the combination of T and B 
induced caspase-mediated apoptosis in 3D-DTMs. W+T did not induce synergistic cell death.  
 
Chronic ER stress is known to induce cell death via mitochondrial depolarization 151, 
which acts as a significant amplifier of cell death during the stress 74. In addition, mitochondrial 
depolarization acts as a point of no return for cellular apoptosis 152. While mitochondria could be 
targeted directly using mitochondrial respiratory inhibitors, our results indicated that mitochondrial 
activity is relatively lower in the T24 3D-DTMs compared to 2D T24 cells, while the total protein 
content is higher (Fig. 3-1 A-B). Previous results have shown that mitochondrial respiratory 
inhibitors can sensitize dormant cancer cells to death in the core of multicellular spheroids 35.  
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Chronic ER stress due to accumulation of misfolded proteins in ER causes the activation 
of two main pathways, the Ire1/XBP-1, ATF6-dependent pathway and PERK/eIF-2alpha 
phosphorylation-dependent pathway which activate chaperone and pro-apoptotic protein 
production  (Fig. 3-2 B) 74, 151. Cell death is achieved by upregulation of pro-apoptotic 
transcription factor such as CHOP, Bak and Bax that puncture the mitochondrial outer 
membrane. We observed an overexpression of the pro-apoptotic protein CHOP following 
treatment of 3D-DTMs with bortezomib and thapsigargin, which was an indication of ER stress 
induced in these cells by the drugs (Fig. 3-4 D) 65. We also observed that treatment with a pan-
caspase inhibitor, z-VAD-fmk, significantly rescued 3D-DTMs from B+T treatment (Fig. 3-4 C), 
which is consistent with findings that indicate involvement of caspases 3, 9, and 12 in ER stress 
mediated apoptosis 153. Mitochondrial depolarization results in generation of apoptosome that 
causes activation and autocatalytic self-cleavage of multiple pro-caspase 9 units. Activated 
caspase-9 further cleaves and activates caspase-3 initiating the caspase cascade 154. Mature 
caspases actively cleave the aspartate units of critical proteins that are involved in structural 
stability, DNA repair leading to regulated cell death 155.  
 
Nanoparticle and ionophore-mediated delivery of calcium accelerated dormant cancer cell 
death under chronic ER stress 
Ablation of 3D-DTMs following treatment with bortezomib and thapsigargin occurs over a period 
of 96 hours; kinetics studies revealed minimal losses in viability (< 2% death) at 24 hours 
following treatment (Fig. 3-5 A). We therefore sought to develop strategies for accelerating death 
of dormant tumor cells. Strategies that can accelerate therapeutic outcomes could save cost and 
time to achieve a therapeutic outcome.  
Upon induction of chronic ER stress, the transcription factor CHOP expression induces 
expression of Bax and Bak, which puncture the outer mitochondrial membrane 65. Concomitantly, 
efflux of calcium ions from the ER and cytoplasm into the inner mitochondrial matrix via the IP3R-
VDAC-MCU channels elevates the calcium concentration in the matrix. Elevation of calcium 
concentration in the matrix results in mitochondrial depolarization leading to influx other counter 
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ions and water 73. These events result in mitochondrial swelling and rupture leading to cell death 
74. We therefore hypothesized that raising the concentration of calcium ions in the cytoplasm 
following exogenous delivery of the cation will accelerate cell death under chronic ER stress 
conditions induced by B+T. Exogenous delivery of calcium will increase the total pool of calcium 
available in the cell for depolarization of mitochondria leading to hastening of mitochondrial 
depolarization and eventual death.  
 
Nanoparticle calcium delivery  
Calcium influx into cells is very tightly regulated in order to prevent sudden necrotic death; 
minimal amounts of extracellular calcium can enter epithelial cells via passive diffusion due to the 
presence of TRP vanilloid family of ion channels that regulate entry 156. Indeed, significantly 
elevated concentrations of extracellular calcium in cell culture media (up to 40 mM) had minimal 
impact on viability of 3D-DTMs even after 96 hours of treatment (Fig. 3-5 B).  
 
A.      B. 
  
Figure 3-5. Cell death after B+T and calcium in cell culture media. (A) Combination of 0.5 µM 
Bortezomib (B) and 0.5-µM thapsigargin (T) induced less than 2% death in 24 hours and induced 
complete cell death only in 96 hours. (B) Dormant cancer cell death after treatment with different 
concentrations of extracellular calcium chloride for 96 hours is shown. Less than 10% cell death 
was observed even with treatment of about 40 mM extracellular calcium chloride. (Cell culture 
media has extracellular calcium of 1.8 mM).  
 
In addition to regulating entry, intracellular calcium spikes are immediately buffered by 
ER and mitochondria 157. However, in presence of thapsigargin-induced stress, the ER 
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demonstrates significantly reduced ability to buffer intracellular calcium levels 136. We therefore 
hypothesized that delivery of calcium using nanoparticles or ionophores (e.g. calcimycin) will 
increase the intracellular levels of the cation in 3D-DTMs, increase the load on mitochondria and 
accelerate cell death. Nanoparticle/Ionophore mediated elevation in intracellular calcium 
concentration coupled with calcium entry via store-operated calcium entry (SOCE) STIM1-Orai1 
channels under thapsigargin induced ER calcium stress could cause further elevation in 
cytoplasmic calcium levels and accelerate cell death 158. 
Dipalmitoylphosphatidylcholine (DPPC) liposomes (average hydrodynamic diameter: 115 
nm and zeta potential value: +25 mV) were loaded with 12 ± 5 mM calcium chloride (n=3 
independent experiments) and delivered to T24 3D-DTMs (Fig. 3-6 A-B). 
Dipalmitoylphosphatidylcholine (DPPC) lipids have a transition temperature of approximately 
41oC, which provide stability to the liposome at room temperature 159. In addition, the permanently 
positive quaternary ammonium group on dipalmitoylphosphatidylcholine (DPPC) lipids can 
effectively resist leakage of loaded positively cargo from these liposomes to the outside. DPPC 
liposomes have also been shown to be stable in presence of serum160. In our studies, these 
liposomes were stable for at least 48 hours in presence of serum, which is sufficient for 
intracellular delivery of calcium (Fig. 3-6 C). We studied the release of calcium from DPPC 
liposomes in presence of 150 mM salt (1X PBS) and 10% fetal bovine serum. As shown in Fig. 3-
7, the release of calcium occurred within the first 6 hours from liposomes, followed by almost no 
release. It is likely that the release of calcium will be accelerated in presence of cells. In-vivo 
liposomal calcium formulations will likely use a more serum stable liposomes prepared with 
distearoylphosphatidylcholine DSPC lipid and other pegylated co-lipids. Liposomes prepared with 
DSPC lipid have a transition temperature of 55oC that is more stable than DPPC due to two 
additional carbons in the hydrophobic chain 161.  
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A.  
      
B.      C. 
 
D.       E. 
 
Figure 3-6. Acceleration of chronic ER stress induced death after exogenous delivery of 
calcium via liposomes. (A) DPPC calcium loaded liposomes were generated using multiple-
freeze thaw method. The size (diameter) and zeta potential were measured approximately at 115 
nm and 26 mV. (B) Free unencapsulated calcium was removed from the liposome system using 
H+ activated ion exchange system. The ion exchange system was noted to remove ~99% of the 
free calcium as measured using the CaCl2.2H2O control (atomic absorption spectroscopy). 
Calcium loaded in liposomes (approximately 12 ± 5 mM). (C) Intracellular calcium fluorescence in 
T24 3D-DTMs was measured using Fluo-4 dye after 3 hours of calcium delivery using calcimycin 
or calcium liposomes. Fold increase over DMSO control is indicated (baseline calcium 
concentration – 1.8 mM in the media) (N=2) (D) Calcium-loaded liposomes (175 µM) accelerated 
T24 3D-DTM death in combination with bortezomib (0.5 µM) and thapsigargin (0.5 µM) at 48 h 
(open bars) and 72 h (shaded bars). Empty DPPC liposomes were also seen to cause a slight 
increase in cell death but significantly lesser than the combination of B, T and calcium liposomes. 
(* - p<0.05, ** - p<0.01, *** - p<0.001, **** - p<0.0001) (E) Single agent calcium loaded DPPC 
liposomes and empty liposomes showed dose dependent toxicity after 24 hours exposure. 175 
µM concentration of calcium in liposomes was chosen to study the acceleration as it induced 
~10% single agent cell death in 24 hours.  
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Liposomal delivery of calcium to the cytoplasm induced a significant acceleration in 3D-
DTM cell death at a concentration of 175 µM (Fig. 3-6 D). Treatment with calcium liposomes 
alone induced death in ~10% of the 3D-DTM cell population (24 and 48 hours) (Fig. 3-6 D-E). A 
concentration dependent cell death was observed in the T24 3D-DTMs after treatment with 
calcium liposomes. We observed ~37% cell death in 48 hours upon using calcium liposomes 
together with B+T, which increased to ~52% at 72 hours. In both these cases, 3D-DTM cell death 
was significantly higher than when cells were treated with B+T in absence of liposomal calcium 
(Fig. 3-6 D). Increasing calcium loading in liposomes can be employed to further enhance cell 
death at earlier times.  
 
Figure 3-7. Release of calcium from DPPC liposomes in presence of 150 mM salt (1X PBS) 
and 10% FBS. DPPC calcium loaded liposomes showed a controlled release profile of calcium 
during dialysis.  
 
Delivery of these drugs in liposomes is an attractive strategy since liposomes can be 
specifically targeted to cancer cells using targeting ligands. In addition, co-formulation of calcium 
with drugs that induce, amplify and accelerate ER stress (e.g. B+T) mediated death is also 
possible. While bortezomib is already FDA approved for multiple myeloma 162, the pro-drug form 
of thapsigargin is in clinical trials against multiple tumor types etc. 163, indicating the translational 
potential of these findings. Formulating chemotherapeutic treatment strategies that can synergize, 
accelerate and reduce treatment times while maintaining efficacy could diminish the side effects 
of toxic anti-cancer drugs and reduce costs in the future. To our knowledge, this is the first report 
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that employs delivery of exogenous calcium in order to accelerate ER stress induced cancer cell 
death. The Amikagel platform can facilitate rapid discovery of such novel drug combinations for 
tumor dormancy and help accelerate their translation to the clinic. 
 
Ionophore mediated calcium delivery  
Calcium ionophore calcimycin shows high affinity to divalent cations such as calcium and 
magnesium and traffics them into the cell via the lipid bilayer 164. Single agent calcimycin 
ionophore treatment with 1.8 mM and 5 mM calcium induced a concentration dependent cell 
death. The cell death was significantly higher after the treatment with higher concentration of 
calcimycin (Fig. 3-8 A).  Higher concentration of calcium with calcimycin likely causes rapid 
delivery of calcium into the cytoplasm of the cell leading to necrotic death.  
Treatment with the ionophore calcimycin together with calcium (calcimycin-calcium) also 
resulted in an acceleration of cell death induced by ER stress. Individual combinations of 
calcimycin (0.5 µM)-calcium (5 mM or 1.8mM) or bortezomib-thapsigargin (0.5 µM each) did not 
induce significant loss in 3D-DTM viability (10-15% cell death at 24 and 48 hours) (Fig. 3-8 B). In 
contrast, their combination caused significantly increased death (~60% in 48 hours) (Fig. 3-8 B), 
indicating acceleration of cell death when low concentration of calcimycin (0.5 µM)-calcium (5 mM 
or 1.8 mM) was treated with B+T (0.5 µM each) (Fig. 3-8 B and C (i)). While B+T induced ~90% 
death over 96 hours, calcimycin-calcium induced the same extent of death within 48 hours (Fig. 
3-8 B). The enhancement in cell death induced by calcium delivery was sustained for 96 hours 
(Fig. 3-8 B). This acceleration was reversible following pan-caspase inhibition, indicating the role 
of caspase-induced apoptosis in accelerated 3D-DTM death at lower concentrations of 
calcimycin-calcium (Fig. 3-8 C (ii)). Pan-caspase inhibition did not rescue dormant cells from 
death under higher concentrations of calcimycin-calcium treated along with B+T, indicating that 
caspase-medicated apoptosis was likely not involved; cell death likely occurs due to necrosis 
following rapid ion influx at these higher concentrations (Fig. 3-9).  
 
 
82 
A.       B. 
 
C. (i)       (ii)  
  
Figure 3-8. Acceleration of chronic ER stress induced death after exogenous delivery of 
calcium via ionophore. (A) Viability of T24 3D-DTMs treated with of different concentrations of 
calcimycin- calcium (1.8 mM or 5 mM). Use of 5 mM calcium concentration resulted in modest 
increase in T24 3D-DTM cell death. Supplementation of 5 mM calcium (checkered bars) with 
calcimycin increased the cell death compared to that seen with 1.8 mM calcium (solid bars). (B) 
T24 3D-DTMs were treated with bortezomib (0.5 µM), thapsigargin (0.5 µM), calcimycin (0.5 µM) 
or calcium (1.8 mM and 5 mM) and their combinations for 24, 48, 72 or 96 hours (sequence of 
bars). While bortezomib and thapsigargin induced approximately 10% death in 48 hours, their 
combination with calcium and calcimycin (0.5 µM) induced significantly higher death (p<0.001) 
(~65%). (C) (I). Viability of T24 3D-DTMs following treatment with bortezomib (0.5 µM), 
thapsigargin (0.5 µM), calcimycin (cal; 0.5 µM) or calcium (Ca; 1.8 mM and 5 mM) and their 
combinations (48 h). (ii). 3D-DTM death induced by calcimycin, calcium, bortezomib and 
thapsigargin (48 h) was reversed upon addition of the pan-caspase inhibitor (5 µM zVAD-fmk) 
indicating an apoptotic cell death acceleration. (One-Way ANOVA, multiple comparisons) (* - 
p<0.05, ** - p<0.01, *** - p<0.001, **** - p<0.0001). 
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Figure 3-9. Pancaspase is ineffective in reversing cell death after high concentration of 
calcimycin. Pancaspase inhibition did not rescue cells from death after treatment with high 
concentration of calcimycin (5 µM) combined with bortezomib (0.5 µM), thapsigargin (0.5 µM) and 
calcium (1.8 mM or 5 mM), indicating a predominant necrotic death at higher concentrations of 
calcimycin (48 hour time point). 
 
 
Increased mitochondrial depolarization drives the acceleration of dormant apoptotic 
cancer cell death under ER stress inducers - calcium supplementation 
We next investigated mitochondrial depolarization, CHOP expression and intracellular calcium 
fluorescence in order to gain a mechanistic understanding into calcium-induced acceleration of 
3D-DTM death. Intracellular calcium fluorescence was significantly higher than the DMSO control 
at 3h following delivery of the cation using calcimycin and calcium liposomes (Fig. 3-10, 3-6C), 
confirming that an increase in calcium levels precedes the enhancement of 3D-DTM cell death 
seen at 48 h. In the absence of B+T-induced ER stress, calcimycin (0.5 µM) with calcium (5 mM 
or 1.8 mM) did not induce CHOP expression that correlated with minimal cell death seen under 
these conditions. However, significantly higher CHOP expression was noted when calcimycin-
calcium was added along with B+T, indicating the role of CHOP in the acceleration of apoptosis 
(Fig. 3-11 A). CHOP expression was high following calcium delivery with calcimycin in presence 
of B+T irrespective of the concentration of calcium delivered (1.8 mM or 5 mM) (Fig. 3-11 A). A 
modest level of mitochondrial depolarization was observed following treatment with B+T (0.5 µM 
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each) alone. However, combination of B+T with calcimycin (0.5 µM)-calcium (5 mM or 1.8 mM) 
(Fig. 3-11 B) caused significantly higher mitochondrial depolarization than B+T alone (Fig. 3-11 
B). Treatment with single agent calcium liposomes caused significantly higher mitochondrial 
depolarization compared to corresponding empty liposomes. Combination of B, T and calcium 
liposomes also caused significantly higher mitochondrial depolarization compared to B+T alone 
(Fig. 3-12). Treatment with calcium alone neither induced CHOP expression nor mitochondrial 
depolarization compared to the live control, which is consistent with its minimal intracellular 
transport and the concomitant negligible loss in cell viability (Fig. 3-8 A-B). Our results indicate 
that chronic ER stress induced by bortezomib and thapsigargin, in concert with calcium delivery, 
can enhance mitochondrial depolarization and CHOP expression, which ultimately results in the 
observed enhancement of 3D-DTM cell death. 
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Figure 3-10. Intracellular calcium fluorescence in T24 3D-DTMs following delivery using 
calcimycin or calcium liposomes. Intracellular calcium concentration was imaged by 
administering Fluo-4-AM dye after 3 hours of exposure to various treatment modalities. Calcium 
fluorescence was imaged at ex: 494 nm and em: 516 nm (green fluorescence). Scale bar = 100 
µm. Representative figure from N=2.  
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A.  
 
 
 
 
 
B.  
 
Figure 3-11. Mechanistic understanding of dormant cell death acceleration. Bortezomib + 
thapsigargin treatment induced significant expression of CHOP (24 h) which is indicative of ER 
stress. Calcimycin-calcium treatments did not induce significant upregulation of the CHOP 
protein. (C) Mitochondrial depolarization activity measured using JC-1 dye after treatment with 
bortezomib (0.5 µM), thapsigargin (0.5 µM), calcimycin (0.5 µM)-calcium (1.8 mM or 5 mM) and 
their combinations for 48 hours. Fluorescence units were measured using Biotek plate reader and 
the ratio of the green and red emissions were calculated. Combination treatments of B, T and 
calcimycin with and without additional calcium induced significantly higher mitochondrial 
depolarization compared to B-T alone (*p<0.05, One way ANOVA).  
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Figure 3-12. Mitochondrial depolarization after B, T and calcium liposome delivery. 
Mitochondrial depolarization activity measured using JC-1 dye after treatment with bortezomib 
(0.5 µM), thapsigargin (0.5 µM), calcium liposomes (175 µM) and the corresponding empty 
liposomes and their combinations for 48 hours. Fluorescence units were measured using Biotek 
plate reader and the ratio of the green and red emissions were calculated. Combination 
treatments of B, T with calcium liposomes induced significantly higher mitochondrial 
depolarization compared to B-T alone. Calcium liposomes also induced significantly higher 
mitochondrial depolarization compared to empty liposomes. (N=2) 
In all cases the significance relates to the following: * - p<0.05, ** - p<0.01, *** - p<0.001, **** - 
p<0.0001, One way ANOVA. 
 
 
Proposed mechanism of acceleration of ER stress mediated apoptotic cell death 
Under stress using thapsigargin, the calcium entry into the endoplasmic reticulum is blocked due 
to SERCA inhibition. Depleted calcium in the ER causes multiple calcium dependent chaperones 
to malfunction leading to the production of misfolded/unfolded proteins and cause ER stress. ER 
stress kickstarts multiple downstream pathways that work to repair the cell and remove the ER 
stress, collectively known as unfolded protein response (UPR effect). This pathway works by 
activating transcription and translation of multiple chaperones to repair the unfolded proteins. In 
addition, translation of new proteins is slowed down in order to reduce the load of protein 
production on the ER. Under chronic ER stress, multifunctional transcriptional regulator CHOP 
protein is produced which transcriptionally activates the production of multiple pro-apoptotic 
proteins such as Bax and Bak. Bax and Bak work to puncture the outer mitochondrial membrane 
leading to mitochondrial depolarization and apoptosis. Simultaneously, calcium from the ER and 
cytoplasm is pumped into the mitochondrial matrix, reducing and removing the potential 
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difference between the inner and the outer membrane, leading to mitochondrial swelling and 
rupture. This two-way mode of cell death, works to depolarize the mitochondria and achieve 
cellular apoptosis in these dormant cells. Under thapsigargin mediated blockade of ER, 
exogenous calcium delivered to the cell cytoplasm cannot be buffered by the ER, leaving all of it 
for mitochondrial depolarization under chronic ER stress (Fig. 3-13).  
 
 
Figure 3-13. Proposed pathway of ER stress induced apoptosis and acceleration of cell 
death after intracellular calcium supplementation. Increase of cytoplasmic calcium in 
presence of thapsigargin is likely to buffer only with mitochondria (as calcium entry into ER is 
blocked) accelerating its depolarization and eventual cell death under chronic ER stress.  
 
3.4. CONCLUSIONS 
These 3D dormant tumor microenvironments were susceptible to drugs that were able to induce 
chronic ER stress. Increase in intracellular calcium levels (e.g. mediated by nanoparticle delivery) 
further accelerated death of 3D-DTMs induced by drugs that induce ER stress. The use of 
liposomal delivery of calcium in concert with ER stress inducers is a novel approach for ablating 
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the dormant tumor phenotype. Taken together, the Amikagel platform facilitates high-throughput 
formation of 3DTMs for applications in drug screening and investigations in fundamental tumor 
biology. This high-fidelity platform can be employed for identifying drugs that can reverse and / or 
ablate the dormant phenotype, as well as obviate cell escape from dormant tumors, leading to 
novel discoveries for the clinical management of cancer diseases. 
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CHAPTER 4: MODULATION OF AMIKAGEL CHEMO-MECHANICAL PROPERTIES LEADS 
TO RELAPSE FROM TUMOR DORMANCY 
  
4.1. INTRODUCTION 
Tumor dormancy is a widely accepted phenomena that is believed to occur in patients 
after primary course of treatment. Dormancy state can confer strong drug resistance in cancer 
cells against therapeutic regimens that are focused exclusively on eliminating actively dividing 
cells. Once the drug regimen is removed or completed, these dormant cancer cells are waiting 
ticking bombs, ready to relapse upon cue. Relapse from tumor dormancy often occurs after an 
indefinite period of time. After relapse, the cancer manifests as metastases in primary or distant 
locations that often result in patient mortality. Mortality due to metastases accounts for the highest 
percentage of deaths associated with the cancer disease. In fact, 90% of cancer deaths are due 
to metastases to distant sites such as bone, liver, lungs etc 28.  Deaths due to breast and prostate 
cancer metastases account for majority of deaths in patients with those diseases 29. Relapse from 
tumor dormancy has been shown to be associated with changes in the extracellular environment 
around the dormant tumor 38. Changes such as angiogenic bursts 165-166, adhesive 
microenvironments 38, TGF-β production 167 have been linked to initiation of relapse from tumor 
dormancy.  
In bladder cancer, changes in extracellular matrix have been associated with metastasis 
and migration of the cancer cells 53. The cancer cells that tend to migrate and metastasize are the 
ones with lower expression of beta-catenin levels, higher MMP expressing cells etc 47. 
Breakdown of ECM by MMP production allows the metastatic cancer cells to migrate and invade 
into the blood stream and other secondary organs such as lymph nodes. Aberrant expression of 
N-cadherin has been associated with poor prognosis of bladder cancer 54. N-cadherin protein 
expression along with E-cadherin down-regulation is a hallmark of epithelial to mesenchymal 
transition (EMT) event and has been linked to poor prognosis for the bladder cancer patients 55. 
However, reduction or complete absence of N-cadherin has been associated with increased 
migration, metastases in multiple cancer cell types including bladder cancer and even poorer 
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prognosis for the patient 55-57. In a study of bladder cancer patient samples by Jager et al. 58, N-
cadherin reduction and absence was identified to be an extremely poorer prognostic indicator 
than expression of N-cadherin (which was also a significant prognostic indicator of invasive 
cancer disease). 
We hypothesized that transferring the dormant T24 3DTMs from non-adhesive and 
mechanically stiff Amikagel formulations to a more adhesive, mechanically pliant Amikagel 
formulations could result in relapse and migration of metastatic populations of the cells. We 
hypothesized that cells with differential expression of N-cadherin could be isolated from within the 
population of T24 cells by modulating the chemo-mechanics and adhesivity of the substrate 
matrix and their propensity to relapse and migrate. In order to do so we varied the ratio of the 
input monomers amikacin and PEGDE to generate different formulations of Amikagel with varying 
adhesivities and studied the relapse of the cancer cells from tumor dormancy. Our goal for this 
work has been to develop a novel high-throughput platform that not only captures complete tumor 
dormancy, but also relapse and further metastatic cell migration and micrometastases formation 
for rapid drug discovery, validation, delivery and development. This chapter describes our work to 
induce relapse from dormancy in bladder cancer by chemo-mechanical modulation of Amikagels.  
 
4.2. MATERIALS AND METHODS 
Materials  
Amikacin hydrate (AH) (referred to as amikacin henceforth), docetaxel, propidium iodide, 
ribonuclease-A, poly (ethyleneglycol) diglycidyl ether (PEGDE), were purchased from Sigma-
Aldrich (St. Louis, MO), and used without further purification. ROCK inhibitor Y-27632 
dihydrochloride was obtained from Santa Cruz Biotech (Dallas, TX). T24 human bladder cancer 
cells were obtained from Professor Christina Voekel-Johnson at Medical University of South 
Carolina, Charleston, SC as part of an existing collaboration. These cell lines were verified for 
their authenticity through Bio-Synthesis Inc (Lewisville, TX). Cell culture media – RPMI media, 
DMEM with L-glutamine, trypsin, and Pen-Strep solution: 10000 units/mL penicillin and 10000 
µg/mL streptomycin in 0.85% NaCl were purchased from Hyclone (Logan, UT). Premium heat 
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inactivated fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, 
GA). Cell culture-treated 24 and 96 well plates were purchased from Corning Life Sciences 
(Corning, NY). Nanopure water was used in all preparations.   
 
Amikagel synthesis 
Ring-opening polymerization between amine groups of amikacin hydrate and epoxide groups of 
poly (ethylene glycol) diglycidyl ether (PEGDE) resulted in the formation of a novel hydrogel 
henceforth called ‘Amikagel’. Different stoichiometric ratios of amikacin and the cross-linker 
PEGDE were dissolved in Nanopure® water, mixed and incubated at 40°C for 7.5 h, in order to 
obtain Amikagels AM1, AM2, and AM3 of different compositions (Table 1). The final concentration 
of amikacin was 10 wt% in all gels. All experiments were carried out in triplicate unless otherwise 
mentioned.   
 
Adhesivity of Amikagels 
Adhesivity of Amikagels was qualitatively estimated by comparing the adhesivity of T24 cells to 
the 2D cell culture plates vs. Amikagels after wash assay. 10,000 T24 cells were added to AM1, 
AM3 and 2D cell culture plates. After 3 hours of incubation at 37oC, 95% humidity, 5% CO2 the 
media was removed and cells were washed thrice with 1X PBS under minor agitation. The 
remaining cells were trypsinized and collected. Cells were counted and the adhesivity was 
qualitatively expressed as a percentage of number of cells attached to the 2D cell culture plates 
versus amikagels.  
 
Generation of 3D-DTMs using Amikagels 
1 ml of amikagel AM1, AM2 and AM3 pre-gel solutions were filtered through a 0.20 µm filter and 
40 µL of the filtrate was added to each well of a 96 well plate.  The plates were sealed with 
paraffin tape (Parafilm, Menasha, WI) and incubated in an oven maintained at 40oC for 7.5 hours. 
After gelation, the surfaces of Amikagels were washed with 150 µL of Nanopure® water for 12 
hours, in order to remove traces of unreacted monomers. All 3D-DTM experiments were set up 
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by liquid overlay culture 104 of cells on top of Amikagel surface in a total volume of 150 mL media 
/well; either 100,000 cancer cells alone (single culture) or 50,000 stromal cells followed by 50,000 
cancer cells (co-culture) were incubated, unless indicated otherwise in specific cases.  After 48 
hours of incubation, 50% of the media in the wells was replaced with fresh media i.e. 
DMEM/RPMI + 10% (v/v) FBS + 1% (v/v) Pen-Strep at regular intervals of 48 hours. Care was 
taken to withdraw and add the media slowly so as to not perturb 3D-DTM formation. Fresh media 
was added every 48 hours following cell plating. For 3D-DTM generation on 24 well plates, 400 
µL of pre-gel volume was used instead of 40µl. Different co-culture 3D-DTM systems are 
represented as fibroblast/stromal cells-epithelial cells (e.g. NIH3T3-T24, WPMY-1-T24) to 
accurately indicate the sequence of their addition. In most cases, 3D-DTMs were formed 5-7 days 
following culture on Amikagels.  
 
Impact of Amikagel Chemo-Mechanical Properties on Resistance and Dormancy of T24 3D-
DTMs. 
T24 3D-DTMs were first formed on AM3, and transferred to AM1s on the seventh day following 
initial cell seeding, in order to investigate the role of chemo-mechanical properties of Amikagels 
on 3D-DTM fate, dormancy and escape from dormancy. Upon transfer, 3D-DTMs were monitored 
for cell spreading and motility on the gel for an additional 7 days. After 7 days, cell cycle analysis 
was carried out on the all 3D-DTMs as described in the previous sections.  
Long-term experiments were also carried out where 3D-DTMs were continuously 
monitored for 15 days after their transfer from AM3 gel to AM1 gel. In order to study the effect of 
drug treatment, T24 3D-DTMs were first treated with 0-100 µM docetaxel for 96 hours after 7 
days of initial seeding of cells on AM3 gel. After 96 hours of this drug treatment, the 3D-DTMs 
were transferred to AM1 gel to study how different chemo-mechanical properties influenced 
escape from dormancy.  Similar studies were also performed using ROCK inhibitor Y-27632 (20 
µM).  
10,000 Individual T24 cells were plated on AM1 gel with 0 and 100 µM docetaxel for 24 hours to 
study the filopodial extensions formed on AM1 gel.  
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N-cadherin expression on Relapsed and Dormant after relapse cells on AM1  
 
After 15 days of transfer of T24 3D-DTM to AM1, the relapsed cells and the remnant mother 3D-
DTM were collected and expanded on fresh 2D cell culture plates. After 48 hours of expansion, 
600,000 cells of the two cell populations were collected for N-cadherin surface expression 
studies. Briefly, the cells were detached from the surface using 20 mM EDTA in ice-cold 1X PBS. 
After 30 minutes of rocking at 4oC, the cells were collected and blocked with wash buffer (1X PBS 
containing 2% FBS) for 30 minutes at 4oC. Wash buffer and block buffer were composed of 1X 
PBS containing 2% FBS. After 30 minutes of washing, the cells were incubated with primary 
antibody at a concentration of 20 µg/mL in 1X PBS containing 2% FBS at 4oC for 1 hour under 
gentle rocking. The cells were collected by centrifugation and washed three times, five minutes 
each in ice-cold wash buffer. The anti-mouse secondary antibody conjugated with Alexa-488 was 
added to the cells at a dilution of 1:200 for 30 minutes in 1X PBS containing 2% FBS at 4oC 
followed by three washes. Flow cytometry was performed as described before. N-cadherin 
expression on cell populations was expressed as mean fluorescent peak. 
 
Dormancy after relapse 
 
Plasticity of relapsed cancer cells was measured by replating them on AM3 after relapse. Cell 
cycle profile was measured to understand whether the relapsed cells can undergo dormancy 
upon returning to the mechanically stiff, non-adhesive environment. 100,000 relapsed cells were 
plated as an overlay culture on AM3 gel. After 7 days of culture, the cell cycle distribution of the 
cells was estimated via procedure described in the previous chapter. 
 
Statistical Analyses 
 
Averages have been expressed as mean ± SD. The effectiveness of the drug combinations were 
quantified using the combination index (CI) by Chou-Talalay method. Two-tailed t-test with 95% 
CI was used analyze and compare the percent cell death data of individual drugs. One-way 
ANOVA has been used to study the differences between the effectiveness of multiple drugs and 
their combinations. Tukey’s multiple comparisons test was used during multiple pairwise 
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comparisons whereas Dunnett’s multiple comparisons test was used while comparing multiple 
means to a single one (control). p<0.05 indicated significance in the analyses. All analyses were 
performed using the Prism GraphPad software. All experiments have been performed at least 
n=2 independent experiments with three replicates each unless specified. 
 
4.3. RESULTS AND DISCUSSION 
 
Cellular escape from tumor dormancy and formation of micrometastasis-like nodules 
Escape from dormancy is characterized by return to a more aggressive and proliferating tumor 
phenotype either at the primary site or at distant metastatic sites, often resulting in patient 
mortality 32. Escape of cancer cells from quiescence / dormancy can be facilitated by changes in 
the microenvironment. Barkan et al. 42 showed that dormancy of  quiescent D2.0R breast cancer 
cells could be reversed by supplementing fibronectin as the extracellular matrix. Fibronectin 
supplementation induced β1 integrin mediated signaling, which, in turn, led to cell proliferation. 
Changes in ECM mechanical properties are known to play a significant role in the metastasis of  
bladder transitional cell carcinoma 168.  
We therefore asked if modulation of Amikagel chemo-mechanical properties could induce 
escape of 3D-DTMs from dormancy. T24 3D-DTMs, generated on mechanically stiff and non-
adhesive AM3, were transferred to more adhesive but mechanically weaker AM1, in order to 
model changes in the tumor microenvironment. T24 cells escaped from the ‘mother 3D-DTM’ 
within just 24 hours following transfer to AM1 (Fig. 4-1A-B).  
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Figure 4-1. Chemo-mechanical engineering of Amikagels induces relapse from dormancy. 
T24 3D-DTMs were transferred from AM3 to AM1 Amikagels and visualized for changes in 
morphology. Phase contrast image of the transferred 3DTM at (A) Day 0, (B). Day 1, and (C) Day 
15 after transfer.  Following transfer of dormant T24 3DTMs from AM3, cell shedding on AM1 
resulted in the formation of microcolonies, 70-100 µm diameter, within 15 days (C). 
Representative images are shown. Scale bar = 100 µm in all cases. (D) Cell cycle distribution 
indicated that the ‘mother’ T24 3DTM remained in near-complete arrest in the G0/G1 phase 
(~90% cells in G0/G1 phase). However, cells that escape the dormant  mother 3D-DTM, spread 
on AM1 and form microcolonies showed a more proliferative profile (17% cells in the G2/M phase 
compared to 5% G2/M cells in the mother spheroid). * indicates p-value = 0.004 (Student’s t-test) 
for the G2/M populations of escaped cells compared to the dormant mother 3DTM, indicating an 
actively proliferating population in the shed cells. 
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However, no cell escape was observed when 3D-DTMs generated on AM3 were transferred onto 
freshly prepared AM3 instead of AM1, (Fig. 4-2), indicating that the different chemo-mechanical 
microenvironment played a key role in escape of cells. At 15 days following transfer, it was clear 
that not all cells had left the mother 3D-DTM placed on AM1.  
 
Figure 4-2. Transfer of T24 3D-DTM to AM3 gel did not cause any relapse. T24 3D-DTMs 
generated on an AM3 did not show any signs of cell spreading and escape when transferred from 
the ‘forming’ AM3 to a newly made AM3. Scale =100 µm. 
 
Interestingly, cells that escaped formed micrometastasis-like nodules, 70-100 µm in 
diameter, on AM1 at significant distances away from the mother 3D-DTM (Fig. 4-1C). Cell cycle 
studies, seven days following transfer, indicated that the ‘mother 3D-DTM’ continued to remain 
dormant (Fig. 4-1D), while the shed cells (Fig. 4-1E) demonstrated increased number of 
proliferating cells (Fig. 4-1D-E). These results clearly show that chemo-mechanical changes in 
the vicinity of the dormant bladder cancer cells can result in immediate relapse from tumor 
dormancy, metastases and microcolony formation.  
 
Chemo-mechanical engineering of Amikagels isolates the aggressive and metastatic cell 
types of the population 
We studied the N-cadherin expression on the expanded populations of the mother 3D-DTM and 
the relapsed cells and found significant differences between them (Fig. 4-3A). N-cadherin 
expression was almost 50% lower in the relapsed cells compared to the cells that remained 
dormant after relapse (Mother 3D-DTM) (Fig. 4-3B-C). Changes in media color was further 
indicative of active metabolism and proliferation in case of shed cells on AM1, indicating a 
reversal of these cells from a dormant to proliferative phenotype compared to the mother 3D-DTM 
(Fig. 4-3C).  
Day 1 Day 5 Day 4 Day 3 Day 2 
Control: Transfer of dormant T24 3D-DTMs to AM3 gel Amikagel 
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B.             C. 
 
Figure 4-3. Relapsed cells have significantly lower expression of N-cadherin on their 
surface (A) Relapsed and mother 3D-DTM were collected and expanded after 15 days of 
transfer. (B) Relapsed cells were observed to have lower N-cadherin levels (significantly lower 
fluorescence) compared to cells that remained dormant after relapse (Mother 3D-DTM). (C) 
Relapsed cells were also observed to actively consume media compared to the expanded mother 
3D-DTM cells. * indicates p-value <0.05 (n=2, Student’s t-test)  
 
T24 cell line is known to be heterogeneous with a mix of metastatic and non-metastatic 
cell fractions 47, 51. Low N-cadherin has been associated with significantly poor prognosis and 
accelerated death in bladder cancer 58. Modulating Amikagel’s adhesivity allowed for selective 
migration, isolation and easy recovery of N-cadherin poor population of T24 cells. Highly 
adhesive substrates such as 2D tissue culture plate caused total invasion and substrate 
integration of the 3D-DTM, making the recovery difficult. Amikagel’s adhesivity was found to be 
~40-50% lower than 2D tissue culture plate and hence made it easier only for metastatic cells to 
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escape (Fig. 4-4A). The non-metastatic cells remained together with the mother 3D-DTM 
allowing for very easy recovery. Transfer of T24-3D-DTM to cell culture treated plate caused 
mass migration of cells in a cell sheet format, which was very difficult to recover without 
trypsinization (Fig. 4-4B). 
A. 
 
B. 
  
Figure 4-4 Cell migration pattern on 96 well plate tissue culture plastic was significantly 
different than Amikagel. (A) Qualitative measurement of amikagel adhesivity compared to 2D 
tissue culture plastic indicated ~40% lower adhesivity (B) Transfer of T24 3D-DTM to tissue 
culture plastic resulted in mass cell migration as cell sheets unlike AM1 which induced selective 
cell relapse (representative day 5 image). Scale =100 µm 
 
After expansion of the two populations of relapsed cells and the mother 3D-DTM, we also 
studied their potential to generate 3D-DTM. We observed that both the cell fractions still generate 
3D-DTMs with different proportions of cells in the G2/M phase. Relapsed cells had slight but 
significantly more number of cells in the G2/M phase of the cell cycle on the plate compared to 
the cells from mother 3D-DTM (Fig. 4-5). Easy formation of 3D-DTMs from cells collected after 
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first round of selection and separation will allow for further iterations of cell separation and 
purification.  
A.      B. 
 
 
C.      D. 
 
Figure 4-5 Expanded relapsed and mother 3D-DTM cell populations resulted in dormant 
formation for further enrichment 
(A-B) Expanded cell populations from dormant mother 3D-DTMs resulted in dormant spheroids 
with G0/G1 arrested cell profile. (C-D) Expanded cell populations from relapsed cells also 
resulted in 3D-DTMs with slight difference in the G0/G1 arrested cell profile. 3D-DTMs generated 
from relapsed cells had significantly higher number of cells in the G2/M phase of cell cycle 
compared to the 3D-DTMs generated from dormant cells. Scale =100 µm 
 
Here, taking a cue from bladder cancer escape and metastasis following ECM 
mechanical changes 169, we show that chemo-mechanical modulation of Amikagel can engender 
relapse of certain cancer cells from dormancy. The relapsed cells demonstrated a proliferative 
5.9	±	0.5	%	
7.5	±	0.3	%	(*)	
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phenotype, with lower N-cadherin levels and a some of these formed micrometastasis-like 
colonies on the gel. Gildea et al. showed that the tumorigenic variant of T24 cells formed 
microcolonies on soft agar and they suggested a paracrine signaling pathway of communication 
between these cells activated upon mutual contact 47. These cells also had higher expression of 
HRAS, lower expression of β-catenin that led to focal adhesion disassembly and invasion. T24 
cells are known to be mesenchymal-like, E-cadherin null and contain heterogeneous N-cadherin 
expression 118, which makes our selective, heterogeneous cell escape and subsequent 
microcolony formation results unique and very interesting. By modulating the adhesivity of the 
substrate, Amikagel could induce the migration of only the most metastatic, N-cadherin poor cells, 
allowing for easy separation and recovery unlike 2D tissue culture plastic.  
Further evidence of heterogeneity was evident in Makridakis et al.’s work 51 of generating 
in-vivo tumors after injecting T24 cells subcutaneously into the flanks of fifteen adult male SCID 
mice. Of these, only five mice bore tumorigenic outgrowths of T24 cells (~33%). Modulation of 
Amikagel chemo-mechanical properties likely facilitated the separation of this heterogeneous 
population into N-cadherin rich dormant and N-cadherin poor relapsed and micrometastases-like 
colony forming cells. While N-cadherin is a significant prognostic factor in bladder cancer 
progression, reduction of N-cadherin was found to be associated with enhanced patient mortality 
rates in multiple cancer including bladder and hepatocellular carcinoma 55, 58, 170. Selective and 
easy substrate assisted isolation and recovery of N-cadherin poor metastatic cells significantly 
improves the clinical relevance of Amikagels in bladder cancer and other metastatic cancers. 
Chemo-mechanical biomaterial strategies could allow for engineering substrate adhesivities to 
directly isolate the most metastatic cell types, rather than doing so repeatedly in the mice 171. For 
example, a previous research by Nicholson et al.171 demonstrated a lengthy procedure of 
isolation and enrichment of highly metastatic fraction of T24 cells by sequential injection into mice 
over 30-40 weeks. T24 cells were injected into six-week– old NCr nu/nu mice and were allowed 
to form metastases. The first generation metastatic cells were collected and reintroduced into 
mice to further enrich the metastatic population and so on. Three generations of enrichment took 
almost 30-40 weeks. Our engineered adhesivity strategy of metastatic cancer cell isolation can 
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drastically cut down the time required to do so. We believe our strategy provides a completely 
synthetic, antibody free method to isolate metastatic fraction of heterogeneous cell populations.  
Contemporary technologies for metastatic cell isolation utilize antibody or serum coated surfaces 
that selectively bind the metastatic cells, antibody based flow sorting, differential rolling of 
metastatic versus non-metastatic cells for specific cell isolation etc 172-175. Our engineered 
adhesivity Amikagel substrate can provide a better modality for metastatic cell isolation due to its 
high chemo-mechanical tunability, ease of preparation, no antibody requirement and easy 
recoverability of the separated cancer cells.  
Taken together, modulating chemo-mechanical properties of Amikagels resulted in 3D 
models of (1) tumor dormancy, (2) cellular escape from dormancy, (3) formation of 
micrometastasis-like nodules, and (4) selective isolation of highly metastatic cell fractions using a 
single completely synthetic platform.  
 
Drugs against relapse and micrometastases formation 
Maintaining cancer cells in a dormant state has been investigated as a strategy for avoiding 
tumor metastasis 176, although eventual relapse from dormancy remains a major concern in this 
approach. The Amikagel platform can facilitate an investigation into drugs that can inhibit relapse 
/ escape from dormancy. Docetaxel treatment (12.5 µM-100 µM) significantly reduced cellular 
escape from the mother 3D-DTM (Fig. 4-6 A-C), likely due to its ability to inhibit cell migration. Li 
et al. 177  previously reported that docetaxel reduced the expression of phospho-AKT and 
phospho-FAK by approximately ~41% and ~34% respectively compared to untreated T24 cells; 
both AKT and FAK are involved in regulating bladder cancer cell migration 177.  In addition, 
docetaxel has also been shown to effectively inhibit cdc42, which promotes formation of actin-rich 
filopodia and their extension prior to cell migration in other cancer cell lines 178-179. Filopodial 
extensions were not observed on cells shed on AM1 after T24 3D-DTMs docetaxel treatment 
(Fig. 4-6 B-C, Black arrows). Culture of individual T24 cells on AM1 gel after being treated with 
docetaxel also showed reduced generation of filopodial extensions (Fig. 4-7, Black arrows).  
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Figure 4-6. Effect of chemotherapeutic drug (docetaxel) treatment on escape from 
dormancy of T24 bladder cancer 3D-DTMs. (A). Experimental sequence. (B). Representative 
image of dormant T24 3D-DTM grown on AM3 and transferred to AM1; this 3DTM was not 
treated with docetaxel. Image taken after 48 hours of transfer of dormant T24 3D-DTM to AM1 gel 
showed significant cell escape from the dormant mother 3D-DTM. (C). Representative image of 
dormant T24 3D-DTM formed and subsequently treated with 100 µM docetaxel on AM3. The pre-
treated 3D-DTM was then transferred to AM1. Image taken after 48 hours of transfer of the 
docetaxel pre-treated dormant T24 3D-DTM to AM1 gel. As seen in the picture, significantly 
lesser number of cells escaped the mother spheroid after pre-treatment with docetaxel. 
Microcolony formation in case of (D) untreated and (E) 100 µM docetaxel pre-treated T24 3D-
DTMs after 15 days of transfer to AM1. Docetaxel pre-treatment significantly reduced cell escape 
and microcolony formation. Scale bar = 100 µm in all cases.   
 
Impact of chemotherapy on dormancy relapse in T24 3D-DTM: 
Sequence of culture 
Day 0 Day 7 
Add  
0,12.5,25,50,100 µM Docetaxel to 3D-
DTMs for 96 hours (microtubule binding 
and stabilizing drug) 
Day 25 
3DTM formation on 
AM3 Amikagel 
Day 10 
Track cell shedding and escape from 
dormant T24 mother 3D-DTM 
Transfer to AM1/
AM2 Amikagel 
! ! ! !
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Formation of micrometastasis-like nodules was also drastically reduced following 
docetaxel-treatment, while untreated 3D-DTMs continued to demonstrate formation of these 
microcolonies (Fig.  4-6 D-E). T24-3D-DTMs treated with docetaxel remained viable and showed 
a dormant cell cycle profile following treatment, indicating that reduction of cell escape from 
dormancy is not due to cell death.  
 
A. 
 
B. 
 
Figure 4-7. Effect of chemotherapeutic docetaxel treatment on filipodial generation in T24 
cells. (A). Untreated T24 cells showed significant filopodial formation (B) and docetaxel treatment 
prevented the formation of filopodia resulting in decrease of total filopodial expression. 100 µM 
docetaxel treated cells on AM1 gel are shown. Scale =100 µm 
 
Cell cycle distribution of docetaxel-treated mother 3D-DTM (Fig. 4-8) showed a modest 
increase of cells in the sub-G0/G1 phase of the cell cycle. This indicates a slight increase in the  
105 
number of cells undergoing apoptosis, which is consistent with previous cell viability results 
observed with docetaxel. No significant differences were observed in cells in the G2/M phase of 
the cell cycle between the untreated 3D-DTM and docetaxel-treated 3D-DTM (Fig. Fig. 4-8). 
However, the escape of some cells from the mother 3D-DTM after docetaxel treatment and 
insignificant changes in the viability of the 3DTM are indicative of the challenges in restricting 
tumors to a dormant state when microenvironment conditions eventually change (e.g.  change in 
adhesivity and / or mechanical properties as in case of transfer from AM3 to AM1). 
A. 
 
B. 
 
Figure 4-8. Cell cycle analysis of T24 3D-DTMs after 96 hours with docetaxel on AM3. (A) 
Cell cycle distribution of T24 3D-DTMs after treatment without and with 100 µM docetaxel for 96 
hours (M1 – Pre G0/G1 phase, M2 – G0/G1 phase, M3 – S phase, M4 – G2/M phase, M5 – 
Multiploid cells). (B) Distribution of cells in pre-G0/G1 and G2/M phases after treatment with 0 
µM, 50 µM and 100 µM docetaxel for 96 hours.  
 
The Amikagel platform can also lead to the identification of drugs that promote cellular 
escape from dormancy. Liu. S et al. reported that ROCK inhibitor (Y-27632) could prevent 
Live Control 100 µM Docetaxel 
Percent cells Live T24  
3D-DTMs  
50 µM 
Docetaxel 
Treated T24 
3D-DTMs 
100 µM 
Docetaxel 
Treated T24 
3D-DTMs 
 
Pre G0/G1 
Phase 
12 ± 7.6 22.6 ± 0.55 28.9 ± 5 
 
G2/M Phase 6 ± 1.27 6 ± 0.07 
 
6.24 ± 0.55 
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invasive MCF-7 cell metastases to bone 180. However, ROCK inhibition was also shown to 
activate dormant MCF-7 cells into invasion 181. Treatment of the mother 3D-DTM with the ROCK 
inhibitor Y-27632 resulted in an increase in the relapse of cells from dormancy upon transfer to 
AM1 (Fig. 4-9), which is consistent with results reported in Yang et al. 181.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
A.   
  
B.  
  
C.   
 
Figure 4-9. ROCK inhibition using Y27632 caused increase in the number of cells that shed 
from the mother T24 3D-DTM after transfer to AM1 gel. (A) Representative images of cells 
shedding after 3 days of transfer to AM1 gels (No Y27632 treatment). (B) Representative images 
of cells shedding after 3 days of transfer to AM1 gels (20 µM Y27632 treatment). Scale = 100 µm 
in all cases.  (C) Treatment with Y27632 showed a significant increase in cell shedding from 
mother T24 3D-DTM. (p=0.013) 
 
Pre-treatment with the ROCK inhibitor did not change the cell cycle profile of T24 3D-
DTMs on AM3 (Fig. 4-10). It however, significantly increased the number of cells leaving the 
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spheroid on AM1 (Fig. 4-9 A-C). Use of a conventional anti-proliferative chemotherapeutic 
(docetaxel) was able to significantly reduce but not completely eliminate escape of cells from 
dormancy. In contrast, use of a ROCK inhibitor further enhanced relapse from dormancy. ROCK 
inhibition has been implicated in activating actin depolymerization on the rear end and activating 
Rac1 leading to the observed increase in migration 182. We did not observe any changes in the N-
cadherin expression after treatment with ROCK inhibitor, which rules out downregulation of N-
cadherin expression after ROCK treatment.  
A. 
 
Figure 4-10. Cell cycle analysis of T24 3D-DTMs after 96 hours with ROCK inhibitor Y-
27632 on AM3. (A) Cell cycle distribution of T24 3D-DTMs after treatment without and with 20 
µM Y-27632 for 96 hours (M1 – Pre G0/G1 phase, M2 – G0/G1 phase, M3 – S phase, M4 – 
G2/M phase, M5 – Multiploid cells). (B) Distribution of cells in pre-G0/G1 and G2/M phases after 
treatment with 0 µM and 20 µM Y-27632 for 96 hours.  
 
Utilizing our high-throughput relapse platform, we showed that common 
chemotherapeutic docetaxel which could not ablate the dormant cell, worked towards actively 
Live Control 100 µM Docetaxel 20 µM Y-27632    
B.	Cell	cycle	phase	 Untreated	3D-DTMs	 20	μM	Y-27632	Treated	
3D-DTMs	
Pre	G0/G1	Phase	 12	±	7.6		 23	±	0.5	
G2/M	Phase	 6	±	1.27	 3.8	±	0.5	
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inhibiting the relapse and ROCK inhibitor that has been shown to inhibit cell migration, actually 
promoted cell escape. Taken together, our results demonstrated the simplicity of the Amikagel 
platform for studying relapse. We put forth a unique regimen of drugs that are very effective in 
complete accelerated ablation of dormant cancer cells and significantly inhibit tumor relapse and 
escape. We believe our hydrogel platform sets the stage for multiple high-throughput studies for 
the discovery of new drugs that can reduce cancer dormancy, relapse and micrometastasis in 
future. 
 
4.4. CONCLUSION 
Modeling microenvironment changes by changing the chemo-mechanical properties of Amikagels 
resulted in escape of cancer cells from the dormant ‘mother 3DTM’. Shed cells formed 
micrometastasis-like nodules 70-100 µm in diameter at significant distances from the mother 
3DTM, indicating that micro-environment changes can promote reversal of the dormant 
phenotype, which is consistent with clinical observations. Relapsed cells had significantly lower 
expression of N-cadherin than cells from mother 3D-DTMs. Engineered Amikagel adhesivity 
strategies allowed easy isolation of metastatic cancer cell fractions from heterogeneous cancer 
cell population. Docetaxel pre-treatment reduced while Y-27632 (ROCK inhibitor) enhanced cells 
shed from the mother 3DTM. Taken together, the Amikagel platform facilitates high-throughput 
formation of 3DTMs for applications in drug screening and investigations in fundamental tumor 
biology. This high-fidelity platform can be employed for identifying drugs that can reverse and / or 
ablate the dormant phenotype, as well as obviate cell escape from dormant tumors, leading to 
novel discoveries for the clinical management of cancer diseases. 
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CHAPTER 5: AMINOGLYCOSIDE ANTIBIOTIC-DERIVED ANION-EXCHANGE 
MICROBEADS FOR PLASMID DNA BINDING AND IN SITU DNA CAPTURE  
  
5.1. INTRODUCTION 
Plasmid DNA (pDNA) is being investigated in several applications in biotechnology and medicine, 
including gene therapy against cancer, AIDS 183-185 and cystic fibrosis186, DNA based gene 
vaccinations 187 and in vitro transfections for cellular manipulation188. Plasmid DNA molecules are 
extra-chromosomal pieces of double-stranded DNA189 which confer selective advantages 
including antibiotic resistance in bacteria, and can be transferred to other species via horizontal 
gene transfer 190-191. In cancer gene therapy, therapeutic plasmids, which code for functional 
tumor suppressor proteins, are delivered to cancer cells 80. DNA-based gene vaccinations involve 
either direct intramuscular / intradermal injection of naked pDNA or lipid-coated delivery of the 
same to the target tissues 192-193. 
Plasmids are usually grown in rapidly dividing Escherichia coli, and can be obtained by 
employing different downstream purification steps 194. Anion-exchange chromatography 195, 
affinity-based chromatography 196, hydrophobic interaction chromatography 197, and size-
exclusion and perfusion chromatography 198 have been explored for purification of pDNA. Affinity-
based chromatography methods utilize specific interactions between pDNA and surface-
immobilized affinity ligands for selective binding 199. Pseudo-affinity and affinity ligands including 
arginine and histidine 200, zinc fingers 201, LacI-LacZ moieties 202 and triple helix forming 
nucleotide sequences 203 have been explored in affinity-based DNA purification approaches. 
Hydrophobic interaction chromatography (HIC) has also been investigated as a purification step 
due to differences in hydrophobicities of RNA, proteins, genomic DNA, lipopolysaccharides and 
pDNA 204-205. 
Anion-exchange chromatography is widely used for pDNA chromatography, and relies on 
electrostatic interactions between the negatively charged backbone of pDNA and positively 
charged microbeads (resin) 195. For example, Q Sepharose Fast Flow resins consist of 6% 
crosslinked solid agarose beads that are approximately ~90 µm in diameter. These resins, 
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functionalized with quaternary amines, have been used for pDNA binding and purification (~1.3 
mg/mL pDNA binding capacity) 84, 206. In addition, super-porous / macroporous flow-through 
beads (e.g. POROS 50) combine high surface areas with high capacities for plasmid DNA binding 
and purification (~10 mg/mL pDNA binding capacity) 84. 
We have previously investigated aminoglycosides and aminoglycoside-derived materials 
for DNA binding and delivery 5, 80, 207. Here, in this chapter we discuss the synthesis, 
characterization and evaluation of novel anion-exchange microbeads (Amikabeads) derived from 
an aminoglycoside antibiotic, amikacin, with an eye towards applications in DNA biotechnology. 
Microbeads displaying quaternary amine functionalities (‘Amikabeads-Q’) demonstrated 
significantly higher pDNA binding compared to parental amikacin-derived microbeads with 
primary / secondary amine moieties (‘Amikabeads-P’). While high salt concentrations were 
effective in desorbing pDNA from Amikabeads-P, recovery of pDNA from Amikabeads-Q was 
greatly improved when hydrophobic modifiers (isopropanol) were included in the elution buffer. 
Finally, Amikabeads were also employed for mammalian cell lysis and concomitant in situ DNA 
sequestration directly from these cells. 
5.2. MATERIALS AND METHODS 
Materials 
Amikacin hydrate and poly(ethylene glycol) diglycidyl ether (PEGDE) were purchased from 
Sigma-Aldrich Inc. (St. Louis, MO). Silicone oil and mineral oil were purchased from Acros 
Organics (Pittsburgh, PA, USA). The surfactant Span-80 was purchased from TCI America 
(Portland, Oregon). Nanopure water was used for all preparations unless otherwise stated. BD 
Precision Glide 27G1 ¼ needles and 5 mL syringes were purchased from Becton, Dickinson and 
Company (Franklin Lakes, NJ). Calcein AM / ethidium homodimer-I Live/Dead stain® was 
purchased from Life Technologies, (Carlsbad, CA). PC3 human prostate carcinoma cells were 
purchased from American Type Culture Collection (ATCC; Manassas, VA). Cell culture media - 
RPMI, Pen-Strep solution: 10000 units/mL penicillin and 10000 µg/mL streptomycin in 0.85% 
NaCl solution were purchased from Hyclone (Logan, UT). Qiagen Giga kit and Maxi kit (pDNA 
extraction kits) were purchased from Qiagen Inc. (Alameda, CA). 
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Preparation of Parental Amikagel microbeads (Amikabeads-P) 
Amikabeads-P (P: parental) were generated using the emulsion polymerization method 208. 
Amikacin hydrate (100 mg, 0.17 mmoles) was dissolved in 1 ml nanopure water followed by 
addition of poly(ethylene glycol) diglycidyl ether (PEGDE) in a mole ratio of 1:2 to generate a 
uniform mixture. The mixture was stirred at 100 rpm and pre-gelled for 4 minutes at 70oC. After 4 
minutes, the solution was collected in a syringe and dispensed slowly into a solution of mineral oil 
and 1% (w/v) Span-80 through 27 G11/4 BD-Precision Guide needle. The mineral oil-surfactant 
solution was maintained at 65oC throughout the process. Approximately ~500 µL of the pre-gel 
solution was dispensed into the heated oil phase within 25 minutes under constant stirring of 260 
rpm. The beads were allowed to gel for 10 minutes after their addition followed by extensive 
washing and size measurements 
The beads were collected by centrifugation for 10 minutes at 5500 rpm. Oil was washed 
off the surface of the beads by using a solution of ~1% (v/v) Tween 20 detergent. Following 
detergent washes, the beads were finally washed multiple times with nanopure water. The 
particle diameters of Amikabeads-P were measured using phase-contrast microscopy; fifty beads 
were chosen randomly from each batch and their diameters were recorded.  The averaged bead 
diameter of these samples was used as an indicator of size in subsequent analyses. 
 
Formation of Amikabeads-Q by Quaternization of Amikabeads-P Microbeads 
Amines and hydroxyls present in Amikabeads-P were quaternized using glycidyl trimethyl 
ammonium chloride in an aqueous solution. Excess glycidyl trimethyl ammonium chloride 
(GTMAC) was mixed with Amikabeads at 200 rpm in nanopure water for 24 hours at 70oC 
followed by extensive washing 209. Quaternization was qualitatively confirmed using the ninhydrin 
assay 80, as well as a fluorescein binding assay 210. Briefly, commercially available ninhydrin 
reagent (200 µL) was added to 1 mg of Amikabeads P and Q and incubated at 99oC for 10 
minutes, and the color change was visually observed and recorded. For fluorescein binding 
studies, Amikabeads P and Q were incubated with 1% (v/v) NaOH solution in nanopure water for 
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20 minutes. Fluorescein sodium (200 µL of 50 mg/mL), in 1% (v/v) NaOH solution (pH > 12) 
made in nanopure water, was added to both bead samples. The beads were mixed with the 
fluorescein solution for 10 minutes, and then separated by centrifugation at 5000 rpm for 5 
minutes. The beads were extensively washed with 1 mL solution of 1% (v/v) NaOH in nanopure 
water. The retention of fluorescein dye was visually observed and used as a qualitative indicator 
of quaternization. 
 
Determination of swelling ratio of Amikabeads 
Twenty wet Amikabeads were randomly chosen, and their diameters were measured using 
phase-contrast microscopy as described before. The volumes of each of these respective beads 
were calculated based on these diameters. The volumes of the swollen wet beads were denoted 
as Vwet. After this measurement, Amikabeads were allowed to dry at 65oC for 24 hours. Once dry, 
the diameters of the same beads were measured again, and their volume, Vdry, was calculated. 
The swelling ratio or SR of the beads was calculated as following: 
SR  = Swollen gel volume/Dry gel volume (v/v) 
 
Determination of Amikabead Amine Content 
Amikabeads-P and -Q (1 mg) were freeze-dried and collected as a powder following which, 1 ml 
nanopure water was added to them. The ninhydrin assay reagent (100 µL) was added to 100 µL 
of 1 mg/mL Amikabead dispersion. The resulting solution was boiled at 99oC for 10 minutes. The 
absorbance of the final colored solution was measured at 570 nm. The amine content was 
determined by comparing the absorbance of the sample solution to a calibration curve generated 
using glycine standards. 
 
Total surface area and porosity estimation using BET method 
Surface area and porosity of Amikabeads were measured via BET nitrogen sorption technique. 
The water in Amikabeads was gradually exchanged with acetone by suspending the beads in 
graded acetone series. Once the Amikabeads were soaked in 100% acetone, they were dried 
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under vacuum before proceeding with the BET analysis.  Dry Amikabeads were weighed into 
analytical glassware and subjected to 35oC temperature for 11 hours under constant purging with 
ultra high purity (UHP) nitrogen on a FlowPrep 060 Degasser. Once degassed, the sample was 
connected to the Micromeritics Tristar II 3020 sample port in order to carry out the experiment 
under vacuum in presence of liquid nitrogen. The porosity and total surface area per mg of 
Amikabeads were calculated. 
 
Scanning Electron Microscopy of Amikabeads 
The surface morphology of Amikabeads was visualized using Field Emission Scanning Electron 
Microscopy (FE-SEM; Philips FEI XL-30 SEM) at 25kV. Amikabeads were placed on double-
sided carbon adhesive tape attached on the aluminum stub, and were sputter-coated with Au-Pt 
for 120 seconds using E1030 ion sputter. Approximately 8 nm thick Au-Pt coating was deposited 
on the beads on double carbon adhesive tape. SEM was performed at a voltage of 3 kV. 
 
pDNA binding to Amikabeads 
Amikabeads-P (~2 mg) were incubated with 15,000-200,000 ng of pDNA (pGL4.5) in 10 mM Tris-
Cl buffer, pH 8.5 (buffer I), for 24 hours at room temperature (25oC) in order to allow pDNA 
binding to the beads. All Amikabeads were washed with buffer I for 6 hours prior to addition of 
any pDNA. NanoDrop Spectrophotometer was used to measure the pDNA content in the 
supernatant after incubation with the beads. The amount of pDNA adsorbed onto the beads was 
calculated by mass balance. An adsorption isotherm was generated by calculating the amount of 
pDNA adsorbed on the beads at corresponding equilibrium pDNA concentrations in the 
supernatant. The isotherm data were fitted to a Langmuir isotherm, in order to determine the 
maximum binding capacity (Qmax) and the binding constant (K) for the Amikabeads.  The 
Langmuir adsorption isotherm equation is shown below: 
Q! = (Q!"# ∗ K ∗ C!)1 + (K ∗ C!)  
where, 
115 
Qe = The amount of pDNA bound to the Amikabeads at equilibrium (µg/mg) 
Ce = Concentration of pDNA in the solution at equilibrium (mg/L) 
K = Langmuir adsorption constant. (L/mg) 
Qmax = Maximum amount of pDNA bound to Amikabeads (µg/mg) 
 
The Langmuir equation was linearized, and 1/Qe vs. 1/Ce were plotted in order to 
calculate Qmax from the slope of the curve and the adsorption constant (K) from the intercept. 
The effect of increasing salt concentration on the adsorption of pDNA on Amikabeads 
was also studied; 10 mM Tris-Cl was supplemented with 290 mM NaCl (buffer II), 690 mM NaCl 
(buffer III), and 990 mM NaCl (buffer IV), and used to allow pDNA to bind to the microbeads. The 
linear form of the Langmuir adsorption isotherm was used to determine parameters under these 
high-salt conditions as described below: x = 𝐾! ∗ 𝐶!; 
where: 
x = The amount of pDNA bound to 1 mg of  Amikabeads (µg/mg) 
Ke = Partition coefficient of pDNA between solution and the adsorbent (Amikabeads) 
(L/mg) 
Ce = Equilibrium concentration of pDNA in the solution (mg/L) 
 
In case of Amikabeads-Q, 15,000-400,000 ng of pDNA were added to ~1 mg of the 
quaternized beads for 24 hours in 200 µL buffer I in order to allow for binding at 25oC. After 24 
hours, the static batch binding capacity of the quaternized beads was studied by determining the 
amount of pDNA adsorbed on to the beads, using procedures similar to those described above. 
The pH was maintained at 8.5 in all cases. 
 
Visualization of pDNA bound to Amikabeads-P and Q 
Amikabeads-P and Q (1 mg) were incubated with 40,000 ng and 200,000 ng of pDNA in 200 µL 
of buffer I for 24 hours at 25oC respectively. pDNA-Amikabead aggregates were imaged at 10X 
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magnification using a Zeiss light microscope to measure their size. The average size of 
aggregates was estimated by measuring their longest length in micrometers. 
Fluorescence confocal microscopy was carried out in order to visualize pDNA on the 
Amikabeads. After incubation of pDNA with Amikabeads for 24 hours at 25oC, 10 µM ethidium 
homodimer-1 was added to both, Amikabeads-P and Q for 20 minutes. Ethidium homodimer-I is a 
high-affinity nucleic acid stain that demonstrates high fluorescence upon binding to DNA, while its 
fluorescence is quenched in aqueous media 211. After 20 minutes, the beads were separated by 
centrifugation, and 200 µL of Fluoro-gel with Tris-Cl buffer (Electron Microscopy Sciences, 
Hatfield, PA) was added to them. The beads were mounted on a glass slide and sealed with nail 
polish. Ethidium homodimer-I fluorescence was observed using excitation at 514 nm, and the 
emission was recorded at 628 nm. The control Amikabead samples were prepared in the exact 
same manner, except that no pDNA was added. Adsorption of pDNA on Amikabeads was 
determined using Leica SP5 confocal microscopy using a 20X objective. 
 
Desorption of bound pDNA from Amikabeads P and Q 
Amikabeads-P (2 mg) were loaded with 15000-100,000 ng of pDNA in buffer I at 25oC, in order to 
ensure loading in the linear as well as non-linear portion of the adsorption isotherm. The pDNA-
loaded Amikabeads-P were first washed with 200 µL of buffer I for 30 minutes before adding the 
salt solution for desorption. The amount of pDNA desorbed during the wash step was also 
determined. The amount of pDNA desorbed following addition of salt solutions was determined 
using absorbance measurements (Nanodrop) after 24 hours of exposure to 1 mL Tris-Cl buffer 
with 1 M salt (0.99 M NaCl and 10 mM Tris-Cl, pH 8.5) and 1 mL Tris-Cl buffer with 1.3 M salt (50 
mM Tris-Cl and 1.25 M NaCl, pH 8.5) with 15% isopropanol at 25oC. The desorption buffers were 
refreshed after every 24 hours for Amikabeads-P until there was no further pDNA desorption from 
the beads. 
Amikabeads-Q (1 mg) were loaded with approximately 250,000 ng of pDNA in buffer I at 
25oC; a lower amount of Amikabeads-Q was used in the desorption experiments due to the 
higher binding capacities of these materials. pDNA-loaded Amikabeads-Q were first washed with 
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200 µL of buffer I for 30 minutes before adding the salt solution for desorption. The amounts of 
pDNA desorbed were determined using absorbance measurements (Nanodrop) after 12 hours of 
exposure to different desorption buffers at 25oC.  These included, 1 mL Tris-Cl buffer with 1 M 
salt (0.99 M NaCl and 10 mM Tris-Cl, pH 8.5), Tris-Cl buffer with 1.3 M salt (50 mM Tris-Cl and 
1.25 M NaCl, pH 8.5), Tris-Cl buffer with 1.3 M salt (50 mM Tris-Cl and 1.25 M NaCl, pH 8.5) 
supplemented with 15% isopropanol, and Tris-Cl buffer with 1.3 M salt (50 mM Tris-Cl and 1.25 M 
NaCl, pH 8.5) supplemented with 30% isopropanol. The desorption was also carried out at 50oC 
using Tris-Cl buffer with 1.3 M salt (50 mM Tris-Cl and 1.25 M NaCl, pH 8.5) supplemented with 
15% and 30% isopropanol respectively. The desorption buffers were refreshed after every 12 
hours for Amikabeads Q until there was no further pDNA desorption from the beads. 
The volume of Amikabead slurry was determined in order to compare pDNA binding 
efficacies of Amikabeads-P and Q microbeads with those of commercially available pDNA binding 
resins. It was determined that ~1 mg of Amikabead-Q  slurry had a volume of 50 µL whereas 2 
mg of Amikabead-P amounted to ~75 µL slurry volume as prepared. The static binding capacities 
of Amikabeads-P and Q resins were extrapolated to 1 mL of slurry volume, and their binding 
capacities were compared to commercially available resins. These analyses were carried out in 
order to enable a back-of-the-envelope comparison of Amikabeads with existing materials. 
 
Agarose gel electrophoresis of the desorbed pDNA 
Agarose gel electrophoresis (AGE) analysis was carried out in order to investigate the integrity of 
the pDNA desorbed from Amikabeads. Briefly, 1 µL pDNA (~200 ng/µL) desorbed from the beads 
was mixed with 10 µL gel loading dye (IBI 6X gel loading dye), loaded on 1% agarose gel, and 
run under a potential of 150 V for 30 minutes using 1X TAE buffer (Tris base, acetic acid and 
EDTA buffer). Qualitative differences between the pDNA stock used for loading on Amikabeads, 
and pDNA desorbed from Amikabeads P and Q were visualized under ultraviolet light. 
 
Cell viability of PC3 prostate cancer cells after exposure to Amikabeads-P and -Q 
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Parental (P) and quaternized (Q) Amikabeads (100-500 µg) were added to 10,000 PC3 prostate 
cancer cells grown in RPMI cell culture media in 96 well plates for 24 hours, in order to first 
determine their effect on cell viability. After 24 hours, the viability of the PC3 cells was estimated 
using a colorimetric MTT assay in which, 10 µL of MTT reagent was added to the cells for 3 hours 
followed by detergent-mediated cell lysis. The absorbance of solubilized formazan crystals was 
measured at 570 nm and the background absorbance was measured at 670 nm. The resultant 
absorbance was used as a measure to estimate the cell viability of the PC3 prostate cancer cells. 
Viability of PC3 prostate cancer cells following treatment with Amikabeads P and Q was 
also determined using the Live-Dead assay. 1 µM calcein AM and 2 µM ethidium homodimer-I in 
RPMI media were added to the PC3 prostate cancer cells for 20 minutes. After 20 minutes, the 
green fluorescence of calcein was observed using excitation: 485 ± 10 nm and emission: 530 ± 
12.5 nm filter, and red fluorescence of nucleic acid bound ethidium bromide was observed using 
excitation: 530 ± 12.5 nm and emission: 645 ± 20 nm filter. 
 
In situ Sequestration of DNA from Cancer Cells using Amikabeads 
Amikabeads-P were used to induce cell lysis of PC3 human prostate cancer cells in order to 
facilitate extraction of cellular DNA. Amikabeads-P (100-500 µg) were added to 10,000 PC3 cells 
following seeding for 24 hours on a 96 well plate. After 24 hours of incubation, 2 µM ethidium 
homodimer-I was added to the cells exposed to the beads as described above. Captured 
genomic DNA, bound on Amikabeads-P was visualized using fluorescence microscopy using 
ethidium homodimer-1. 
 
5.3. RESULTS AND DISCUSSION 
Generation of Microbeads (Amikabeads) derived from an Aminoglycoside Antibiotic 
Aminoglycoside antibiotics including neomycin, streptomycin, kanamycin, apramycin and 
paromomycin are known to prevent growth of gram-negative bacteria by inhibiting protein 
synthesis 212. The mode of action of aminoglycoside antibiotics involves binding and stabilizing 
16s rRNA and complexing with 30S subunit of ribosome. This, in turn, inhibits protein synthesis 
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and causes bactericidal activity 213. Aminoglycosides possess biocompatible sugar groups as well 
as multiple amines in the same molecule. Their natural affinity towards nucleic acids, makes them 
excellent candidates for generating diverse materials in nucleic acid biotechnology 5, 80, 214. Here, 
we report the generation of amikacin antibiotic-derived microbeads, ‘Amikabeads’, as anion-
exchange resins for potential use in pDNA purification as well as in situ capture of DNA from 
mammalian cells 215. 
 
Figure 5-1. Amikagel as micro-resins for pDNA binding. Schematic of the reaction between 
amikacin hydrate and poly(ethylene glycol) diglycidyl ether (PEGDE), resulting in the formation of 
Amikagel (hydrogel). 
 
Reaction between amines present in amikacin with the epoxide groups in PEGDE resulted in the 
formation of a crosslinked hydrogel (‘Amikagel’) as shown in Figure 5-1. It was hypothesized that 
multiple amines in Amikagel, particularly in the form of microbeads, can be exploited for nucleic 
acid (pDNA) biotechnology. Parental Amikabeads-P were generated using an emulsion 
polymerization method (Figure 5-2 A-B); a crosslinking ratio of 1:2 amikacin to PEGDE was 
used.  
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B. 
 
C.       D. 
   
Figure 5-2. Schematic of Amikabead-P synthesis. (A-B) Amikabeads were prepared by pre-
gelling the Amikagel solution for 4 minutes at 70oC. The pre-gelled Amikagel solution was added 
to mineral oil bath supplemented with 1% Span 80 surfactant and maintained at 65oC. (C) Phase-
contrast image of Amikabeads-P generated after emulsion polymerization of Amikacin-PEGDE in 
mineral oil-1% Span 80 solution. Scale bar: 100 µm. (D) Scanning electron microscopy (SEM) 
image of Amikabeads indicates spherical particles with an average diameter of ~9 ± 4 µm 
(calculated over 50 beads).  
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The amikacin-PEGDE mixture formed a solid hydrogel within ~8 minutes when stirred at 
100 rpm at 70oC. Hence, a pre-gelling time of 4 minutes was chosen, following which, the pre-
gelled Amikagel solution was introduced into the heated mineral oil phase (65oC, constant stirring 
at 260 rpm) (Figure 5-2). In all cases, mineral oil was supplemented with 1% Span-80 surfactant 
(w/v) in order to stabilize the water-in-oil microemulsion. Microbeads synthesized in absence of 
Span-80 were irregular, non-spherical, and appeared aggregated (Figure 5-3). 
 
 
Figure 5-3. Optical image of Amikabeads-P prepared with silicone oil. Amikabeads prepared 
in silicone oil in absence of stabilizing surfactant were irregularly shaped. Scale bar = 100 µm 
 
Amikabeads-P formed in mineral oil were separated from the oil phase by centrifugation 
at 5000g for 10 minutes following which, the microbeads were extensively washed with nanopure 
water supplemented with 1% (v/v) Tween 20. Addition of Tween 20 allowed the removal of 
remaining Span-80 and mineral oil. Tween and Span surfactants are often mixed together in 
order to generate surfactants of desired Hydrophilic : Lipophilic Balance (HLB) values (Note: An 
HLB value of more than 10 is necessary in order to ensure surfactant solubility in water). Given 
the insolubility of Span-80 in water (HLB value of 4.3), Tween-20 (HLB value of 16.3) was added 
to solubilize and remove any remaining Span-80 and mineral oil 216. The steps used to generate 
Amikabeads-P are shown in Figure 5-2 A-B. 
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Characterization of Amikabeads 
Shape and Particle Size of Amikabeads 
Amikabeads-P generated using the above emulsion system had spherical morphologies and 
demonstrated minimal aggregation (Figure 5-2C, Figure 5-3), although in eventual 
chromatographic applications, Amikabeads will be tightly packed together as the solid phase. 
Amikabeads-P were sputter-coated with 8 nm thick coating of Au-Pt in order to visualize them 
using scanning electron microscopy (SEM). As shown in Figure 5-2D, Amikagel-P microbeads 
had a predominantly spherical shape with smooth as well as rough surface morphology, which is 
similar to other hydrogel microbeads described previously 217.  The average diameter of 
Amikabeads-P was ~ 9 ± 4 mm (Figure 5-2D), and was dependent on the number of times the 
mixture of mineral oil and span 80 was used in serial batches. Upon repeated usage of mineral oil 
and span 80, the diameters of Amikabeads demonstrated a modest increase (p<0.01, one-way 
ANOVA) (Figure 5-4A). 
A.                                                                                  B. 
 
 No Span-80 added Span-80 added 
p–value of One-way 
ANOVA 
0.00162 0.174 
 
Figure 5-4. Amikabeads diameter after emulsion polymerization method of preparation. 
Average Amikabead-P diameter ± one standard deviation (in microns) of three consecutive 
batches (A) in absence and (B) in presence of Span-80. The p-values for the one-way ANOVA 
test are also shown for n=5 independent experiments. 
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We hypothesized that introduction of additional fresh Span-80 after every batch of 
Amikabead synthesis could limit the batch-to-batch variation in the bead size. This 
supplementation would account for any losses in Span-80 by thermal degradation during the 
preparation of each batch. As seen in Figure 5-4B, the diameter of Amikabeads-P did not change 
significantly with addition of 400 mg of fresh Span-80 after each batch of preparation. An 
observed p-value of 0.174 indicated that it is not possible to reject the null hypothesis that particle 
diameters in all three consecutive batches are the same in Figure 5-4B (p-value threshold of 0.05 
for statistical significance). Thus, addition of Span-80 indeed reduced the batch-to-batch variation 
in particle diameter / size. Following this observation, we were able to mix different batches in 
order to obtain high amounts of Amikabeads-P for subsequent investigations. 
Amikabeads-P demonstrated a swelling ratio of approximately 1.74 ± 0.2 (or 174%).  This 
behavior is similar to commercially available anion-exchange resins, which demonstrate swelling 
ratios of up to 200% 218. For example, quaternary ammonium group-containing polystyrene-
divinylbenzene (PS-DVB) beads, used as strong anion exchange resins, demonstrated a swelling 
ratio of 1.7, which is very similar to that of Amikabeads 219. 
 
Amine content of Amikabeads 
The presence of accessible amine moieties is critical for the use of Amikabeads in anion-
exchange applications. Furthermore, presence of reactive amines allows for subsequent 
conjugation chemistries if required. The reaction of ninhydrin reagent with reactive (primary and 
secondary amines) results in colorimetric changes; a bluish-purple color can be observed upon 
reaction with primary amines 220. Reaction of a 0.5 mm model Amikabead with 100 µL of 
ninhydrin reagent at 70oC for ten minutes resulted in the formation of intense bluish-purple color 
throughout the bead (Figure 5-5). The amine content of lyophilized Amikabeads-P was estimated 
to be 1.8 ± 0.3 µmoles of amine per milligram of Amikabeads. 
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A.     B. 
   
Figure 5-5. Amikabeads-P ninhydrin assay. (A) Optical image of 0.5 mm model Amikabead-P 
indicated by an arrow. (B) Reaction with the ninhydrin assay reagent resulted in blue-purple color 
throughout the Amikabead (red arrow), indicating presence of reactive primary amines. 
 
pDNA Binding to Amikabeads-P 
The binding of pDNA to Amikabeads-P was determined using batch adsorption assays, in order 
to determine the potential use of these microbeads as anion-exchange resins. The pGL4.5 
luciferase pDNA was used as a model plasmid in all batch binding experiments. The pGL4.5 
plasmid codes for luciferase reporter protein, which is commonly used for analyzing the 
transfection efficacy of various non-viral vectors 221. A Langmuir adsorption isotherm was used to 
fit the experimental data and obtain parameters including the maximum binding capacity (Qmax) 
and equilibrium binding constant (K). Table 5-1A shows the different parameters generated by 
fitting the experimental adsorption isotherm data to a Langmuir isotherm; the Langmuir adsorption 
equation was converted to its linear form in order to determine the Qmax value.  
 
 
 
 
 
 
 
 
a" b"a" b"
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Table 5-1. Langmuir adsorption isotherm parameters of plasmid DNA binding to 
Amikabeads at 25oC 
A. Adsorption of plasmid DNA to Amikabeads-P in presence of 10 mM Tris-Cl buffer (pH 8.5) 
(Buffer I) 
  
B. Adsorption of plasmid DNA to Amikabeads-P in presence of 300 mM Tris-Cl -NaCl buffer (pH 
8.5) (Buffer II) and 600 mM Tris-Cl -NaCl buffer (pH 8.5) (Buffer III) 
 
The average (n=3) maximum adsorption capacity (Qmax) calculated by fitting the adsorption 
isotherm of the Amikagel-P microbeads was approximately 44.5 µg pDNA/mg of Amikabeads-P 
with an equilibrium constant K of 0.04-0.06 L/mg at an equilibrium pDNA concentration (solution 
phase) of 300-400 mg/L. Further increasing the concentration of pDNA in the solution phase did 
not result in any increase in the amount of DNA adsorbed on Amikabeads-P, indicating saturation 
(Figure 5-6A, diamonds). 
 
 
 
ID Average bead size 
(µm) 
Qmax  
(µg/mg) 
K  
(L/mg) 
R-square 
1 10 ± 3 56.0 0.01 0.97 
2 11 ± 5 46.4 0.02 0.88 
3 12 ± 4 31.5 0.05 0.96 
ID Average bead size 
(µm) 
Salt 
concentration 
K 
(L/mg) 
R-square 
Buffer II 
1 12 ± 4 300 mM 13.0 0.63 
2 10 ± 3 300 mM 13.2 0.71 
3 10 ± 4 300 mM 17.8 0.79 
Buffer III 
4 12 ± 6 600 mM 13.8 0.31 
5 11 ± 5 600 mM  18.3 0.27 
6 10 ± 5 600 mM 21.7 0.49 
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A. 
 
B. 
 
Figure 5-6 Plasmid DNA adsorption and desorption from Amikabeads-P. (A) Isotherm of 
pGL4.5 plasmid DNA adsorption on Amikabeads-P of diameter 11 ± 4 µm in presence of (Buffer 
I) 10 mM, Tris.HCl buffer, pH 8.5, at 25oC for 24 hours (diamonds). Maximal adsorption (Qmax) = 
44.5 µg of plasmid DNA / mg of Amikabeads-P (n=3) (diamonds). Effect of (Buffer II) 0.3 M salt 
on plasmid DNA adsorption on Amikabeads of average diameter 12 ± 4 µm (squares). Reduced 
pDNA binding can be observed, indicating that electrostatic interactions drive adsorption. 
(B) Desorption of plasmid DNA from Amikabeads-P (1 mg) using Tris-Cl buffer with 1 M 
salt (0.99 M NaCl, 10 mM Tris-Cl, pH 8.5) after 24 hours (diamonds), and Tris-Cl buffer with 1.3 
M salt (1.25 M NaCl, 50 mM Tris-Cl, pH 8.5) supplemented with 15% isopropanol  (squares) at 
25oC. 
 
pDNA binding to Amikabeads-P was significantly reduced in presence of 0.3 M (buffer II) 
and 0.6 M salt (buffer III) (Table 5-1B). As expected, higher salt concentrations screen 
electrostatic charges and obviate interactions between negatively charged DNA molecules and 
the positively charged Amikabeads-P. The saturation amount of pDNA on Amikabeads-P was not 
calculated under these elevated salt concentrations, since the adsorption isotherm was found to 
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be in the linear range, even for very high pDNA concentrations in the solution phase (Figure 5-
6A; squares). 
Recovery of pDNA from Amikagels-P bound under low salt conditions (i.e. 10 mM Tris-Cl, 
pH 8.5) was investigated using Tris-Cl buffer with 1 M salt (0.99 M NaCl and 10 mM Tris-Cl, pH 
8.5) and Tris-Cl buffer with an organic modifier (50 mM Tris-Cl and 1.25 M NaCl, with 15% 
isopropanol, pH 8.5). Approximately 70-100% of originally adsorbed pDNA was desorbed when a 
salt concentration of 1M was used. No enhancement in desorption was observed when a buffer 
with higher salt concentration and isopropanol was used (Figure 5-6B), indicating that 
hydrophobic modifiers did not help recovery from Amikabeads-P. Higher percentages of 
desorption was observed when lesser amounts of pDNA were adsorbed onto the beads, 
indicating marginal losses in recovery at higher loadings (Figure 5-6B). 
 
Quaternization of Amikagel-P beads enhances pDNA binding 
Amikacin has 4 primary amines, one secondary amine and 8 hydroxyl groups. It was 
hypothesized that quaternization of amine groups can help increase the content of positive 
charges in the microbeads. This in turn, was anticipated to result in enhanced pDNA binding 
efficacy. The amines on the microbeads were therefore modified to quaternary amines using 
glycidyl trimethyl ammonium chloride (GTMAC); at neutral or acidic pH, only the amines of the 
amikacin react with the epoxide group of GTMAC as an addition reaction 209 (Figure 5-7A).  
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A. Amikagel Microbead Quaternization 
 
B.     C. 
   
Figure 5-7. Conversion of Amikabeads-P to Amikabeads-Q. (A) Amikabeads-P were reacted 
with excess glycidyl trimethyl ammonium chloride (GTMAC) at 70oC for 24 hours in order to 
generate quaternized Amikabeads-Q. (B) Ninhydrin test on ~1 mg unmodified Amikabeads-P 
(left) and quaternized Amikabeads-Q (right) are shown. Formation of blue-purple color indicates 
presence of reactive (primary) amines. (C) Fluorescein binding assay after incubating (i) 
Amikabeads-P and (ii) Amikabeads-Q with 200 µL of 50 mg/mL of fluorescein sodium in 1% (v/v) 
NaOH solution (pH>12) in nanopure water for 10 minutes, followed by extensive washing. 
Formation of intense red color in the pellet indicates increased retention of by Amikabeads-Q, 
and thus, presence of quaternary amine groups. Lesser retention of fluorescein was observed in 
the case of the parental Amikabeads-P. 
 
Formation of quaternary amines on Amikabeads was verified using both, the ninhydrin 
assay as well as the fluorescein-binding assay. Ninhydrin reagent reacts with primary amines 
resulting in the formation of a blue-purple colored product. However, as expected, quaternized 
	
!
!
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129 
Amikabeads-Q did not demonstrate a blue color unlike unmodified Amikabeads-P (Figure 5-7B). 
The fluorescein-binding assay was also able ascertain quaternization in Amikabeads-Q; in 
presence of 1% (v/v) NaOH (pH > 12), the primary amines present on amikacin are no longer 
positively charged, whereas the quaternary amines on the quaternized beads retain the 
permanent positive charge. Hence, the negatively charged fluorescein can interact with and bind 
the quaternary ammonium moieties in Amikabeads-Q, but not the primary amines in Amikabeads-
P (Figure 5-7C). Adsorption experiments indicated that Amikabeads-Q demonstrated significantly 
higher (p<0.001) pDNA loading capacities than Amikabeads-P (Figure 5-8 A-B).  
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A. 
 
B. 
Batch of Amikabeads-Q  Average Diameter (µm) ± 1 S.D 
(Standard Deviation) 
Qmax DNA Binding Capacity 
(µg pDNA bound/mg of beads) 
n=1 12 ± 6 333.3 
n=2 15 ± 7 277 
n=3 10 ± 6 296 
 
C.     D. 
 
Figure 5-8. Plasmid DNA adsorption and desorption from Amikabeads-Q. (A) Adsorption 
isotherm of pGL4.5 plasmid DNA on quaternized Amikabeads-Q (Average diameter: 12 ± 6 µm) 
in (Buffer I) 10 mM, Tris.HCl buffer, pH 8.5, at 25oC following equilibration for 24 hours. 
Quaternization of Amikabeads greatly enhanced the plasmid DNA binding capacity compared to 
Amikabeads-Q (p<0.001). (B) Qmax calculated for three independent adsorption experiments in 10 
mM, Tris.HCl buffer, pH 8.5, at 25oC. Average Qmax calculated for Amikabeads-Q was ~ 300 µg of 
plasmid DNA / mg of Amikabeads-Q. (C) The percentage of bound pDNA desorbed with Tris-Cl 
buffer with 1 M salt (0.99 M NaCl, 10 mM Tris-Cl, pH 8.5), Tris-Cl buffer with 1.3 M salt (1.25 M 
NaCl, 50 mM Tris-Cl, pH 8.5) and Tris-Cl buffer with 1.3 M salt (1.25 M NaCl, 50 mM Tris-Cl, pH 
8.5) supplemented with 15% isopropanol is shown. Significantly higher desorption of pDNA was 
observed when isopropanol was used in the eluent (p<0.05*, Students’ t-test). (D) Desorption of 
pDNA from Amikabeads-Q at elevated temperature (50oC) and higher percentage of isopropanol 
(30%). Increasing the temperature from 25oC to 50oC significantly improved the amount of pDNA 
desorbed (p<0.05*, Students’ t-test) while increasing the percentage isopropanol in the buffer 
from 15% to 30% had the opposite effect (p<0.001**, Students’ t-test). 
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Average Qmax values, determined after n=3 independent experiments, were approximately 300 µg 
pDNA/mg of Amikabeads-Q at an equilibrium pDNA concentration of 150-200 mg/L. This pDNA 
loading was approximately 30% of the weight of the Amikabeads-Q and is almost 7-fold higher 
than that on Amikabeads-P. It is likely that the primary amines on Amikabeads-P are only partially 
protonated at the pH employed in the pDNA binding studies (pH=8.5), while the quaternary 
amines in Amikabeads-Q have a permanent positive charge222. This difference in positive charge 
content could partly be responsible for higher pDNA binding to Amikabeads-Q compared to 
Amikabeads-P. 
In a recent study by Koga et al. 223, methyl groups on a tetramethylammonium ion were 
found to promote hydrophilicity at a range of 0-0.08 mole fraction of the solute. Coulombic 
interactions between the permanent positive charge on Amikabeads-Q and the strongly anionic 
moieties on pDNA likely overcome the hydration of the hydrophilic quaternary amine groups on 
the microbeads, and result in strong pDNA-Amikabead-Q binding. Following the primary 
Coulombic binding, it is possible that multiple methyl groups on Amikabeads-Q participate in 
collective additional secondary (e.g. hydrophobic) interactions, resulting in enhanced binding to 
pDNA. However, the hydrophobic character / interactions is likely to be relatively modest in 
comparison to the high hydrophilic / cationic character imparted by quaternized amines. 
Amikabeads-Q demonstrated a slightly higher average diameter than Amikabeads-P  
(10.8 µm for Amikabeads-P and 13.9 µm for Amikabeads-Q; Figure 5-9).  
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A.            B. 
 
C. 
 
Figure 5-9. Representative images of Amikabeads before and after quaternization. 
Amikabeads  ~11 ± 4 µm in diameter (A) before and (B) after quaternization using glycidyl 
trimethyl ammonium chloride (GTMAC) are shown. Scale bar = 100 µm. (C) Graphical 
representation of diameter of Amikabeads-P and -Q. Quaternization did not change the spherical 
shape, but modestly increased the average diameter of Amikabeads by ~1.3 fold (* indicates 
p<0.005). 
 
This increase in average diameter of Amikabeads-Q could be due to repulsion between 
the quaternized charges. However, this is likely to have a minimal contribution to the observed 
increase in pDNA binding capacity of Amikabeads-Q since the increase in surface area over 
Amikabeads-P is not significant (~1.66-fold increase in Amikabead-Q surface area over 
Amikabead-P surface area). 
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Static binding capacities of commercially available resins typically range from 1 to 10 mg 
of pDNA/mL of resin slurry. Gigaporous rigid ceramic HyperD-Q polymerized hydrogel resins 
containing quaternary amine moieties and quaternized polyethyleneimine-containing porous 
resins (POROS HQ resins) possess among the highest static binding capacities at ~10 mg of 
pDNA/mL of resin slurry 84. Static pDNA binding capacities of Amikabeads-Q and Amikabeads-P 
were estimated to be ~6 mg of pDNA/mL of resin slurry and ~1.2 mg of pDNA/mL of resin slurry, 
respectively, which are comparable to that of several commercially available resins. 
 
Desorption of pDNA from Amikabeads-Q 
Up to 40% of bound pDNA was desorbed from Amikabeads-Q when eluted with Tris-Cl buffer 
containing 1M salt (0.99 M NaCl and 10 mM Tris-Cl, pH 8.5) at 25oC (Figure 5-8C). This relative 
desorption was significantly less in percentage than that from Amikabeads-P. Thus, while 
Amikabeads-Q were able to bind higher quantities of pDNA, complete recovery of the beads was 
not possible using 1 M salt as the elution buffer. It is known that addition of small organic 
molecules to desorption buffers reduces the polarity of the solution, which can facilitate 
desorption of molecules from resins 224-225. Improved recovery was seen when Tris-Cl buffer 
containing 15% isopropanol (1.25 M NaCl and 50 mM Tris-Cl, pH 8.5) was employed for pDNA 
desorption at 25oC  (Figure 5-8C). However, use of 1.25M NaCl did not enhance desorption of 
pDNA from Amikabeads-Q in absence of isopropanol (Figure 5-8C), indicating that the 
hydrophobic modifier was important for pDNA recovery from Amikabeads-Q. It is important to 
note that use of 15% (v/v) isopropanol did not enhance pDNA desorption from Amikabeads-P 
(Figure 5-6B) indicating that secondary hydrophobic interactions did not play a role in pDNA 
binding to the parental microbeads. 
We observed that while use of 15% isopropanol (v/v) in the elution buffer signficantly 
enhanced desorption of pDNA from Amikabeads-Q, use of 30% isopropanol resulted in lower 
pDNA desorption from the microbeads (Figure 5-8D). Our results are consistent with previous 
observations in the literature. For example, Chang et al. 226 reported higher pDNA desorption 
from a substrate modified with tetraethyl quaternary ammonium groups in presence of ~20% 
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isopropanol (v/v), when compared to ~40% isopropanol (v/v). Tseng et al. 225, 227 suggested the 
existence of a threshold volume percentage up to which, presence of an alcohol in the liquid 
phase can help overcome hydrophobic interactions while not greatly influencing the solution 
dielectric constant. This, in turn, allows for increased desorption of an adsorbed molecule from 
the surface, as seen in case of pDNA desorption from Amikabeads-Q when 15% isopropanol was 
used in the desorption buffer. Once this threshold is crossed, increased alcohol content in the 
desorption buffer results in an increase in the dielectric constant of the liquid phase. This, in turn, 
can strengthen the magnitude of electrostatic interactions between a biomolecule and the 
adsorbent material. This is likely the cause for lower pDNA desroption from Amikabeads-Q when 
30% isopropanol was employed in the liquid phase desorption buffer. 
Finally, pDNA desorption was significantly increased when the temperature was raised 
from 25oC to 50oC (p<0.001) (Figure 5-8D) in presence of 15% isopropanol; a recovery of ~ 70 ± 
6% of initially adsorbed pDNA was obtained at 50oC. Higher temperatures are known to facilitate 
increased desorption of pDNA from chromatographic columns 228, and our results are along 
expected lines. The quality of the recovered pDNA from the unmodified Amikabeads-P and the 
quaternized Amikabeads-Q was determined by running it on a 1% agarose gel. As shown in 
Figure 5-10, the desorbed pDNA recovered by the addition of salt was of the same integrity as 
that of the pDNA that was loaded on the resin, indicating that Amikabeads did not induce any 
visible or gross damage to pDNA. 
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Figure 5-10. Agarose gel electrophoresis of desorbed and recovered pDNA. Agarose gel 
electrophoresis (AGE; 1% agarose gel) of desorbed plasmid DNA recovered from unmodified 
parental (P) and quaternized (Q) Amikabeads. Vertical Lanes 1 and 2 – Plasmid DNA desorbed 
from quaternized Amikabeads-Q (n=2). Lanes 3 and 4 - Plasmid DNA desorbed from unmodified 
Amikabeads-P (n=2). Lane 5 – Stock solution of plasmid DNA used in the binding studies. No 
visible differences can be seen between the desorbed pDNA and the stock pDNA, indicating that 
gross integrity of pDNA is maintained upon binding and desorption from Amikabeads P and Q. 
 
Visualization of Amikabeads before and after pDNA Binding 
Confocal fluorescence microscopy was employed in order to visualize the localization of pDNA on 
the Amikabeads upon binding. As shown in Figure 5-11, pDNA was predominantly found to 
adsorb on the surface of both, Amikabeads-P and -Q.  
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A. 
 
B. 
 
C. 
 
Figure 5-11. Confocal microscopy of pDNA loading on Amikabeads. Confocal microscopy of 
pDNA loading on (A) Amikabeads-P (average diameter: ~9 ± 4 µm) and (B) Amikabeads-Q 
(average diameter: ~14 ± 6 µm) is shown. Amikabeads-P and Q (1 mg each) were incubated with 
40,000 ng and 200,000 ng of pDNA respectively, in 10 mM Tris-Cl buffer, pH 8.5 at 25oC for 24 
hours. Following washes, the beads were stained with 2 µM ethidium homodimer-1 for 20 
minutes prior to imaging. Fluorescence of ethidium homodimer-1 was visualized using an 
excitation of 528 nm and emission of 617 nm (red color). Plasmid DNA adsorbed on the surface 
of both, Amikabeads-P and Q, with minimal penetration into the beads. Amikabead clusters were 
observed after addition of plasmid DNA, possibly due to the bridging. (c) Amikabeads not treated 
with pDNA did not demonstrate ethidium homodimer-1 fluorescence and clustering. A 
representative image of Amikabeads-Q is shown. Scale bar = 100 µm in all cases. 
 
BET analysis indicated that Amikabeads-P possessed a surface area of approximately 
2.0 m2/g and a pore size of 4.0 nm. This pore size is consistent with that of several existing ion-
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exchange resins, but indicates challenges that may be associated with pDNA transport and 
penetration into the beads, given the larger size (70-100 nm) of super-coiled pDNA 229. These 
results can explain the observation that pDNA binding is primarily observed on the surface of 
Amikabeads. 
Amikabeads-P and -Q were found to aggregate following binding of pDNA on their 
surfaces, likely due to bridging of the biomacromolecule and the beads (Figure 5-11 A-C). It is 
important to note that pDNA loading was in the non-linear part of the adsorption isotherm in both 
cases. Neither Amikabeads-P nor Amikabeads-Q were found to aggregate in absence of pDNA 
loading (Figures 5-2, 5-9, and 5-12 A-B). The average aggregate size of pDNA with 
Amikabeads-Q was significantly higher than that of Amikabeads-P (p<0.001, Students’ t-test; 
Figure 5-12 C-E). It is likely that the higher cationic content on Amikabeads-Q allows the 
formation of bigger aggregates upon pDNA binding, compared to those seen in case of 
Amikabeads-P. 
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A.           B. 
    
C.       D.  
    
E. 
 
F.       G. 
     
Figure 5-12. Optical image of (A,C) Amikabeads-P and (B,D) Amikabeads-Q before and 
after loading with (C) 40,000 ng and (D) 280,000 ng of pDNA/mg of beads respectively. (E) 
Comparison of average aggregate sizes of Amikabeads P and Q after loading with pDNA. pDNA-
Amikabeads-Q aggregates were significantly bigger than pDNA-Amikabeads-P aggregates 
(*p<0.001, Students’ t-test). Optical images of (F) Amikabeads-P and (G) Amikabeads-Q after 
desorption with Tris-Cl buffer with 1 M salt (10 mM Tris-Cl, 990 mM NaCl, pH 8.5) and Tris-Cl 
buffer with 1.3 M salt (50 mM Tris-Cl, 1.25 M NaCl, pH 8.5) respectively. Scale bar = 100 µm.  
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Desorption of pDNA from both, Amikabeads-P and -Q, resulted in a decrease in 
aggregate size (Figure 5-12 F-G), likey due to reduction in bridging between the 
biomacromolecule and the microbeads. Larger aggregate sizes were seen in case of 
Amikabeads-Q compared to Amikabeads-P following desorption of pDNA. This is likely due to 
differences in the initial amounts of pDNA present on the microbeads, as well as in the amounts 
of pDNA desorbed in both cases. As described before, lower relative amounts of pDNA were 
desorbed from Amikabeads-Q compared to that from Amikabeads-P (~40% of initially adsorbed 
pDNA for Amikabeads-Q vs. ~75% of initially adsorbed pDNA for Amikabeads-P using 1 M salt). 
It is also possible that desorption is more challenging from Amikabeads-Q given the larger size of 
the aggregate first formed upon pDNA adsorption on these microbeads comapred to pDNA-
Amikabead-P aggregates. This, in turn, can contribute to the higher aggregate sizes observed for 
Amikabeads-Q compared to those for Amikabeads-P seen after pDNA desorption (Figure 5-12 F-
G). 
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A.    B.       C. 
 
D. 
 
E.        F. 
  
 
Figure 5-13. Amikabead aggregate size after desorption. Phase contrast images (10X zoom) 
of Amikabeads-Q loaded with 280,000 ng of pDNA/mg of beads treated with different desorption 
media (a) Tris-Cl buffer with 1.3 M salt (50 mM Tris-Cl, 1.25 M NaCl, pH 8.5) (b) Tris-Cl buffer 
with 1.3 M salt (50 mM Tris-Cl, 1.25 M NaCl, pH 8.5) supplemented with15% isopropanol in 
absence and (c) presence of elevated temperature (50oC) for 36 hours. (d) Average aggregate 
size of pDNA-Amikabeads-Q measured before and after treatment with different elution media. 
Average sizes of aggregates decreased following pDNA desorption (*p<0.001). Equilibration with 
15% isopropanol at elevated temepratures (50oC) significantly decreased the aggregate size 
(**p<0.05), whch was consistent with highest amounts of pDNA desorption seen under these 
elution conditions. (e) pDNA-Amikabead-Q aggregate size decreased with increasing desorption 
of the biomacromolecule from the microbead surface using different desorption buffers. Triangle: 
Tris-Cl buffer with 1.3 M salt (50 mM Tris-Cl, 1.25 M NaCl, pH 8.5) ; Diamond: Tris-Cl buffer with 
1.3 M salt (50 mM Tris-Cl, 1.25 M NaCl, pH 8.5) supplemented with 15% isopropanol in absence 
and Square: in presence of elevated temperature (50oC)  (f) Undesorbed pDNA was found to be 
bound to the surface of Amikabeads-Q after desorption. Scale bar = 100 µm. 
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Sizes of pDNA-Amikabead-Q aggregates following equilibration with different elution bufferes 
were further investigated. (Figure 5-13 A-D). It was observed that, in general, the size of pDNA-
Amikabead-Q aggregate decreased with increasing desorption of the biomacromolecule from the 
bead surface (Figure 5-13E). Plasmid DNA that was not desorbed remained bound to the surface 
of Amikabeads (Figure 5-13F). It is important to note that this colloidal aggregation behavior may 
be moot in cases of well-packed chromatographic columns that may employ Amikabeads as the 
stationary (solid) phase for biomolecule (e.g. pDNA) separations. 
 
In situ capture of DNA from Mammalian Cells 
Cationic microparticles and membranes have been previously used for on-site capture of 
genomic DNA for polymerase chain reactions 230. For example, Cao et al. 231 reported chitosan 
coated beads that could extract DNA from lysed whole blood sample for PCR analyses. Here, we 
investigated if Amikabeads-P and -Q could be employed for extracting DNA directly from 
mammalian cells. PC3 human prostate cancer cells were incubated with different amounts of 
Amikabeads-P and -Q in order to investigate their effect on viability following cell lysis; we 
hypothesized that direct lysis mediated by the microbeads can facilitate extraction of DNA from 
cells. Amikabeads-P (500 µg, 24 hour incubation) resulted in loss of viability of ~80% of the cell 
population, as determined by the MTT assay (Figure 5-14A, diamonds). The LC50 (amount 
required to reduce cell viability to 50%) value of Amikabeads-P was approximately 400 µg for 
PC3 prostate cancer cells under these experimental conditions. 
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A. 
 
B. 
 
C. 
 
 
Figure 5-14. Whole cell DNA isolation with Amikabeads. (A) Cell viability of PC3 human 
prostate cancer cells after exposure to different amounts of unmodified and quaternized 
Amikabeads for 24 hours as determined using the MTT assay (n=2). *1 – statistical significance 
p=0.003 between cell viability of cells exposed to 300 µg Amikabeads-P and Q. *2 – statistical 
significance p=0.00002 between cell viability of cells exposed to 500 µg Amikabeads-P and Q. 
Amikabeads-P (approximate diameter: ~12. ± 4 µm) and Amikabeads-Q (approximate diameter: 
~11 ± 6 µm). Students’ t-test was used to determine statistical significance. (B) Amikabeads-P 
(500 µg; approximate diameter: ~12 ± 4 µm) and (c) 500 µg Amikabeads-Q (approximate 
diameter: ~11 ± 6 µm) were exposed to 10,000 PC3 prostate cancer cells for 24 hours followed 
by live (green)-dead (red) staining. Scale bar = 100 µm. Green fluorescence emission of Calcein 
inside the live cells was detected using 38 HE filter set (Excitation: 470/40; Emission: 525/50) and 
red fluorescence of nucleic acid bound-EthD-1 was detected using a 43 HE filter set (Excitation: 
550/25; Emission: 605/70). 
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In contrast, unlike Amikabeads-P, Amikabeads-Q did not induce significant cell death in 
PC3 cells even when amounts as high as 500 µg were employed (Figure 5-14B, squares). These 
results from the MTT assay were further confirmed using Live/Dead® analyses, in concert with 
fluorescence microscopy (Figures 5-14 A-B and Figures 5-15).  
 
 
 
 
 
Figure 5-15. Amikabeads-Q were not toxic to PC3 prostate cancer cells. Amikabeads-Q (500 
µg; approximate diameter: 11 ± 6 µm) were exposed to 10,000 PC3 prostate cancer cells for 24 
hours, followed by staining with Calcein AM. The beads likely on the surface of the PC3 prostate 
cancer cells can be seen as dark spheres. Green fluorescence emission of calcein inside the live 
cells was detected using 38 HE filter set (Excitation: 470/40; Emission: 525/50). Scale bar= 100 
µm 
 
Cells treated with Amikabeads-P demonstrated significantly higher levels of red 
fluorescence compared to those with Amikabeads-Q, since cell lysis by the former results in 
damage and exposure of cellular DNA to the red-fluorescent ethidium homodimer-I dye. In all 
cases, the microbeads were seen in close proximity with the cells (Figure 5-14C and 5-15). 
Incubation of Amikabeads-P and -Q with PC3 cells in absence of serum proteins for 6 hours did 
not change the toxicity of parental (P) or quaternized (Q) Amikabeads (Figure 5-16), indicating 
that serum proteins have minimal or no role in determining Amikabead cytotoxicity under the 
conditions employed. 
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Figure 5-16. Cell viability of PC3 prostate cancer cells after treatment with Amikabeads-P 
and –Q. Beads were treated (Average diameters: Amikabeads-P: 12 ± 4 µm Amikabeads-Q: 11 ± 
6 µm) for 6 hours in serum-free media, followed by 18 hours in serum containing RPMI media as 
determined using the MTT assay. Statistical test (Students’ t-test) was used to test the statistical 
difference between the unmodified and quaternized Amikabeads. At all concentrations, the 
parental Amikabeads-P (squares) were significantly more toxic than the quaternized Amikabeads-
Q (diamonds) (p<0.05).  
 
The above results are along the lines of previous reports in literature that indicate 
reduced cytotoxicity of cationic polymers after quaternization 232-235. For example, Brownlie et al. 
showed that quaternization of amines in polyethyleneimine (PEI) reduced its cytotoxicity by 
almost 4 fold in A431 lung cancer cells 234. Previous reports in literature 222 indicate that 
conversion of primary amines to quaternary amines (e.g. in case of Amikagel-P to Amikagel-Q) 
results in increasing hydrophilicity of the resulting derivative. This, in turn, results in increased 
hydration of these molecules, which is thought to be responsible for their lower hemolytic 
activities 222, 235. The relatively mild negative charge on the surface of mammalian cells 236 is likely 
not sufficient to overcome the hydration of Amikabeads-Q (in contrast to strong Coulombic 
interactions of the microbeads with the strongly anionic plasmid DNA). This can likely indicate 
minimal interactions between the cells and Amikabeads-Q, and therefore explain the low 
cytotoxicity of these microbeads towards PC3 cells. However, given the lower hydration of 
primary amines compared to quaternary amines 222, it is more likely for Amikabeads-P to interact 
with cell membranes, leading to their disruption, and eventual cell lysis. Thus, although 
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quaternization of Amikabeads-P led to microbeads with significantly lower toxicities, Amikabeads-
P were employed for directly sequestering cellular DNA following lysis of mammalian cells. 
Fluorescence microscopy indicated in situ capture of cellular DNA in case of PC3 cells 
treated with 12 ± 4 µm Amikabeads-P for 24 h (Figure 5-17A). As seen in Figure 5-17A, 
Amikabeads-P were able to simultaneously lyse cells, extract DNA molecules, and bind them. 
This activity of Amikabeads-P may have application in point-of-care testing 237, on-chip nucleic 
acid extraction and detection 238, and on-site/on-chip whole cell lysis and DNA/RNA capture for 
PCR reactions 239. Amikabeads-P, in absence of bound DNA, did not demonstrate any red 
fluorescence, which is along expected lines (Figure 5-17B). 
 
A.      B. 
 
 
Figure 5-17. In situ DNA capture using Amikabeads-P from mammalian cells. (A) 500 µg 
Amikabeads-P (approximate diameter: ~12 ± 4 µm) were exposed to 10,000 PC3 prostate cancer 
cells for 24 hours followed staining with the nucleic acid binding dye, ethidium homodimer-1. 
Nucleic acids adsorbed to the beads were stained red. (B) No red fluorescence was observed 
with ethidium homodimer-1 stained Amikabeads in the absence of bound DNA. Scale bar = 20 
µm. 
 
5.4. CONCLUSION 
We have developed a novel anion-exchange resin material based on hydrogel microbeads 
(‘Amikabeads’) generated from amikacin and poly(ethylene glycol) diglycidyl ether, with an eye 
towards applications in biotechnology. Parental Amikabeads-P demonstrated a Qmax of 44.5 µg 
pDNA / mg of the microbeads as determined by fitting a Langmuir isotherm to experimental batch 
adsorption data. Near-complete recovery of pDNA was possible from Amikabeads-P using high 
salt concentrations, indicating electrostatic binding between the biomolecule and the microbeads. 
!
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Quaternization of amines present in parental Amikabeads resulted in the formation of microbeads 
(Amikabeads-Q), which demonstrated Qmax values approximately 7-fold higher than those for 
Amikagels-P under the conditions employed. Desorption of the pDNA from these beads was not 
as efficient as Amikabeads-P, although recovery could be significantly improved by using 
isopropanol as an organic modifier. Amikabeads-P were able to extract and bind cellular DNA 
following lysis of mammalian cells, indicating their use for in situ DNA extraction; Amikabeads-Q 
however, were not able to lyse cells and demonstrated lower cytotoxicities. Our results indicate 
that Amikabeads are a versatile platform, with multiple easily conjugable groups for several 
applications in DNA biotechnology ranging from purification to cellular DNA recovery. 
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CHAPTER 6: SENSITIZING CANCER CELLS TO TRAIL-INDUCED DEATH BY MICELLAR 
DELIVERY OF MITOXANTRONE  
  
6.1. INTRODUCTION 
 
Tumor necrosis factor alpha-related apoptosis inducing ligand (TRAIL) has generated 
considerable interest as a targeted cancer therapeutic due its ability to selectively induce cell 
death in various cancers, with minimal toxicity to normal cells 240. However, many tumors are 
inherently resistant or acquire resistance to TRAIL 76. Mechanisms of TRAIL resistance include 
overproduction of cellular FLICE inhibitory protein (c-FLIP) which, as a mimic of caspase-8, leads 
to binding and inactivation of death inducing signaling complex (DISC) 241, overproduction of 
decoy receptors on cancer cell surface, mutational inactivation of the death receptor gene, 
dysfunction in the formation of the DISC complex 242, overexpression of Bcl-2 243, and deficiency 
of caspase 8 76. Strategies that can effectively sensitize resistant cells to TRAIL-induced death 
could provide a path to new therapeutic options.   
Mitoxantrone is an anthracenedione that binds DNA and acts as a topoisomerase II 
inhibitor, leading to DNA fragmentation. Mitoxantrone intercalation within DNA causes DNA 
damage, induces expression of the p53 protein, and ultimately results in cellular apoptosis 244. 
Mitoxantrone has been shown to be involved in the production of free radicals (reactive oxygen 
species or ROS), although to a lower extent than doxorubicin 245-247. Mitoxantrone has also been 
shown to cause caspase-3 activation in immortalized NIH-3T3 cells 248. Recent studies on parallel 
screening of a panel of anti-neoplastic drugs in our laboratory led to the identification of several 
FDA-approved candidates, including mitoxantrone 25, as sensitizers of a variety of cancer cells to 
TRAIL-induced death 154. 
Nanoscale micelles 249-257 and liposomes 258-259 can be effective for enhanced delivery of 
poorly water-soluble therapeutics to cancer cells. The efficacy of these vectors is reflected in the 
FDA approval of the anti-cancer drug formulation Doxil (liposomal formulation of doxorubicin) 260-
261. Several other micellar drug formulations, including Genexol-PM 262, NK105 and NC-6004 263, 
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are in different phases of clinical trials. PEG (2000)-DSPE i.e. 1,2–Distearoyl-sn-glycero-3-
phosphoethanolamine–N-(methoxy(polyethylene glycol)-2000), an FDA approved 264, 
biodegradable polymer 265-266, is an important component of liposomes owing to its ability to 
sterically stabilize liposomes, resulting in long-circulating particles in-vivo. The relatively low 
critical micelle concentration (CMC) (0.5-1 µM) of PEG-DSPE results in its self assembly into 
stable 10- to 20-nm micelles 267; CMC is the concentration of surfactant molecules in an aqueous 
solution that is required to initiate micelle formation. These micelles have been employed for 
delivery of therapeutic agents to a variety of cancers 265, 268-270, and their small size is thought to 
enable deep tumor penetration 268. 
In this chapter, we generated and characterized PEG-DSPE micelles loaded with 
mitoxantrone, and investigated their ability to sensitize prostate and breast cancer cells to TRAIL-
induced death. Further, we investigated the influence of different terminal groups on the 
hydrophilic PEG shell of PEG-DSPE micelles-particularly methoxy, amine and carboxylic acid-on 
mitoxantrone loading, stability, size, zeta potential, single agent cytotoxicity and synergistic 
cytotoxicity with TRAIL. To our knowledge, this is the first report of micellar delivery of 
mitoxantrone for sensitization of cancer cells to TRAIL induced death. 
 
6.2. MATERIALS AND METHODS 
Materials 
1,2 –Distearoyl-sn-glycero-3-phosphoethanolamine–N-(methoxy(polyethylene glycol)-
2000)(ammonium salt) (CH3O-PEG-DSPE) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-(amino(polyethylene glycol)-2000) (ammonium salt) (NH2-PEG-DSPE) 
were purchased from Avanti Polar Lipids (Alabaster, AL, USA) and used without further 
purification. Mitoxantrone was purchased from Ontario Chemicals Inc. (Guelph, Ontario, Canada) 
and was verified for purity using 1H NMR. Mitoxantrone.2HCl, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), succinic anhydride and 4-dimethylaminopyridine (DMAP) 
were purchased from Sigma-Aldrich Inc. (St. Louis, MO). Float-A-Lyzer 8-10K Dialysis 
membranes were purchased from Spectrum Labs (Rancho Dominguez, CA). Cell culture media - 
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RPMI 1640 with L-glutamine, Pen-Strep solution: 10000-units/mL penicillin and 10000-µg/mL 
streptomycin in 0.85% NaCl, and fetal bovine serum (FBS), were purchased from Hyclone 
(Logan, UT). The MTT assay kit was purchased from ATCC (Manassas, VA). TRAIL (TNF-a 
Related Apoptosis Inducing Ligand) was purchased from R&D systems (Minneapolis, MN) and 
suspended in 1 mL of 1X PBS to a concentration of 10 µg/mL. Disposable PD-10 desalting 
columns, packed with Sephadex™ G-25 medium, were purchased from GE Healthcare 
(Piscataway, NJ).  
 
Synthesis of HOOC-PEG-DSPE 
Amine-terminated PEG-DSPE (NH2-PEG (2000)-DSPE, 20 mg, 0.007 mmoles), succinic 
anhydride (10 mg, 0.01 mmoles) and 4-dimethylaminopyridine (DMAP) (5 mg, 0.041 mmoles) 
were stirred at room temperature for 24 hours in 5 mL of anhydrous tetrahydrofuran (THF). After 
removing THF under vacuum, the residue was dialyzed against nanopure water and the product 
was freeze dried. Yield: 60%. 1H NMR (CDCl3, 400 MHz, δ, ppm):  5.19 (1H, -CONH-), 4.38 (1H, -
OCH-), 4.20 (2H, OCH2), 3.94 (2H, OCH2), 3.2-3.7 (184H, OCH2CH2O, OCH2CH2NHCO), 2.63 
(2H, NHCOCH2CH2COOH), 2.50 (2H, NHCOCH2CH2COOH), 2.23 (4H, CH2CH2COO), 1.23 
(60H, CH2), 0.86 (6H, CH3). (Fig. 6-1) 
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Chemical shift (ppm) 
 
Figure 6-1. 1H NMR spectra of micelles. (A) Amine-terminated PEG-DSPE micelles (M2) in 
CDCl3, (B) Modified Carboxyl-terminated PEG-DSPE micelles (M3) in CDCl3. 
 
Micelle preparation and Mitoxantrone Loading 
Methoxy-terminated PEG-DSPE (CH3O-PEG(2000)-DSPE, 10 mg, 0.0035 mmoles, M1) , amine-
terminated PEG-DSPE (NH2-PEG(2000)-DSPE, 10 mg, 0.0035 mmoles, M2), carboxyl-
terminated PEG-DSPE (HOOC-PEG(2000)-DSPE, 10 mg, 0.0034 mmoles, M3) polymers and 
mitoxantrone (1 mg, 0.0022 mmoles) were weighed and mixed in methanol. In brief, 10 mg of 
each polymer was mixed with mitoxantrone in methanol. Once mixed, the methanol was removed 
under vacuum using a rotavapor, leaving a dried crust of mitoxantrone and the lipid polymer 
behind. After drying overnight to remove all traces of methanol, 1 mL of HEPES buffer (10 mM, 
pH 7.4) was added to the system with continuous stirring for 30 minutes, followed by 
ultrasonication for 20 minutes to yield uniform sized drug-encapsulated micelles, M4, M5 and M6 
with methoxy, amine and carboxyl terminated micelles, respectively. Detailed compositions of the 
micelles, M1 – M6 and their properties are given in Table 1. Drug-loaded micelles M4, M5 and 
a
b
b
a
A
B
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M6 were then subjected to size exclusion chromatography using disposable PD-10 desalting 
column to separate mitoxantrone-loaded micelles from the free drug. Eluates of 1 mL each were 
collected and measured for mitoxantrone content using absorption spectroscopy. (Fig. 6-2). 
 
Figure. 6-2. Elution profile of free (unencapsulated) mitoxantrone and mitoxantrone in 
PEG-DSPE micelles through PD-10 column. Black diamonds represent the elution profile of 
mitoxantrone loaded in micelles (M4) and grey squares represent the elution profile of the free 
mitoxantrone. 
 
Micelle characterization 
Size and Zeta potential determination 
The hydrodynamic diameters of  micelles M1 – M6 (Fig. 6-3) were characterized by dynamic light 
scattering (DLS) using the Zetasizer Nanosystems Nano-ZS (Malvern Instruments, Mission Viejo, 
CA) at a concentration of 0.1-mg/mL concentration of respective PEG-DSPE polymer. Dilution of 
PEG-DSPE micelles to 0.1 mg/mL corresponds to a polymer concentration of approximately 35 
µM, which is higher than the CMC (0.5 – 1 µM) of these micelles 267. Zeta potential 
measurements of all micelles were carried out using the Zetasizer. Micelle formulations were 
diluted to 0.1mg/mL polymer concentration for these measurements. 
152 
 
 
Figure 6-3. Schematic of micelles used in the study. M1 - M3 and M4 – M6 micelles, 
mitoxantrone and CH3O-PEG-DSPE micelles were employed in the study. Red circles represent 
mitoxantrone. 
 
NMR spectroscopy 
Micelles generated in HEPES buffer were dialyzed against nanopure water for 24 hours and 
lyophilized. Lyophilized micelles were resuspended in Dimethyl sulfoxide (DMSO) or D2O. Next, 
1H-NMR measurements were carried out to investigate mitoxantrone encapsulation. 1H-NMR 
spectrum was obtained with a Varian 400 spectrometer (Varian, Palo Alto, CA) operating at 400 
MHz in the Fourier transform mode. Control spectra of mitoxantrone in DMSO, empty micelles in 
Mitoxantrone (   ) DSPE-PEG-OCH3 (     )
.– terminal groups on PEG
(Empty micelles)
CH3 O – M1
NH2 – M2
COOH – M3
.– terminal groups on PEG 
(Mitoxantrone loaded micelles)
CH3O – M4
NH2 – M5
COOH – M6
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DMSO and empty micelles in D2O were obtained in order to confirm mitoxantrone encapsulation. 
Previous studies have demonstrated that protons of paclitaxel and doxorubicin, encapsulated 
within PEG-DSPE micelles, exhibit minimal mobility, and are therefore absent in 1H NMR spectra 
265, 271. The absence of the chemical shifts of mitoxantrone in 1H NMR spectra of drug-loaded 
micelles in aqueous solutions was used as an indicator of encapsulation.  
 
Determination of drug loading 
The light absorption profile of mitoxantrone in DMSO was used to measure its loading in micelles. 
The absorbance of known concentrations of mitoxantrone in DMSO was used to generate a 
standard calibration curve. The peak intensity of mitoxantrone at 682 nm (wavelength for 
maximum absorbance of mitoxantrone) measured using Shimadzu UV-3600 UV-VIS-NIR 
Spectrophotometer was used in these calculations. The concentration of mitoxantrone loaded in 
micelles was determined by disrupting the micelles in THF and resuspending them in DMSO to 
measure absorbance at 682 nm. The corresponding concentration of the drug in micelles was 
calculated based on the standard curve.  
 
Stability measurements 
Mitoxantrone-loaded micelles were stored in 10 mM HEPES buffer at 4oC and periodically tested 
for stability as a function of time. A 10-µL sample of the micelle dispersion was diluted to 1 mL in 
10 mM HEPES buffer (final polymer concentration 0.1 mg/mL) and the absorbance was 
measured at 669 nm in order to determine the amount of drug released, if any. The size of the 
micelles was also determined as a function of time. Stability studies were also carried out by 
suspending the micelles in cell culture media (RPMI 1640 supplemented with 10% fetal bovine 
serum (FBS) and 1% Penicillin/Streptomycin: 10000 units/mL penicillin and 10000 µg/mL 
streptomycin in 0.85% NaCl) at 37oC for 24 hours and measuring their absorbance as described 
above. 
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In-vitro drug release 
In order to determine the release properties of mitoxantrone from micelles, 1 mL micelle sample 
(M4) was added into the 8- to 10-kD cut off Float-A-Lyzer dialysis tubing (Spectrum Labs, Rancho 
Dominguez, CA) at 37oC and dialyzed against 200 mL 10-mM HEPES buffer at pH 7.4, 200 mL of 
1X PBS buffer at pH 7.4 (150 mM equivalent salt concentration) and 200 mL of 1X PBS buffer at 
pH 7.4 supplemented with 10% FBS respectively. The concentration of mitoxantrone was 
measured at regular intervals for a period of 48 hours by carefully removing a 10-µL sample from 
within the dialysis tubing and determining mitoxantrone concentration. The absorbance 
immediately upon set up (time=0 min) was denoted as 100% mitoxantrone and subsequent 
absorbance readings were calculated with respect to this value. Drug release was studied for up 
to 48 hours. Release characteristics of the free mitoxantrone drug in 10-mM pH 7.4 HEPES buffer 
from the dialysis tubing was also determined and used for comparison with that observed with the 
micelles. 
 
Confocal microscopy  
Cell uptake of mitoxantrone.2HCl free drug and mitoxantrone loaded in micelles (M4) were 
imaged by laser scanning confocal microscopy using a Leica SP5 Confocal Microscope (Leica 
Microsystems, Wetzlar, Germany) and Nikon C2 laser scanning confocal system with a TE2000 
inverted microscope. PC3 human prostate cancer cells (4 x 104) were grown on autoclaved 1-cm 
diameter circular coverslips for 24 hours before treatment. Cells were treated with 
mitoxantrone.2HCl and mitoxantrone in micelles (M4) at a final drug concentration of 6.6 and 13.3 
µM, and imaged at four different time points to visualize their sub-cellular localization.  
Prior to imaging, cells were fixed in 2% paraformaldehyde solution for 30 minutes 
followed by three washes with 1X PBS. Cells were mounted on the glass slide with glycerol 
based mounting medium (90% glycerol in PBS) and imaged using Leica 63X, NA1.4 oil 
immersion lens or Nikon 60X, NA 1.3 oil immersion lens.  Cells were stained with DAPI in order to 
visualize the nucleus. Cells were fixed as described previously at 30 minutes, 1 hour, 2 hours and 
3 hours after treatment with 6.6 and 13.3 µM of mitoxantrone and mitoxantrone-loaded micelles. 
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Cells were excited at 633 nm (He/Ne laser) (Leica microscope)/637 nm (Nikon microscope) and 
emission was collected using a 670-nm long pass filter to visualize mitoxantrone. Image J 
software (NIH, Bethesda, MD) was used to evaluate the cellular fluorescence of mitoxantrone. 
The raw fluorescence intensity of mitoxantrone was acquired and corrected to account for 
background fluorescence as calculated by the software. 
 
Cell culture and cytotoxicity analysis 
Cell culture 
PC3 human prostate cancer cells, MDA-MB-231 breast cancer cells 272 (purchased from ATCC at 
Manassas, VA) and T24 bladder cancer cells 273 (obtained as part of an existing collaboration 
with Professor Christina Voekel-Johnson at Medical University of South Carolina, Charleston, SC) 
were cultured in RPMI 1640 medium supplemented with 10% (v/v) FBS and 1% (v/v) penicillin 
and streptomycin (Pen-Strep solution: 10000 units/mL penicillin and 10000 µg/mL streptomycin in 
0.85% NaCl).  
 
Evaluation of single-agent mitoxantrone 
The effect of treatment with free mitoxantrone and micelle-encapsulated mitoxantrone (M4-M6 in 
Fig. 1) on cell viability was investigated. Cancer cells (8,400 /well in a 96-well plate) were plated 
with 150 µL of cell culture medium and allowed to adhere for 24 hours before the addition of free 
or micelle-encapsulated drug. The efficacy of micelle-encapsulated mitoxantrone (free base form) 
was compared to mitoxantrone.2HCl (salt form) that was used as the free drug only in cytotoxicity 
and imaging experiments. (Note: To avoid confusion between mitoxantrone free base and 
mitoxantrone.2HCl, the free drug in both forms is subsequently referred to as ‘free mitoxantrone’). 
Empty micelles (M1 – M3 in Fig. 6-3) and HEPES buffer were used as controls in the 
cytotoxicity studies. After 24 hours of administering the drug formulations, cell viability was 
determined using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell 
proliferation assay 274. The MTT dye reports for cellular metabolic activity and can be used as an 
indicator of cellular viability and proliferation using methods similar to those described in our 
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previous studies 154. Fig. 6-4 (Top panel) shows a schematic of the single-agent treatments 
investigated. 
 
  
Figure 6-4. Schematic of treatments:  
Top panel – Single agent cytotoxic treatments 
Middle panel – Sequential drug-TRAIL treatments 
Bottom panel – Simultaneous drug-TRAIL treatments 
 
Sequential treatment with mitoxantrone and TRAIL 
Cells were first treated with free mitoxantrone or mitoxantrone-loaded micelles (M4-M6) for 24 
hours as described above. Then, the cell culture media was replaced with fresh media, followed 
by treatment with 10 ng/mL TRAIL for an additional 24 hours. Cell viability was determined using 
the MTT assay following TRAIL treatment. Total treatment time in the case of sequential 
mitoxantrone-TRAIL treatments was 48 hours as opposed to 24 hours for single-agent 
(mitoxantrone alone or TRAIL alone) treatments. Cells treated with TRAIL alone and TRAIL 
treatment in combination with empty PEG-DSPE micelles (M1 – M3 in Fig. 6-3) were used as 
controls. Fig. 6-4 (middle panel) shows a schematic of the sequential treatments. 
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Simultaneous treatment of mitoxantrone and TRAIL 
Cells were simultaneously treated with 10 ng/mL of TRAIL and free mitoxantrone or 
mitoxantrone-loaded M4 – M6 micelles. After 24 hours of incubation with the two treatments, cell 
viability was determined using the MTT assay as described above (Fig. 6-4 bottom panel). 
6.3. RESULTS AND DISCUSSION 
Encapsulation of mitoxantrone in micelles 
Fig. 6-3 shows the structures of mitoxantrone and DSPE-PEG and a schematic of the different 
micelles employed in this study. Drug-loaded CH3O-PEG-DSPE (M4), NH2-PEG-DSPE (M5), and 
HOOC-PEG-DSPE (M6) micelles were generated using a PEG-DSPE polymer concentration of 
10 mg/mL. Fig. 6-2 shows the characteristic elution profile of free mitoxantrone compared to 
representative M4 micelles from PD-10 column. As expected, micelles with the encapsulated 
drug elute faster because of their larger size. 
Micelle properties are shown in Table 6-1. As seen in the table, different micelles were 
saturated at various concentrations of mitoxantrone during the preparation process. The 
phosphate group of the DSPE in the micelle is negatively charged at pH 7.4 258.  Mitoxantrone, in 
turn, has two ionizable amines with pKa values of 8.3-8.6 275 which are positively charged at pH 
7.4. Electrostatic interactions between these moieties can accelerate encapsulation and 
intercalation of mitoxantrone 276-279.  
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Table 6-1. Physical characteristics of micelles employed in the current study. The 
corresponding PEG-DSPE concentration was 0.1 mg/mL in all Size and Zeta potential 
studies shown as Mean ± SD. 
 
a: Weight percentage of the drug loaded into the micelles when 1 mg drug was mixed with 10 mg 
of the respective PEG-DSPE polymer. 
*1: Statistical significance (p<0.05) between loading percentage of M4 and M5 micelles. 
*2: Statistical significance (p<0.05) between loading percentage of M5 and M6 micelles. 
**3: Statistical significance (p<0.01) between zeta potential values of (M1- M2) and (M1-M3) 
micelles. 
*4: Statistical significance (p<0.05) between zeta potential values of M2 and M3 micelles.  
The zeta potential across all three micelles (M1-M4, M2-M5, M3-M6) was more positive after 
mitoxantrone loading (statistical significance (p<0.05)). 
Zeta potential across three micelles after drug loading (M4-M5 (**), M4-M6 (**) and M5-M6 (**)) was 
significantly different (p<0.01) 
 
Although we have not verified this experimentally, the positive charge on the secondary 
amines on mitoxantrone may enhance interactions with the phosphate group at the core-shell 
junction of DSPE-PEG micelles. In addition, it is likely that the hydrophobic portion of the drug 
partitions into the hydrophobic DSPE core. Similar interactions have been suggested between 
doxorubicin and PEG-DSPE where the aminoglycoside moiety of doxorubicin is thought to extend 
into the PEG layer while the anthracycline component interacts with the  hydrophobic core 268.  
The CH3O-PEG-DSPE and HOOC-PEG-DSPE micelles were saturated with approximately 
equivalent amounts of mitoxantrone/10 mg polymer to form M4 and M6, whereas the NH2-PEG-
DSPE amine-terminated micelles (M5) were saturated with smaller amounts of the drug (p < 
Polymeric micelles Micelles Drug loadinga Size 
diameter
(nm) 
Zeta potential 
(mV) 
CH3O- PEG-DSPE
only (Empty)
M1 -- 11.8 ± 3.2 -12.1 ± 1.9 **3
Mitoxantrone loaded
CH3O- PEG-DSPE
M4 67.0% ± 3.75% *1 13.3 ± 4.0 -4.0 ± 1.7
NH2 - PEG-DSPE
only (Empty)
M2 -- 12.0 ± 3.0 -5.5 ± 1.6 
Mitoxantrone loaded
NH2 - PEG-DSPE
M5 45.6 ± 6.11% 11.3 ± 3.3 7.3 ± 2.0
HOOC - PEG-DSPE 
only (Empty)
M3 -- 13.9 ± 3.0 -41.0 ± 7.5 *4
HOOC - PEG-DSPE
Mitoxantrone loaded
M6 66.0 ± 3.88 % *2 14.7 ± 3.8 -20.5 ± 5.1
*
*
*
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0.05). This reduction could be due to the repulsion of the terminal amine of the NH2-micelle and 
the amine group in mitoxantrone during loading. It is also possible that terminal amines on the 
DSPE-PEG molecule compete with mitoxantrone for interactions with the phosphate on the 
DSPE molecule. However, similar loading efficiencies for M4 and M6 micelles suggest that their 
phosphate entity remains available for mitoxantrone binding irrespective of these terminal groups. 
The drug loading percentages in Table 6-1 are indicative of the saturation (maximum) 
concentration of mitoxantrone that can be loaded in the respective micelles.  
 
Micelle size and zeta potential  
The diameters of all micelles before (M1 – M3) and after mitoxantrone loading (M4 – M6) were 
determined to be less than 20 nm, indicating that micelle size is unaltered by drug loading (Table 
6-1 and Fig. 6-5). It has been observed previously that loading drugs within PEG-DSPE micelles 
leads to a minimal changes, if any, in their hydrodynamic size 265, 268, 280.  
A.      B. 
 
Figure 6-5. DLS profile of micelles. (A) Empty methoxy terminated PEG-DSPE micelles (M1) 
and (B) Mitoxantrone-loaded methoxy terminated PEG-DSPE micelle (M4). (PEG-DSPE 
concentration in both species was 0.1 mg/mL). 
 
All three micelles were stable for up to two months in HEPES buffer (10 mM, pH 7.4) based on 
size and drug release analyses (data not shown). No precipitation of the drug was observed 
during storage.  
The zeta potentials of the micelles with and without encapsulated mitoxantrone were 
measured to determine whether drug loading and the micelle terminal groups affect the micellar 
surface charge properties (Table 6-1). Carboxyl-terminated micelles exhibited the highest 
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negative zeta potential of approximately -40 mV.  Empty methoxy micelles (M1) and amine 
micelles (M2) were found to possess significantly lower, but negative zeta potential values 
compared to the empty carboxyl terminus PEG-DSPE (M3) micelle (p<0.05)(not shown in the 
table). The ionizable phosphate group of DSPE is primarily responsible for the negative zeta 
potential observed in all empty micelles.  
Following mitoxantrone loading, all micelles demonstrated a reduction in their negative 
zeta potential values with statistical significance (p<0.05) for (M1 vs. M4) (M2 vs. M5) and (M3 vs. 
M6) (Table 6-1). For example, empty NH2-PEG-DSPE micelles showed a slightly negative zeta 
potential that reversed polarity following mitoxantrone loading (p<0.05). The positively charged 
moieties on mitoxantrone can shield some of the negative charge of the DSPE phosphates, 
thereby reducing the micelle’s negative zeta potential. This reduction in the negative zeta 
potential value, observed across all the three micelle species, can be used as another indicator of 
mitoxantrone encapsulation. Similar phenomena have been observed for other drugs loaded 
within PEG-DSPE micelles 281. 
 
Spectral characterization of mitoxantrone-loaded micelles 
Free mitoxantrone dissolved in HEPES buffer showed an absorbance spectrum with two maxima, 
one at 610 nm and the other 660 nm, corresponding to the dimer and monomer forms of the drug, 
respectively 282 278. These absorption peaks showed a bathochromic shift (redshift) when 
mitoxantrone was encapsulated within PEG-DSPE micelles. As shown in Fig. 6-6, the absorption 
maxima for the monomer shifted from 660 nm in HEPES buffer (black dots) to 669 ± 1 nm when 
loaded within micelles (dotted line). The dimer peak exhibited a smaller red shift. At equivalent 
drug concentrations, an increase in the overall absorption intensity profile of the drug was 
observed following encapsulation (Fig. 6-6). This is consistent with other observations in literature 
on mitoxantrone absorbance in CTAB and SDS micelles 283-284, and is likely since some drugs 
exhibit lower absorption in aqueous media compared to that in hydrophobic environments. No 
shift in absorption maxima were noticed when mitoxantrone was dissolved in presence of PEG 
(2000) alone. 
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Figure 6-6. Absorption spectra of free mitoxantrone in various modalities. Absorption 
spectra of free (unencapsulated) mitoxantrone (35µM) in 10 mM pH 7.4 HEPES buffer (dotted 
line), 0.5 mg/ml PEG(2000)-DSPE micelles M4 ( - - ), methanol ( _._._), and DMSO (black and grey 
solid lines). Black and grey solid lines indicate the absorption profile of 35 µM of free 
mitoxantrone and M4 micelles in DMSO respectively. 
 
The positions of mitoxantrone monomer and dimer maximal absorption peaks are different for the 
free drug and encapsulated drug due to differences in the local microenvironment. 
 It has been previously reported that the absorbance peak of mitoxantrone is sensitive to 
its surrounding environment. Enache et al. 278, 283 reported that the wavelength of maximal 
absorbance of mitoxantrone depends on the dielectric constant of the surrounding medium. In 
case of mitoxantrone encapsulated within micelles, we observed a shift in the monomer peak to 
669 ± 1 nm. This peak position was similar to that observed for mitoxantrone in methanol (Fig. 2). 
This suggests that the environment surrounding mitoxantrone may be similar to that in methanol, 
which is less hydrophobic than the lipid core of DSPE. This could likely indicate that mitoxantrone 
localizes at the interface of the DSPE-PEG with the hydrophobic part of the drug interacting with 
the lipid core, and the protonated amines interacting with the anionic phosphates of DSPE at the 
interface. This is consistent with other reports in the literature 284, which discuss the orientation of 
mitoxantrone in SDS micelles. It was suggested the chromophore ring in mitoxantrone is 
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immersed in the micelle core and positively charged exterior interacts with the polar head groups 
of the SDS. Although this is likely to be consistent in DSPE-PEG micelles, it is important to 
mention the difficulty of exactly pinpointing the location of mitoxantrone, due to the dynamic 
nature of the micelles as well as the drug. 
As an additional study, we determined the absorption spectra of mitoxantrone in 1, 4-
dioxane (Fig 6-7). Hydrophobic hydrocarbon cores typically possess dielectric constants around 2 
to 5, which is similar to that of 1,4 dioxane 285.  
 
Figure 6-7. Absorption spectra of free (unencapsulated) mitoxantrone in various solvents. 
Absorption spectra of free (unencapsulated) mitoxantrone (35µM) in methanol (Black line) and 
1,4-Dioxane (Grey line). 
 
 
We found that the absorption spectra of the drug in 1, 4-dioxane is significantly different from its 
absorption spectra in methanol or PEG-DSPE micelles, which is likely an additional indicator that 
mitoxantrone might be predisposed to locate near the core-shell junction. 
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NMR measurements 
Mitoxantrone-loaded micelles in HEPES buffer were dialyzed against nanopure water for 24 
hours and freeze dried. 1H-NMR measurements were carried out on freeze-dried micelles to 
investigate mitoxantrone encapsulation. Fig. 6-8 shows the 1H-NMR spectrum of mitoxantrone-
loaded micelles (M4) measured in D2O (a), free mitoxantrone in DMSO (b), and micelle-
encapsulated mitoxantrone in DMSO (c).  
 
Chemical shift (ppm) 
 
Figure 6-8. 1H NMR spectra of micelles before and after rupture. 1H NMR spectra of (A) 
mitoxantrone-loaded M4 micelle in D2O, (B) free mitoxantrone in DMSO, and (C) mitoxantrone-
loaded M4 (ruptured) micelle in DMSO. 
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In D2O, spectral peaks corresponding to PEG (-CH2-CH2-O-) can be seen from 3.5-3.8 ppm and 
peaks corresponding to distearoyl can be seen at 1.2 ppm (-CH2-CH2-) and 0.8 ppm (-CH2-CH3). 
The distearoyl peaks are broad and intensity is reduced compared to its intensity in DMSO. This 
is due to restricted mobility of the hydrophobic distearoyl chains in the micelle cores. The 1H-NMR 
spectra of micelle-encapsulated mitoxantrone in D2O did not show peaks corresponding to 
mitoxantrone, likely due to its core-shell location in the micelles, causing restricted proton 
mobility. This is consistent with previous NMR observations of drug encapsulation within PEG-
DSPE micelles (e.g. for paclitaxel 265). However, spectral peaks corresponding to mitoxantrone 
and polymer were observed in 1H-NMR spectra recorded in DMSO, due to disruption of micelles 
by DMSO and release of mitoxantrone in the solvent. Comparison of spectra of free 
mitoxantrone, empty PEG-DSPE micelles and mitoxantrone loaded PEG-DSPE micelles in 
DMSO with mitoxantrone-loaded micelles in D2O indicated that mitoxantrone was encapsulated 
within micelles (Fig. 6-8).  
 
Micelle stability 
As may be expected, mitoxantrone is sensitive to its surrounding environment, which allows for 
investigations into time-dependent stability of the micelle-encapsulated drug by following changes 
in absorbance profiles. While free mitoxantrone possesses absorbance peaks at 610 nm (dimer) 
and 660 nm (monomer), mitoxantrone inside micelles demonstrates peaks at 614 ± 1 nm and 669 
± 1 nm. These differences in absorbance profiles can be monitored to determine stability. We 
periodically determined the absorbance profile of micelle-encapsulated mitoxantrone (M4-M6) 
stored at 4oC in 10-mM pH 7.4 HEPES by methods previously described. We observed minimal 
absorbance peak shifts and size changes of the drug-encapsulated micelles for over two months, 
which indicates stability under these storage conditions.  
Fig. 6-9 A,B shows time-dependent changes in the absorption profile of 35 µM free 
mitoxantrone and mitoxantrone in micelles (M4) for over 24 hours in RPMI 1640 cell culture 
media supplemented with 10% FBS and 1%  penstrep antibiotic at 37oC. It was observed that the 
drug, in both formulations, shows reduced absorbance after 24 hours.  
165 
A.      B. 
 
Figure 6-9. Absorbance profiles indicating stability of mitoxantrone in micelles. Absorbance 
profiles indicating stability of  (A) 35 µM mitoxantrone and (B) M4 micelles containing 35 µM 
mitoxantrone in RPMI 1640 cell culture media supplemented with 10% fetal bovine serum (FBS) 
and 1% Penicillin/Streptomycin (10,000 units/mL) at 37oC over 24 hours. Note that the 
absorbance intensity of mitoxantrone in micelles is higher than the free mitoxantrone at 
equivalent concentrations at all times. Data shown are representative of two independent 
experiments (n=2). 
 
These similar changes in the absorption profile could indicate dimerization of the drug when left 
for prolonged intervals in the cell culture media. However, it should be noted that mitoxantrone 
monomer peak stays at 669 ± 1 nm in the case of micelles in RPMI media. We also calculated 
time-dependent change in the ratio of dimer/monomer peak absorbance for both species. As 
shown in Table 6-2, (free mitoxantrone in RPMI media has a higher percentage of dimers than 
mitoxantrone in M4 micelles suspended in RPMI. Comparing the time-dependent changes in the 
ratio, we observe that there is a slow change in the dimer/monomer mitoxantrone population in 
both species. However, the M4 micelle absorbance curve does not resemble that of the free drug. 
Over 24 hours, only ~25% decrease is observed in the M4 micelle monomer peak absorbance, 
which remains at 669 ± 1 nm, a characteristic of the drug retained in micelles.  
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Table 6-2. The absorbance intensities of peaks of free mitoxantrone (dimer: 610 nm and 
monomer: 660 nm) and M4 micelles (dimer: 614 ± 1 nm and monomer: 669 ± 1 nm) 
measured in RPMI 1640 cell culture media during time dependent stability studies. 
 
 
 
 
 
Species Dimer peak 
Absorbance 
Monomer peak 
Absorbance 
Ratio 
Dimer/Monomer 
Free drug 0 hour 0.516 0.425 1.21 
Free drug 1 hour 0.515 0.422 1.22 
Free drug 2 hour 0.508 0.403 1.26 
Free drug 4 hour 0.486 0.373 1.30 
Free drug 6 hour 0.484 0.367 1.32 
Free drug 12 hour 0.456 0.328 1.39 
Free drug 24 hour 0.465 0.324 1.44 
Species Dimer peak 
Absorbance 
Monomer peak 
Absorbance 
Ratio 
Dimer/Monomer 
M4 micelles 0 hour 0.687 0.648 1.06 
M4 micelles 1 hour 0.663 0.634 1.05 
M4 micelles 2 hour 0.666 0.632 1.05 
M4 micelles 4 hour 0.656 0.615 1.07 
M4 micelles 6 hour 0.653 0.598 1.09 
M4 micelles 12 
hour 
0.629 0.552 1.14 
M4 micelles 24 
hour 
0.610 0.502 1.21 
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It has been previously observed that Amphotericin B-containing PEG-DSPE micelles were stable 
for only 45 minutes 286. However, this was not observed in case of mitoxantrone loaded micelles 
(M4):  An absorbance change of less than 3% was observed over the first hour after suspension 
in RPMI 1640 (Table 6-2). We also measured the size of the micelles in RPMI media and found 
that micelle size changes minimally in RPMI media over time (Fig. 6-10). Analyzing the changes 
in the absorption profile of mitoxantrone, we observe them to be minimal over a 6-hour time 
period (~ 10% reduction, Fig 6-9B) which is acceptable for micellar delivery of the drug to cells 
287.   
 
Figure 6-10. Time-dependent change in the Z-average (diameter in nm) of M4 micelles. 
Time-dependent change in the Z-average (diameter in nm) of M4 micelles containing 35µM 
mitoxantrone in RPMI cell culture media. The error bars denote the polydispersity in nanometers. 
The Z-size average has a +/- 5.4% change in the 24 hours in RPMI cell culture media. Data 
shown is representative of two independent experiments. 
 
In-vitro drug release 
Release of mitoxantrone from micelles was investigated under various conditions by monitoring 
release of the drug from an 8- to 10-kD Float-A-Lyzer membrane. The release profile was 
compared to diffusion of the free drug under similar experimental conditions. As shown in Fig. 6-
11, over 48 hours approximately 7%, 20% and 25% of initially encapsulated mitoxantrone was 
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released from the micelles at pH 7.4 in 10-mM HEPES buffer, 150-mM phosphate buffered saline 
(PBS) and 150-mM phosphate buffered saline supplemented with 10% FBS, respectively.  
Higher salt concentration of 150 mM in case of 1X PBS (physiological salt concentration) led to 
an increase in drug release (p<0.05) compared to release in 10-mM HEPES buffer. This could be 
due to the shielding of ionic charge at higher salt concentration leading to lower retention of the 
mitoxantrone in the micelle and, therefore, higher release. Nevertheless, the release was only 
approximately 20% of the initially encapsulated mitoxantrone over a period of 48 hours. 
Introduction of FBS to M4 micelles in PBS resulted in a statistically significant (p<0.05) increase 
in mitoxantrone release at 4, 6 and 12 hours compared to micelles in PBS alone. Approximately 
25% of the encapsulated drug was released after 48 hours in the presence of FBS (Fig. 6-11). As 
may be expected, the diffusion of free mitoxantrone from the dialysis tubing was significantly 
more rapid; approximately 85% of the drug diffused out of the dialysis membrane in 48 hours in 
10 mM pH 7.4 HEPES buffer. 
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Figure 6-11. Kinetics of mitoxantrone release from micelles. Kinetics of mitoxantrone release 
from micelles (M4) in 1X PBS pH 7.4 (150 mM equivalent salt concentration) supplemented with 
10% fetal bovine serum (grey diamonds), 1X PBS pH 7.4 (crosses) at 37oC and 10 mM HEPES 
buffer pH 7.4 (grey squares). Diffusion of the free (unencapsulated) mitoxantrone in the dialysis-
based study in 10 mM HEPES buffer at pH 7.4 is shown by dark grey triangles. *1 indicate 
statistical significance between grey diamonds and triangles, *2 indicate statistical significance 
between grey triangles and grey crosses and *3 indicate statistical significance between grey 
crosses and grey squares. *4 indicate statistical significance between grey crosses and grey 
diamonds. 
 
Cellular uptake 
Free mitoxantrone and mitoxantrone-loaded micelles (M4) were administered to PC3 prostate 
cancer cells and imaged at different time points using confocal fluorescence microscopy in order 
to investigate cellular uptake. Our results indicate that mitoxantrone was internalized by the cells 
in both free and micellar formulations. Fig. 6-12 A-D and Fig. 6-13 show confocal microscopic 
images of drug fluorescence at 3 hours following administration of 13.3 µM mitoxantrone loaded 
micelles (M4) and free mitoxantrone respectively.  
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Figure 6-12. Cell uptake of mitoxantrone micelles into PC3 cancer cells. (a-c) Confocal 
microscopy image showing internalization of mitoxantrone (13.3 µM)-loaded micelles (M4) in PC3 
prostate cancer cells after 3 hours of treatment. The nucleus was stained with DAPI (A) (stained 
blue; excitation: 358 nm, emission: 461 nm). Mitoxantrone (B) was excited with 637 nm laser and 
emission was detected in the far red region (670 nm) with long pass filter (red false color was 
used to indicate mitoxantrone emission). Image (C) shows the phase contrast image and Image 
(D) shows the overlay image of a,b and c. Scale Bar : 10 µm 
E. Average mitoxantrone fluorescence calculated over 10 different representative PC3 prostate 
cancer cells following treatment with 13.3 µM of free mitoxantrone (grey bars) and M4 micelles 
(black bars) at different time intervals. Minimal intracellular drug fluorescence was observed in 
case of M4 micelles (p<0.01) compared to the free drug in the first 30 minutes following 
treatment. Higher fluorescence was noticed after 3 hours of addition than 0.5 hours for both M4 
micelles (p<0.01) and free mitoxantrone (p<0.01).  
F. Concentration-dependent fluorescence observed in cells after exposure to different 
concentrations of free mitoxantrone and M4 micelles after 2 hours. Significant differences were 
observed between the two doses (both free drug and M4 micelles).  (p<0.01) 
 
The drug, detected by its characteristic far-red emission, was observed to be present in the whole 
cell in case of both free mitoxantrone and micellar formulations. This is similar to the observations 
by Smith et al. who reported preferential accumulation of mitoxantrone drug molecules within the 
cytoplasm, nuclear membrane, and nucleoli in drug-resistant murine cancer cells 288. In our 
experiments, quantification of intracellular fluorescence indicated that in the initial 30 minutes 
following administration, lower fluorescence intensity was observed in the case of M4 micelles 
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compared to that observed with free mitoxantrone (p<0.01) (Fig. 6-12E). This could be due to the 
slow release of drug from the micelles in vitro. Further, a time- (Fig. 6-12E) and concentration-
dependent (Fig. 6-12F) difference in the fluorescence of mitoxantrone (p<0.01) was observed in 
both treatments (free mitoxantrone and mitoxantrone-loaded M4 micelles). As may be expected, 
higher fluorescence intensities were observed at longer time points (p<0.01 between 0.5 and 3.0 
hours; Fig. 6-12E). 
 
Figure 6-13. Cell uptake of free mitoxantrone into PC3 cancer cells. Confocal microscopy 
image showing the internalization of free (unencapsulated) mitoxantrone (13.3 µM) by PC3 
human prostate cancer cells 3 hours following treatment. The nucleus was stained with DAPI (A) 
(blue; ex: 358 nm em: 461 nm). Mitoxantrone (B) was excited with 637 nm laser and emission 
was recorded in the far-red region at 670 nm with long pass filter.  A false red color was 
employed to indicate mitoxantrone emission. Image (C) shows the phase contrast image and 
Image (d)  shows the overlay image of a,b and c. Scale Bar : 10 µm. 
 
Control equivalent concentrations of HEPES buffer alone and M1 PEG-DSPE micelles (without 
mitoxantrone) did not show intracellular fluorescence due to absence of the drug in these cases 
(data not shown). Previous studies with mitoxantrone indicated similar intracellular behaviour at 
these equivalent concentrations 246, 288-289. For example, Sophie et al. 246 showed that cytosolic 
accumulation of mitoxantrone resulted in significant increase in breast cancer cell death. As 
shown in Fig. 6-12E, we observed similar integrated intracellular fluorescence intensity for the 
free and micelle-encapsulated drug after 1 hour.  
A recent study on the internalization kinetics of the PEG-DSPE micelle loaded with 
doxorubicin indicated that PEG-DSPE micelles disassemble at the cell membrane lipid bilayer, 
resulting in release of doxorubicin at the cell surface 290. PEG-phospholipid micelles have a 
hydrophobic core that is very similar to the phospholipids in the lipid bilayer, thus creating a 
strong driving force for the micelle core to ‘open’ at the cell surface due to hydrophobic 
C	 D	A	 B	
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interactions between these moieties. Similar intracellular fluorescence intensity after 1-hour 
incubation with free and micelle-encapsulated (M4) mitoxantrone (Fig. 6-12E) could be an 
indication that the PEG-DSPE micelles release mitoxantrone at the cell surface followed by 
mitoxantrone entry into the cell by a flip-flop mechanism 291 across the lipid bilayer, or by its 
passive diffusion through the membrane.  
 
Loss of cancer cell viability 
Single agent (mitoxantrone alone; free drug vs. drug in micelles (M4)) 
The loss of cell viability following treatment with micelle-encapsulated mitoxantrone compared 
with that induced by free drug was studied in three different cancer cell lines: PC3 and T24 
bladder cancer cells and MDA-MB-231 human breast cancer cells. Fig. 6-4 shows a schematic of 
the different treatments. Both, free mitoxantrone and drug-loaded micelle (M4) induced a dose-
dependent loss in viability of PC3 cells (Fig. 6-14 A-B, grey triangles).  
 
 
173 
 
Figure 6-14. Efficacy of free mitoxantrone and mitoxantrone-loaded micelles in different 
cancer cells. Efficacy of free mitoxantrone and mitoxantrone-loaded micelles in (A-C) PC3, (D-F) 
T24 bladder cancer cells and (G-I) MDA-MB 231 breast cancer cells is shown. Lines connecting 
data points are for visualization alone. 
A,D,G. Single-agent cytotoxicity of free mitoxantrone (grey triangles) compared to cytotoxicity 
induced by sequential treatment of mitoxantrone and TRAIL (10 ng/mL)(black diamonds). 
Statistically significant differences between cell viability following single-agent and sequential 
mitoxantrone-TRAIL combination treatments are indicated by asterisks.  
PC3 prostate cancer, T24 bladder cancer and MDA-MB-231 breast cancer cell viability after 
single-agent TRAIL treatment (24 h) was (94.55 ± 4.2%),(99.48 ± 7.17%) and(91.2 ± 5.7%) 
respectively.  
B,E,H. Cytotoxicity of mitoxantrone-loaded micelles (M4) (grey triangles) as compared to 
cytotoxicity of sequential treatment of M4 micelles and 10 ng/mL TRAIL (black diamonds). 
Statistically significant differences between cell viability among single-agent and sequential 
treatments for the M4 micelles are shown by asterisks. 
C,F,I. Comparison of sequential combination treatments of free mitoxantrone (black diamonds) 
and mitoxantrone encapsulated M4 micelles (grey triangles)is shown. 
 
M4 micelles and the free mitoxantrone at equivalent drug concentrations caused similar levels of 
cytotoxicity, as shown in (Fig. 6-14 A-B, grey triangles). Negligible decrease in cell viability was 
observed in the case of empty micelles (Fig. 6-15 A).   
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  A.         B. 
 
C. 
 
 Figure 6-15: Impact of empty micelles on cell viability. Cell viability (%) in PC3 prostate 
cancer cells after single-agent treatment with M1 micelle (A) M2 micelle (B) M3 micelle (C) is 
shown in black diamonds. Sequential treatment of various polymers and 10 ng/mL of TRAIL are 
shown in grey triangles. Cell viability was estimated using the MTT cell viability assay. Lines 
connecting the data points are for visualization purpose only. 
 
These results are well correlated with previous observations of cellular uptake of the drug 
(Fig. 6-12 A-D and Fig. 6-13). Free mitoxantrone and micelle-encapsulated mitoxantrone 
resulted in similar levels of intracellular fluorescence intensity within 1 hour of administration (Fig. 
6-12E), suggesting equivalent accumulation of drug in the cells for both treatments. This is 
reflected in similar decreases in cell viability:  Free mitoxantrone and drug-containing M4 micelles 
showed near-identical LC50 (equivalent drug concentration that induces a 50% decrease in cell 
viability) of approximately 13.3 µM (Table 6-3). Encapsulation of mitoxantrone in M4 micelles 
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resulted in enhanced levels of T24 bladder cancer cell death compared to free mitoxantrone (Fig. 
6-14 D-E; grey triangles; p<0.05). The LC50 value of mitoxantrone in M4 micelles was 3.8 µM 
compared to 9 µM for the free mitoxantrone treatment.  
 
Table 6-3. LC50 values of mitoxantrone (free drug or encapsulated in M4 micelles) in the 
different cancer cell lines investigated and reported as Mean ± SD. LC50 = concentration of 
drug required to induce loss of viability in 50% of cell population. 
 
Treatment with empty M1 micelles resulted in negligible loss of T24 viability (data not shown).  
Differences in efficacy of micellar formulations compared to free drugs have been previously 
reported 292 and attributed to the delivery of drug as packets to the cells rather than in the free 
diffused form293.   
The MDA-MB-231 breast cancer cell line was more resistant to both, free and encapsulated 
mitoxantrone (Fig. 6-14 G-H; grey triangles). A 25-35% loss of viability was observed at 6.6 µM 
concentration of the drug, and 40-50% loss was seen beyond 13.3 µM concentration range. 
Empty micelles produced only a 10% reduction in viability at the highest concentration tested 
(micelle concentration equivalent to that required to deliver 13.3 µM mitoxantrone) (data not 
shown).  
 
 PC3 cells T24 cells MDA-MB-231 cells 
Treatment Free drug 
Drug in 
micelles 
(M4) 
Free 
drug 
Drug in 
micelles 
(M4) 
Free  
drug 
Drug in 
micelles 
(M4) 
Single-agent 
treatments (without 
TRAIL) 
> 13.3  µM  
(15 ± 2.0) 
13.3 ± 1.9 µM 9 ± 1.7 µM 3.8 ± 0.5 µM 
>> 13.3 µM  
(16.5 ± 2.0) 
13.3 ± 1  
µM 
Sequential treatments 
with  10 ng /mL TRAIL  
2.2 ± 0.7 µM 2.1 ± 0.4 µM 1.3 ± 0.6 µM 0.9 ± 0.3 µM 3.3 ± 0.5 µM 3.5 ± 0.3 µM 
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Combination Treatments: micellar delivery of mitoxantrone to sensitize cancer cells to 
TRAIL 
Sequential treatments with TRAIL 
Following micelle characterization and an investigation into the single-agent efficacy of free and 
encapsulated mitoxantrone, we conducted experiments designed to test whether micelle-
encapsulated mitoxantrone was able to sensitize cancer cells to TRAIL-induced loss of cancer 
cell viability. We chose to employ a 10-ng/mL TRAIL concentration in these and previous 154 
studies, since we are particularly interested in identifying combination treatments that are 
effective at lower TRAIL concentrations than previous studies294-295 which employed a ten-fold 
higher concentration of the cytokine.  
As a single-agent treatment, 10 ng/mL TRAIL induced ~5-10% cell death in PC3, T24 
and MDA-MB-231 cells (Fig. 6-16), indicating resistance of these cells to TRAIL-induced death.  
 
Figure 6-16: Impact of TRAIL treatment alone on cell viability. Cell viability (%) after single-
agent treatment with 10 ng/mL of TRAIL for 24 hours in various cell lines. Cell viability was 
estimated using the MTT cell viability assay. 
 
In addition, empty micelles (without mitoxantrone) did not induce cell death in combination with 
TRAIL, indicating that the micelles by themselves did not play a role in TRAIL sensitization. 
However, micelle-encapsulated mitoxantrone (M4) and free mitoxantrone were able to sensitize 
PC3 prostate cancer cells to TRAIL-induced death (Fig. 6-14 A-B; black diamonds).  The 
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highest levels of synergy were observed at equivalent mitoxantrone concentrations of 3.8 µM and 
6.6 µM in M4 micelles followed by 10 ng/mL TRAIL in PC3 prostate cancer cells. Single-agent 
TRAIL induced ~10% cell death and single-agent mitoxantrone in micelles (M4) at the two 
concentrations resulted in ~30% and ~35% cell death. However, the combination treatment 
resulted in ~75% (p<0.05) and ~85% (p<0.05) cell death at the respective M4 concentrations. 
These results are indicative of synergy between micelle-encapsulated mitoxantrone and TRAIL; 
the extent of cell death induced by the combination treatment (e.g. 75% at 3.8 µM) is greater than 
the sum (additive effect) of the two individual treatments (e.g. 10% for TRAIL alone + 30% for 
micelle-encapsulated mitoxantrone). 
Table 6-3 shows LC50 values in the three cancer cell lines for free and micelle-
encapsulated mitoxantrone (M4) in combination with TRAIL. Both free and micelle-encapsulated 
mitoxantrone were able to augment the effects of TRAIL in all these cells, leading to synergistic 
enhancement of cancer cell death. Although encapsulation in M4 micelles resulted in an increase 
in the efficacy of single-agent mitoxantrone in T24 cells, no such enhancement by encapsulation 
was seen in the case of the mitoxantrone-TRAIL combination in this cell line (Fig. 6-14 D-E; 
black diamonds). A similar sensitization profile was observed when M4 micelles were used to 
pretreat MDA-MB-231 breast cancer cells (Figs. 6-14 G-H; black diamonds). 
Potential mechanisms involved in the synergy could include upregulation of death 
receptors following mitoxantrone treatment, downregulation of c-FLIP, a caspase 8 inhibitor, 
mitochondrial depolarization and ROS production induced by mitoxantrone. These collectively 
can help overcome cancer cell resistance to TRAIL-induced death. The total amount of 
chemotherapeutic drug needed to achieve same amount of cell death is reduced in case of 
synergistic combinations. This, in turn, can help reduce dose-dependent side effects associated 
with chemotherapeutic drugs. In addition, due to the selectivity of TRAIL for malignant cells, the 
combination of micelle-encapsulated mitoxantrone and TRAIL is an attractive synergistic 
treatment for ablation of cancer cells.  
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Comparison of sequential and simultaneous treatments of micelle-encapsulated 
mitoxantrone in combination with TRAIL 
In addition to sequential treatments, cells were treated simultaneously with the free or micelle-
encapsulated mitoxantrone (M4) and TRAIL in order to investigate whether this method of dosing 
had a different effect on cancer cell viability. Compared to the sequential treatments, 
simultaneous dosing with TRAIL and mitoxantrone resulted in reduced synergy (Fig. 6-17) 
between the drug-TRAIL combinations, (Fig. 6-14 A-I). These trends were observed for both free 
and micelle-encapsulated mitoxantrone and are consistent with our previous observations 154, 296. 
One explanation for this observation could be that a finite period of time is required for 
sensitization to take place, and for cellular resistance mechanisms to TRAIL-mediated death to 
be overcome. It may also be the case that hitherto unknown interactions between micelles and 
TRAIL attenuate the latter’s lethality when simultaneous treatments are applied. Taken together, 
our results demonstrate that sequential treatment with micellar mitoxantrone and TRAIL results in 
enhanced cell kill compared to simultaneous treatment with the same agents.  
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A.       B. 
 
C.       D. 
 
Figure 6-17. Comparison of different treatment modalities in PC3 human prostate cancer 
cells. Lines connecting data points are for visualization alone. 
A. Single-agent treatment cytotoxicity of M1 micelles (grey triangles), simultaneous treatment of 
M1 micelles with TRAIL 10 ng/mL (grey squares) and sequential treatment of M1 micelles and 
TRAIL 10 ng/mL (black diamonds). Data points represent the concentration of PEG-DSPE 
associated with mitoxantrone in various treatments (30 µM polymer concentration was the 
highest used).  
B. Single-agent treatment cytotoxicity of free mitoxantrone (grey triangles), simultaneous 
treatment of free mitoxantrone with 10 ng/mL TRAIL (grey squares) and sequential treatment of 
free mitoxantrone and 10 ng/mL TRAIL (black diamonds). 
C. Single-agent treatment cytotoxicity of M4 micelles (grey triangles), simultaneous treatment of 
M4 micelles with 10 ng/mL TRAIL (grey squares) and sequential treatment of M4 micelles and 10 
ng/mL TRAIL (black diamonds). 
D. Control: Cytotoxicity of 10 ng/mL TRAIL (sequential treatments) (black bar) and cytotoxicity of 
10 ng/mL TRAIL (simultaneous treatments) (grey bar). Experimental details provided in text. 
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Influence of terminal groups on micellar efficacy (single agent and sequential treatments) 
In addition to the neutral (methoxy-terminated) micelles described previously, we employed 
empty (M2) and mitoxantrone-loaded (M5) amine-terminated micelles, as well as empty (M3) and 
mitoxantrone-loaded (M6) carboxyl-terminated micelles in order to investigate the effect of micelle 
surface chemistry on treatment efficacy. As shown in Fig. 6-18, the nature of the exterior micellar 
charge did not affect the efficacy of mitoxantrone-mediated cancer cell death, either as a single-
agent treatment or in combination with TRAIL when administered as a sequential treatment. The 
synergy with TRAIL was maintained for all micelle types (M4-M6) (Fig. 6-14B Fig. 6-18 B,D). 
Empty micelles M2 and M3 (Fig. 6-3) showed no significant cytotoxicity (Fig 6-15 B-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
181 
A.       B. 
 
C.       D. 
 
Figure 6-18. Influence of micelle terminal groups on cytotoxicity on loss of PC3 human 
prostate cancer cell viability. Lines connecting data points are for visualization alone. 
 A-B. Amine terminated micelles:  A. Loss of cell viability following single agent treatment with 
free mitoxantrone (black diamonds) compared to mitoxantrone-loaded, amine-terminated M5 
micelles (grey triangles) B. Loss of viability following sequential treatment of free mitoxantrone 
and 10 ng/mL TRAIL (black diamonds) compared to mitoxantrone-loaded, amine-terminated M5 
micelles + 10 ng/mL TRAIL (grey triangles).  
C-D. Carboxyl terminated micelles: C. Loss of viability following single agent treatment with free 
mitoxantrone (black diamonds) compared to mitoxantrone-loaded, carboxyl-terminated M6 
micelles (grey triangles). D. Loss of viability following sequential treatment of free mitoxantrone 
and 10 ng/mL TRAIL (black diamonds) compared to mitoxantrone-loaded and carboxyl-
terminated M6 micelles + 10 ng/mL TRAIL (grey triangles).  
 
 
The lack of efficacy differences among the three micelle species may stem from micelle 
disassembly at the cell surface due to the previously-described interactions between 
phospholipids of these two entities 290, 297-298. It has been suggested that due to the overall 
negative charge on the cell surface exterior, internalization of negatively charged species could 
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be hindered compared to the favorable electrostatic interactions between cells and positively 
charged counterparts 299. However, it is possible that the energetics of attraction between the 
hydrophobic DSPE core of the micelle and the phospholipid bilayer outweigh the energetics of the 
repulsion between cells and the micelle. In addition, the flexibility of the outer PEG layer can 
facilitate interactions with the cell membrane.  
 
6.4. CONCLUSION 
We have successfully encapsulated mitoxantrone within PEG-DSPE micelles and have used the 
micellar form for ablation of prostate and breast cancer cells, both as a single-agent treatment 
and in synergistic combination with TRAIL. The efficacies of the micelle-based single-agent and 
synergistic treatments were similar to those observed with free mitoxantrone, indicating that 
encapsulation did not compromise efficacy of the drug. The advantages of encapsulation, 
compared to free-circulating mitoxantrone, arise from the extended longevity in the blood 
compartment of the micelle-enclosed form. Micelles with different surface functional groups – 
methoxy, amine, and carboxylic acid – demonstrated similar levels of drug loading of 
mitoxantrone and cancer cell ablation efficacy. Successful encapsulation, stability and efficacy of 
mitoxantrone-containing micelles opens up the door for sequential targeting of cancer with 
nanoparticles decorated with biomolecules for targeting, followed by delivery of TRAIL for 
targeted synergistic ablation of tumors in vivo. 
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CHAPTER 7: ADDITIONAL DEVELOPED METHODS: HIGH-THROUGHPUT FABRICATION 
OF SCALABLE POLYMERIC SCAFFOLDS FOR NOVEL PDNA LIGAND SCREENING 
 
7.1. INTRODUCTION 
 
Cells in human body associate with neighboring cells and tissues in three dimensions, 
but the laboratory cell culture techniques used to mimic the same in-vivo processes rely on two 
dimensional cell culture plates 34, 85. Cells grown on these 2D plates do not mimic the human 
body 33. They lack extensive cell-cell contact, nutrient and metabolite gradient, complex waste 
disposal system that exists in the body 21, 111. Hence it is necessary that appropriate systems be 
used to capture the 3D nature of human body in the petridish in the research lab.  
Macroporous scaffolds provide a 3D substrate with extensive surface area that matches 
the 3D environment the cells in the body reside in 300. For example, these macroporous scaffolds 
can be designed to be extensively interconnected, mimicking the bone trabecular structure 301. 
Bone trabeculae are characterized with a highly porous structure filled with bone marrow. Multiple 
macroporous materials have been used to create bone mimics that can capture stem cell growth 
and differentiation on them etc 300, 302-303. Macroporous monoliths or scaffolds also find their use in 
industrial plasmid DNA chromatography 304. Their macroporous structure provides higher surface 
area for reactivity, high permeability, large number of channels, without the issue of big pressure 
drops that occur with smaller microbead resin columns 305. Traditional monolithic cultures are 
prepared via cryo-gelation/cryo-polymerization. Briefly, scaffold monomers are mixed with specific 
initiators (example: photoinitiators 306) in an aqueous porogen system that is incubated below 0oC, 
above the freezing temperature of the monomers. Freezing of water (porogen) causes monomers 
to accumulate in highly concentrated pockets allowing robust reaction upon initiation. 
Temperature is increased to retrieve the macroporous monolithic column after sufficient 
polymerization 307.  
These macroporous materials can also be made by using a porogen such as salt/glucose 
or sucrose etc, which are insoluble in polymer slurry, but are soluble in aqueous solvents 302. The 
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polymer pre-gel is mixed with insoluble salt crystals and casted on a special device. 
Polymerization is initiated either by a catalyst or an enzyme added to the pre-gel mixture. Heat 
and light are also used to initiate polymerization. Once the polymerization and gelation are 
complete, the porogen is leached out using aqueous solvents such as water, leaving behind a 
macroporous scaffold. 
A significant challenge in this approach is the absence of a device that can be used to 
create these systems in high throughput and easily retrieve them. We found existing technologies 
to be tedious and poor in yield. A critical problem exists in easy recovery of the polymeric 
macroporous scaffolds after their preparation. Hence, we wished to design and develop devices 
and methods for preparation of user desired polymeric scaffold materials (macroporous or non-
macroporous) in high-throughput and their easy retrieval out of the device. This brief chapter 
describes the technique developed to generate macroporous amikagel (‘Amikalith’) in high-
throughput for multiple biomedical applications such as plasmid DNA binding and cell culture. The 
chapter also describes the methodology for conjugation novel ligand doxorubicin to Amikagels 
and Amikaliths for enhanced pDNA binding. The high-throughput device described in chapter 2 
was used to generate macroporous columns with NaCl porogen.   
 
7.2. MATERIALS AND METHODS 
 
Materials 
Amikacin hydrate was purchased from TOKU-E (Bellingham, WA). Poly(ethylene glycol) diglycidyl 
ether (PEGDE) was purchased from Sigma-Aldrich Inc. (St Louis, MO). NaCl crystals were 
purchased from Avantor Performance Materials (Center Valley, PA). Doxorubicin was purchased 
from Ontario Chemicals (Guelph, Ontario). Qiagen Giga kits for pDNA extraction were purchased 
from Qiagen Inc. (Alameda, CA). 27 G needles were purchased from Becton, Dickinson and 
Company (Franklin Lakes, NJ). Chloroform was purchased from Acros Organics (Morris Plains, 
NJ). Different acrylic geometries were designed and cut using a Universal Laser Systems CO2 
laser cutter.  
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Preparation of Amikaliths I and II 
For each monolith type, a pregel solution was formed by dissolving amikacin hydrate (100 mg, 
0.17 mmoles) in dimethyl sulfoxide (DMSO) followed by the addition of poly(ethylene glycol) 
diglycidyl ether (PEGDE) in a mole ratio of 1:2. Amikacin hydrate and PEGDE were each 
dissolved in 0.5 mL DMSO. Both mixtures were combined and vortexed to form a uniform pregel 
solution.  
Amikaliths II and I were formed using unfused salt and fused salt crystals respectively. 
NaCl crystals with an average initial diameter of 520 ± 170 µm were used in all experiments. Both 
acrylic device components were wrapped in a layer of paraffin wax tape and joined together to 
form an array of cylindrical gaps. A single side of the device was provided with a layer of parafilm 
to serve as a base for the hollow wells. To form Amikaliths I, cylindrical device wells were filled to 
the brim with NaCl crystals. The porogen in each well was treated with 10 µL of the pregel 
solution. The entire device-salt-pregel setup was incubated at 40oC for 48 hours. Following 
incubation, the device was cracked open and salt-gel columns were removed using a 27 G 
needle. Columns were subjected to three washes in nanopure water, resulting in the final 
Amikalith I structure.  
In preparation of Amikaliths II, a monolayer of salt crystals was deposited into a parafilm-
wrapped container. The open container was placed in a 37oC incubator with 95% humidity for one 
hour to achieve uniform wetting of the salt crystals. During this time, the device was prepared with 
parafilm wrappings. Immediately following one hour, the container was removed from the 
incubator and the wetted crystals were packed into the wells of the prepared acrylic device. After 
addition of the wetted crystals, excess salt was swept away until the thickness of the salt columns 
was equal to that of the device height. The salt filled device was left undisturbed at room 
temperature for 12 hours to allow the packed crystals to fuse and harden. The device was then 
cracked open and salt fused columns were carefully removed. Recovered salt columns were 
wetted with 10 µL of the Amikagel pregel solution. Gelation was initiated by incubating the 
monoliths at 40oC for 24 hours after which the salt was dissolved in washes of nanopure water. 
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Amikalith II Swelling Ratio 
Swelling ratio of Amikaliths II was calculated using the following equation obtained from Park et 
al. They define the swelling ratio of a hydrogel as the increase in weight caused by absorption of 
water: 
Swelling Ratio = (Ws – Wd) / Wd 
The weight of the dried Amikalith Wd was obtained after incubating the gel at 40ºC for 24 
hours, while the weight of the saturated Amikalith Ws was taken upon swelling the gel in 
nanopure water. Three Amikaliths composed of 30 µL of pregel solution were chosen for swelling 
ratio measurements.    
 
Amikalith II Surface Area using BET Analysis 
Total surface area of macroporous Amikaliths II was calculated using a Brunauer-Emmett-Teller 
(BET) adsorption isotherm. Amikaliths II were prepared by submerging in increasing gradients of 
acetone. Once subjected to 100% acetone, the monoliths were dried and BET analysis was used 
to calculate total surface area per gram.  
 
Scanning Electron Microscopy of Amikaliths I and II 
Amikalith and PLGA surface morphologies were visualized using a field emission scanning 
electron microscope (FE-SEM; Philips FEI XL-30 SEM) at a voltage of 25 kV. Carbon tape 
attached to the aluminum stub was used to anchor scaffolds in place during preparation and 
imaging. Columns were sputter-coated with Au-Pt particles for 120 s (E1030 ion sputter). An 
accelerating voltage of 20 kV was used during SEM imaging.  
 
pDNA Binding to Amikaliths II and I 
Final Amikalith scaffolds used in plasmid DNA adsorption and desorption possessed a cylindrical 
shape characterized with a diameter of 2.5 mm and a thickness of 4.5 mm.  Binding profiles were 
generated by incubating Amikaliths I and II with 15,000-60,000 ng of pDNA in 10 mM Tris-Cl 
buffer, pH 8.5 for 5 hours at room temperature (25ºC). Each Amikalith was deposited into a single 
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microtube containing a pDNA-buffer suspension with a total volume of 1 mL. Initial efforts to bind 
pDNA to Amikaliths using a rotisserie shaker yielded poor results. Rotation of the microtube 
containing the Amikalith in a pDNA-buffer suspension did not provide adequate mixing to allow 
pDNA to enter into the inner structure of the monolith. A force sufficient to push the pDNA through 
the Amikalith was needed. For this reason, a jerk motion was desired. Microtubes (2.0 ml) 
containing the suspension and a single Amikalith each were organized in a hammock-like fashion 
with both ends of the hammock clipped to a single side of the shaker. Each full rotation made by 
the shaker caused the microtube base of the hammock to reach a peak height, which quickly 
succumbed to gravity, producing the desired swing motion to thrust the pDNA in each microtube 
through its respective Amikalith structure.  
Plasmid DNA concentration in the supernatant was measured using a NanoDrop 
Spectrophotometer after 5 hours of mixing. Mass balance was used to calculate the amount of 
pDNA adsorbed onto the matrix surface. The data obtained was used to form adsorption isotherm 
profiles for both Amikalith types. Following surface adsorption measurements, Amikaliths were 
submerged in acetone for 30 minutes and again in a second acetone wash for 15 minutes to 
sufficiently dehydrate the monoliths. Acetone was completely removed and Amikaliths were 
incubated at 40ºC for 24 hours. Dried Amikaliths were weighed and the weights were 
incorporated into binding profiles to normalize pDNA bound per unit volume of Amikalith. The 
data were fitted to a Langmuir isotherm in order to calculate the maximum binding capacity 
(Qmax) of Amikaliths I and II.  
 
Conjugation of doxorubicin to Amikabeads and Amikaliths: Towards novel ligands for 
pDNA binding 
Preparation doxorubicin Drug Solution 
Doxorubicin (100mg, 543g/mol) was dissolved in 10mL of Dimethyl sulfoxide (DMSO) followed by 
addition of 50uL of triethylamine (TEA). The stock mixture of doxorubicin, DMSO and TEA 
(10mg/mL) was stored in a 20mL glass via at 4⁰C for future use. 
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Conjugation of doxorubicin with crosslinker 
Stock mixture was retrieved from 4oC and preheated at 37oC for 5 minutes. 1 mL of the 10 mg/mL 
of the stock mixture was mixed with 1, 4-Cyclohexanediol diglycidyl ether (CHDDE) in a mole 
ratio of 1:3. 5 mole equivalents of TEA was added to the mixture in a 20 mL glass vial and the 
final volume was brought upto 2 mL in DMSO. The glass container was covered by aluminum foil 
for minimizing any photobleaching and the mixture was stirred with magnetic beads for 8 hours at 
320 rpm at room temperature to link one end of the crosslinker with the doxorubicin.  
 
Formation of doxorubicin conjugated Amikabeads/Amikaliths 
1mg of Amikabeads/ individual Amikalith unit was collected and washed with DMSO. Supernatant 
was decanted and Amikabeads/Amikaliths were transferred to the prepared doxorubicin-linker 
solution. The solution stirred at 320rpm for 8 hours at 25⁰C. After reaction, the beads were 
thoroughly washed with DMSO and the diameter of conjugated doxo-beads were measured using 
an inverted microscope. 
 
7.3. RESULTS AND DISCUSSION 
 
Design of Acrylic Geometry for Amikagel Monolith Generation and Recovery 
 
Current macroporous scaffold generation methods suffer from several drawbacks that we 
addressed while designing the high-throughput device. The device makes use of the molding 
technique in which a polymer pregel is added to a solid template which supports subsequent 
gelation 308. While this is a well-established technique for gel formation, existing mold templates 
do not allow for easy removal of the 3D hydrogel following polymerization. For example, PLGA 
scaffolds may be formed by depositing the gel precursor into a polydimethylsiloxide (PDMS) mold 
and heating the construct to initiate polymerization. However, the mold provides no inherent 
means of releasing the final scaffold and tweezers are needed to remove the gel 309. This 
presents the potential to damage the final structure. Similarly, a method of producing 
macroporous PLGA sheet and cylindrical scaffolds reports that a porogen-containing polymer 
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slurry is cast into a glass mold. Once semi-solidified, the sheet morphology required 1.5 h of air 
drying to remove from the mold 310.  
In order to address these shortcomings, we developed a device to allow for the high-
throughput fabrication and easy recovery of Amikalith scaffolds. Figure 2-5 shows the final device 
design that consists of two mirror components with semi-circular teeth that may be linked to 
generate a central array of cylindrical wells. As described before, the greatest design strength 
and distinguishing factor was the incorporation of a central break line in the design that allowed 
very easy recovery. Both device sections were wrapped with a layer of paraffin wax tape for easy 
assembly and disassembly. A single layer of parafilm was applied to the bottom side of the device 
to close off the wells at one end. We were able to create the acrylic geometries in multiple shapes 
such as cylinder and cuboid (Fig. 7-1 A-C).  
 
A.    B.              C. 
 
Figure 7-1. Various geometries of the polymeric scaffold generation device. Device 
components are all formed from laser cut acrylic sheets. (A.) Cylindrical monoliths are possible 
and were used to form Amikaliths for pDNA binding and elution. (B-C) Cube-shaped scaffolds are 
also possible using the same technology. Additional middle inset pieces may be included to 
increase the throughput of each device. 
 
 
Synthesis of Amikaliths I and II 
Amikaliths I and II were formed using unfused salt and fused salt crystals respectively. The 
specially developed device served as a support for unfused salt crystals and prevented columns 
from collapsing during sample preparation (Amikaliths I, II) and incubation (Amikalith I). Salt 
crystals underwent separate preparation stages in order to form Amikaliths I and II. Amikaliths I 
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were formed as a first proof of concept. No alterations were made to the salt crystals prior to 
pregel addition and gelation. In order to form the non-interconnected porous network of 
Amikaliths I, dry salt was poured into the wells of the device whereupon the porogen was wetted 
with the pregel mixture and columns were incubated at 40ºC. It was hypothesized that fusion of 
the salt crystals prior to the addition of pregel would facilitate the formation of interconnected 
pores in the final gel monolith. To validate this, Amikaliths II were prepared by packing the device 
wells with crystals that were previously exposed to 95% humidity at 37ºC for 1 hour (Figure 7-
2A). The wetted NaCl crystals were allowed 12 hours to dry undisturbed in the device wells after 
which the device was cracked opened and the partially-fused salt columns were removed. Pregel 
was then added to the stand alone salt columns. Following incubation at 40ºC, all columns were 
subjected to three washes in nanopure water to completely dissolve the porogen, leaving behind 
a macroporous scaffold. The increased incubation time of Amikaliths I (48 hours) compared to 
Amikaliths II (24 hours) was to ensure complete gelation throughout the entire monolith contained 
in the device. Figure 7-2B outlines the fabrication processes for Amikaliths I and II.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
191 
A. 
 
B. 
 
Figure 7-2.  Salt fusion method to generate macroporous Amikaliths. (A) Monolayer of salt 
after exposure to 37ºC, 95% humidity for one hour. Salt crystals are visibly fused in order to 
bridge gaps between the crystals in order to facilitate formation of Amikaliths II. (B) The process 
of preparing each Amikalith type. Unfused salt crystals used to form Amikaliths I must be kept in 
the acrylic device during gelation while fused salt columns used for Amikaliths II may be removed 
before addition of pregel without collapsing. 
 
Characterization of Amikaliths 
No significant difference was observed in the pore sizes of salt unfused Amikaliths I (279 ± 83 
µm) and salt fused Amikaliths II (280 ± 54 µm). Both monoliths provide pore diameters sufficiently 
large to allow for the adsorption of plasmid DNA macromolecules within the internal structure of 
the monoliths. Amikaliths I prepared using salt alone did not show any interconnections between 
the pores as observed in Fig. 7-3A image. It is likely that dry salt crystals with no prior fusion 
become completely encapsulated by pregel during its addition. Gelation occurs between the 
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spaces among the salt crystals, leading to separated pores following porogen leaching. In 
contrast, Amikalith II pores appear highly interconnected (Fig. 7-3B). Amikaliths II also display 
numerous bumps protruding from the surface.  
A. 
 
B. 
 
Figure 7-3. SEM images of Amikalith I (A) and Amikalith II (B). Amikaliths display macroscale 
pores following salt leaching. Amikalith I pores appear as separate compartments while Amikalith 
II pores appear interconnected (collapsed due to sample dehydration) and possess uneven 
surface topography, increasing surface area for pDNA binding.   
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As stated earlier, Amikaliths with a total pregel volume of 30 µL were selected for swelling 
ratio characterization. Larger volume and consequently heavier Amikaliths were chosen for 
swelling ratio studies to minimize variance in the measurements caused by scale sensitivity. Salt 
fused Amikaliths displayed a swelling ratio of 11.3 ± 2.1. BET analysis performed using 32 
Amikalith structures revealed a surface area of approximately 1.5 m2/g, which is comparable to 
the Amikabead surface area of approximately 2.0 m2/g 83.  
 
Plasmid DNA Binding to Amikaliths I and II 
We hypothesized that a monolith structure with interconnected pores would offer a higher plasmid 
DNA binding potential compared to a matrix of non-interconnected pores. To validate this, 
plasmid DNA binding with unfused salt Amikaliths (I) and fused salt Amikaliths (II) was 
investigated. Amikaliths were incubated with 15,000-60,000 ng of pDNA for 5 hours. Because of 
the fragility of the Amikaliths, we looked to minimize the time required to adsorb pDNA to the 
structure surface. A total binding time of 5 hours was found to be a sufficient to reach the 
maximum binding capacity of the Amikaliths while preserving structural integrity of the columns. 
Figure 7-4 shows the maximum binding capacity (Qmax) values for pDNA binding to Amikaliths I 
and II. Experimental data was fitted using a Langmuir isotherm. Qmax values were calculated by 
creating linearized adsorption isotherms for pDNA binding to Amikaliths I and II (n=3). Amikaliths 
II bound significantly higher pDNA (25.9 ± 6.1 µg pDNA / mg of Amikalith) compared to Amikaliths 
I (9.1 ± 3.5 µg pDNA / mg of Amikalith) (p < 0.02). It is likely that the interconnected pore 
structure allowed for significantly higher pDNA binding compared to the non-interconnected 
Amikaliths. T24 cells and Bj5ta human foreskin fibroblasts cultured on Amikaliths showed high 
viability indicating its use as novel cell culture platforms.  
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Figure 7-4. pDNA binding to Amikaliths. pDNA adsorption results show that Amikaliths II have 
a significantly higher binding capacity compared to Amikaliths I (p < 0.02*). 
 
Doxorubicin Conjugation to Amikabeads and Amikaliths 
The presence of numerous easily conjugable groups on Amikabeads and Amikaliths allows for 
incorporation and conjugation of multiple novel ligands on the surface. Doxorubicin is a very well 
known anticancer drug, which works by binding to the DNA double helix and prevents cell 
duplication 311. We hypothesized that conjugation of DNA binding drugs such as doxorubicin, 
mitoxantrone to the surface of Amikaliths could allow for the exploitation of the DNA binding anti-
neoplastic agents towards pDNA chromatography. Doxorubicin and mitoxantrone exploit either 
hydrophobic or a combination of hydrophobic and electrostatic interactions to bind DNA 277, 312-313. 
Hence a resin with multiple copies of displayed doxorubicin or mitoxantrone can provide multi-
modal capabilities to the resin for selective binding. These also provide an opportunity for 
screening of DNA binding ligands that have been used elsewhere for DNA interactions. Here, we 
provide the method developed to conjugate anticancer drug doxorubicin to the surface of 
Amikabeads. As shown in Fig. 7-5, excess 1,4 cyclohexanedimethanol diglycidyl ether was used 
to link one doxorubicin/Mitoxantrone to one of the epoxy ends of the cross-linker. Next, 
Amikabeads/Amikaliths were added to the solution and the other end of the epoxy was 
conjugated to the amines on the beads. Fig. 7-6 A-C shows the drug conjugated Amikabeads 
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and Amikaliths after the conjugation process. The process also gave rise to non-clumped beads 
after the final conjugation step (Fig. 7-7 A-B). 
 
A. 
 
B. 
 
Figure 7-5. Doxorubicin conjugation to Amikabeads/Amikaliths. (A) Doxorubicin was stirred 
with 1,4-cyclohexanedimethanol diglycidyl ether with Triethylamine (1:3:5) in DMSO for 8 hours at 
25oC. (B) Next, the Amikabeads/Amikaliths were added to the mixture for 8 hours followed by 
extensive washing steps to remove unreacted doxorubicin. 
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A.     B. 
                
C. 
 
Figure. 7-6 Novel pDNA ligand conjugation to Amikabeads and Amikaliths. (A-B) 
Doxorubicin and Mitoxantrone conjugated Amikabeads (C) Doxorubicin conjugated monoliths. 
 
Reversing the protocol by adding excess crosslinker to the beads at the first step did not 
yield good results. As shown in supporting information, big chunks of cross-linked beads were 
found when the cross-linker was added to the beads as the first step. Tuning the mole ratio of 
cross-linker: Amikabeads did not help either (Fig. 7-7A). Hence, it was hypothesized that working 
backwards, doxorubicin could be conjugated to one end of the epoxy end of the crosslinker, 
which could then be added to the intact beads (Fig. 7-7B). We propose this is as a better 
mechanism of conjugating any ligand to the surface of the any microbead or monolith surface. 
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A.      B. 
 
Figure. 7-7 Strategies to achieve non-aggregated ligand conjugated Amikabeads. (A) 
Reacting beads with 1,4-CHDDE initially before conjugating the drug yielded very poor results. 
Beads were seen to extensively clump. (B) Conjugating 1,4-CHDDE to doxorubicin followed by 
addition of the intermediate to the beads gave rise to minimal clumping and uniform conjugation. 
 
Conjugation of anticancer drugs to the surface of Amikaliths could give rise to novel 
materials that can be used for plasmid DNA binding. These DNA binding anticancer drugs could 
provide multi-modal affinity to the resin to allow increased pDNA binding.  
 
7.4. CONCLUSION 
We present an novel methodology involving a novel, scalable, easy-to-use device to 
generate user defined 3D macroporous polymeric scaffolds in a high-throughput format for their 
use in substrates for plasmid DNA chromatography, cell culture, stem cell differentiation etc. The 
device’s uniqueness comes from its smart design with parafilm coating, in-situ porogen fusion, in-
situ polymerization and gelation and breakaway piece design that allow for easy recovery of 
formed matrices after gelation/polymerization. The unique design of the device has been tested 
numerous times to demonstrate its reproducibility. Amikaliths were generated in high throughput 
and conjugated with DNA binding anticancer drugs. Plasmid DNA was bound to the Amikaliths, 
which were found to be similar to Amikabeads in their plasmid DNA binding ability.  
 
 
 
	 	
198 
CHAPTER 8: CONCLUSIONS AND FUTURE PERSPECTIVES 
 
8.1. SUMMARY OF FINDINGS 
 
A complete cancer cure cannot be achieved till the problems of tumor dormancy and 
relapse are solved. Fundamental biological understanding of the underlying processes that 
control the tumor dormancy and relapse phases can help guide the design and development of 
targeted novel drugs and biologics. In parallel, development of novel high-throughput platforms 
that can capture the dormant phase of cancer in high-throughput will allow for rapid screening of 
drugs that work to ablate the target. Drug libraries in pharmaceutical companies can contain 
many thousands of molecules that need to be screened against a specific target 11. High-
throughput models allow for the establishment of massive parallel screens for that purpose. 
Despite decades of work in cancer, fundamental understanding of underlying phenomena 
regulating dormancy and relapse are still unclear. This dissertation work focuses on design and 
development of novel aminoglycoside based hydrogels that capture tumor dormancy and relapse 
in high-throughput for rational drug discovery and delivery. In this dissertation, we establish novel 
tumor dormancy and relapse model based on T24 bladder cancer cells and also utilize the high-
throughput model for rational drug discovery and delivery. Further, we experimentally show novel 
strategies to accelerate the ablation of dormant tumors by modulating intracellular cation levels. 
Accelerating therapy will not only save the time required to achieve an appropriate outcome, but 
also provide cost benefits to the patient and the healthcare infrastructure etc.  
 Results in chapter 2 describe the design and development of novel 
aminoglycoside based hydrogel (‘Amikagel’) platform for high-throughput 3D tumor 
microenvironment generation. Multiple important physico-chemical properties such as mechanical 
stiffness, adhesivity, gelation kinetics, pore size and surface roughness of the hydrogel were 
tunable based on the monomer ratios used. Different formulation of Amikagels resulted in 
differential cell adhesivity and mechanical stiffness that further impacted the 3DTM formation on 
the hydrogel surface. We believe Amikagel to be the first hydrogel prepared using 
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aminoglycoside amikacin as a starting material towards its use in high-throughput 3D cell culture. 
Availability of multiple easily conjugable groups such as amino and hydroxyl groups allow for 
conjugation of other ligands on the Amikagel surface towards further biological studies. T24 
bladder cancer cells were noted to undergo complete tumor dormancy on Amikagel substrate 
likely due to formation of extensive cell-cell contacts in a 3D format. High N-cadherin expression 
on cell surface has been shown to lead cells into cell cycle arrest via p27 CDK inhibitor 
modulation. Dormant 3DTMs generated on Amikagel surface were almost completely arrested in 
the G0/G1 phase of cell cycle (~95%), low in metabolite consumption and were also highly 
resistant to conventional chemotherapeutics such as mitoxantrone and docetaxel (even at high 
concentrations of 100 µM). Amikagels also allowed for generation of fibroblast co-culture 3DTMs 
with likely hypoxic and necrotic central core that were also resistant to conventional anticancer 
drugs.  
 Results obtained in chapter 3 define a new strategy for dormant cancer cell 
ablation. Dormant cancer cells had slight but significantly higher per cell protein content due to 
their arrest in the G0/G1 phase of cell cycle. We hypothesized that by targeting the protein 
production pathway, we can likely sensitize these dormant cells to ER stress mediated death. 
Targeting the ER to induce ER stress for apoptosis is a very widely explored area of research. 
Multiple drugs such as cycloheximide (translation inhibitor), thapsigargin (SERCA calcium 
channel inhibitor- chaperone inhibitor), brefeldin A (inhibitor of protein transport from ER to Golgi), 
bortezomib (proteasome inhibitor) have been used and studied to ablate the actively dividing 
cancer cells by targeting ER 64. In dormant melanoma cancer cells, Ranganathan et al.37, 67 found 
key adaptations in the ER that allowed dormant cells to mitigate chemotherapeutics and deal with 
ER stress. We found that inducing ER stress via thapsigargin mediated SERCA inhibition 
(calcium dependent chaperone inhibition) in concert with proteasome inhibition significantly 
sensitized the dormant cancer cells to death. The dormant bladder cancer cells were also very 
susceptible to proteasome inhibition alone, indicating an active proteasome is essential to 
maintain the dormant phenotype. However, the combination of both the drugs (bortezomib and 
thapsigargin) was significantly better in inducing total ablation of the dormant tumors compared to 
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individual drugs. We also showed that the dormant cancer cell death could be significantly 
accelerated by exogenous delivery of calcium cation under chronic ER stress. Under chronic ER 
stress, mitochondrial depolarization drives the apoptotic dormant cancer cell death that is initiated 
by two main pathways. Multifunctional transcriptional factor CHOP produced as a response to 
chronic ER stress, causes transcriptional activation of multiple pro-apoptotic proteins such as Bax 
and Bak that work to puncture the outer mitochondrial membrane. In addition, the calcium from 
cytoplasm and the ER are pumped into the mitochondrial matrix, depolarizing the potential 
difference thereby causing mitochondrial lysis. Our results strongly indicated that exogenous 
delivery of calcium cation could significantly accelerate the apoptotic dormant cancer cell death 
by increased mitochondrial depolarization under chronic ER stress induced by bortezomib and 
thapsigargin. Makridakis et al. 51 found active proteasome function in both metastatic and non-
metastatic variant of T24 bladder cancer cells, further lending credence to our finding of dormant 
cancer sensitization via proteasome inhibition and chronic ER stress. Delivery of calcium to 
accelerate chronic ER stress mediated dormant cancer cell death is one of the most novel 
findings in this dissertation. This approach can be applied to multiple other cancers where ER 
stress pathways have shown promise in cancer ablation (Example: multiple myeloma). 
 Relapse from tumor dormancy occurs after an indefinite period of time and 
strategies to understand and prevent the phenomena are of urgent need. Results obtained in 
chapter 4 demonstrate that the chemo-mechanical modulation of Amikagel could result in relapse 
from tumor dormancy. Transfer of dormant T24 3D-DTMs to a pliant Amikagel (less stiff, more 
adhesive gel) resulted in selective separation and relapse of N-cadherin poor metastatic fraction 
of the bladder cancer cells. Specific engineering of Amikagel adhesivity resulted in selective 
migration and isolation of only the metastatic cancer cell fraction in the heterogeneous population. 
The N-cadherin rich population was seen to remain behind in the mother 3DTM. As described, N-
cadherin downregulation and absence has been identified as an extremely poor prognostic 
indicator of metastases and death in bladder cancer patients. Selective isolation and separation 
of the metastatic fraction of the cancer cells makes Amikagel platform further unique and very 
important for future biological uses. Transfer of the dormant 3D-DTMs to 2D tissue culture plastic 
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did not cause selective isolation like that observed on Amikagels. Our results strongly indicate the 
need of engineering of the adhesivity of the surface to isolate only the most metastatic cell types. 
While highly adhesive surfaces cause complete cell migration and relapse (2D tissue culture 
plates), high non-adhesivity results in no migration and escape at all (AM3 Amikagel). 
Engineering adhesivity of the hydrogel in high-throughput can quickly identify the best formulation 
required to isolate the most metastatic cell fraction of the population. Such an approach would 
significantly lower the time required to isolate the most metastatic cell fractions. For example, a 
previous research by Nicholson et al.171 demonstrated a lengthy procedure of isolation and 
enrichment of highly metastatic fraction of T24 cells by sequential injection into mice over 30-40 
weeks. T24 cells were injected into six-week– old NCr nu/nu mice and were allowed to form 
metastases. The first generation metastatic cells were collected and reintroduced into mice to 
further enrich the metastatic population and so on. Three generations of enrichment took almost 
30-40 weeks. Our engineered adhesivity strategy of metastatic cancer cell isolation can 
drastically cut down the time required to do so. Cells expressing differential N-cadherin on their 
surface can also be separated using this platform technology. 
We used the high-throughput relapse platform to further identify drugs that not only can 
inhibit relapse from tumor dormancy, but also those that might accidently promote it. Docetaxel, a 
well-known microtubule inhibitor is also a cdc42 inhibitor that prevents the formation of actin rich 
filopodial extensions. Addition of docetaxel prior to chemo-mechanical modulation completely 
prevented the relapse from T24 3D-DTM. ROCK inhibitor on the other hand promoted the relapse 
likely due to Rac1 activation 181. ROCK inhibitor did not change the cell cycle profile of the treated 
3D-DTMs.  
 
   8.2. OTHER DEVELOPED TECHNOLOGIES 
Natural binding affinity of aminoglycosides towards nucleic acids was exploited to design 
novel chromatographic resins for plasmid DNA binding and desorption. Amikagel was converted 
into microbead (‘Amikabead’) formulation via emulsion polymerization. Additional Span-80 was 
added after each batch process to reduce batch-to-batch size variations in the microbead 
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preparation. The pDNA binding affinity of parental Amikabeads was significantly improved by 
quaternization of the amines using glycidyl trimethyl ammonium groups. While 1M salt was 
sufficient to desorb almost all the adsorbed pDNA from the parental Amikabeads, it was not 
sufficient to desorb pDNA from the quaternized Amikabeads. We noted that additional of 15% 
isopropanol coupled with a temperature of 50oC was required to desorb ~70% of adsorbed 
plasmid DNA from the Amikabeads. Mild hydrophobicity of the isopropanol (balance between 
increase in hydrophobicity and decrease in dielectric constant) likely played an important role in 
enhancing desorption of the plasmid DNA.  
Additional methods were developed to generate macroporous amikagels (‘Amikaliths’) in 
high-throughput for plasmid DNA binding and novel substrates for cell culture. Novel high-
throughput devices were prepared for rapid generation and recovery of multiple macroporous 
scaffolds in large numbers. Central break line in the acrylic devices was found to be highly useful 
and aided easy recovery of the macroporous gels. Additional insets allowed further improvements 
in the throughput of the system. As described, Amikabeads and Amikalith surfaces are rich in 
several easily conjugable groups such as amines and hydroxyls. This provides an opportunity to 
conjugate several ligands and spacers on the Amikagel surface for improving the specificity of the 
resin towards pDNA binding resin. Method to conjugate two such novel ligands is shown. 
Doxorubicin and mitoxantrone, bind DNA via a mixture of electrostatic and hydrophobic 
interactions were conjugated to the surface of Amikabeads and Amikaliths via an easy technique. 
Easy conjugation of multi-modal ligands on the surface of Amikagel will likely significantly 
advance the use of Amikabeads towards pDNA binding and desorption.  
The dissertation also describes the development of mitoxantrone-loaded PEG-DSPE 
micelles for mitoxantrone delivery to prostate, bladder and breast cancer cells for TRAIL 
sensitization. TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis in cancer cells by 
specifically binding to the surface expressed death receptors. However, multiple resistance 
adaptations in the cancer cells reduce the efficacy of TRAIL therapies. We previously identified 
mitoxantrone as a novel TRAIL sensitizer in cancer cells 105. We developed novel nanoparticle 
(micelle) based delivery vehicles of mitoxantrone to improve the pharmacokinetics of the drug. 
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Sequential delivery of the mitoxantrone loaded micelles followed by TRAIL delivery was seen to 
be better than simultaneous delivery of the micelles and TRAIL. Modification of the end group of 
the micelles from methoxy to positive amino and negatively charged carboxyl group did not have 
any impact on the efficacy of mitoxantrone TRAIL sensitization likely due to the mechanism of 
micelle unimers fusion with the cell membrane during the drug delivery.  
 
8.3. FUTURE PERSPECTIVES 
Future Direction 1 – Exosome Diagnostics - Diagnosis and continuous monitoring of 
tumor dormancy and relapse by studying the cell derived exosomal content 
Exosomes are small lipid bilayer containing membrane vesicles that are secreted by a number of 
different cells in the body 314. They are typically 40-100 nm and are secreted into the intracellular 
milieu. There has been an explosion of new findings regarding exosomes that cement their 
integral role in cell-cell communication 314-319. Exosomes released from cancer cells have been 
shown to modulate distant metastatic sites to prepare them for cancer cell arrival 320. Cancer cell 
exosomes were seen to induce the preparation of pre-metastatic niche in lungs and liver for 
eventual cancer cell arrival 320-321.  Exosomal content is cell type dependent and can be 
composed of lipid, DNA, mRNA, microRNAs and protein. Some of the most commonly identified 
proteins in exosomes are proteins such as β-actin, β-catenin, cofillin, tubulins and other heat 
shock proteins. Some of these proteins such as loss of β-catenin has been strongly implicated in 
bladder cancer progression and poor patient prognosis 322. Often the exosomal content is a clear 
snapshot of the cell at any particular time-point. Melo et al. 323 showed that compared to 
exosomes derived from healthy cells, exosomes from cancer cells had disproportionately higher 
amount of mature miRNAs. Exosomal miRNA expression levels were significantly higher in serum 
exosomes isolated from 25 glioblastoma multiforme patients compared to the age and sex 
matched healthy volunteers. Serum exosomal levels of miR-17-5p and miR-21 were found to be 
significantly higher in pancreatic adenocarcinoma patients compared to the healthy ones 324. High 
levels of HSP90 protein were found in exosomes isolated from lung cancer patients compared to 
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the healthy patients 325. These exosomal attributes further strengthen their utilization towards 
development of novel diagnostic tools that can track and monitor the disease 326 
Multiple factors such as high stability of exosomal content, rich and varied content, 
shedding of exosomes via urine, easy exosome isolation make them a good candidate for 
monitoring cancer growth, dormancy status and metastases 327. Exosomal content secreted from 
a dormant cancer cell likely to be very different from a relapsed, actively dividing cell. Monitoring 
the content of exosomes shed through urine to diagnose tumor dormancy versus relapse can 
make the disease highly manageable. Rapid detection of relapse from tumor dormancy via urine 
paper tests can significantly reduce the fear associated with relapse from the cancer disease. T24 
cells have already been shown to secrete exosomes into the extracellular media. Franzen et al. 
328 found significant sensitization and epithelial to mesenchymal transition in primary urothelial 
cells when they were exposed to exosomes isolated from conditioned media of T24 and UMUC3 
cells. Increased expression of several mesenchymal markers such as snail, α-smooth muscle 
actin, S100A4 and decreased expression of epithelial markers such as E-cadherin was observed 
in the urothelial cells. Further, they showed that exosomes isolated from bladder cancer patient 
could also cause the EMT in urothelial cells 328. Their study also provides direct proof that T24 
cells produce exosomes that have functional role in advancing the disease. After isolation of 
exosomes from the supernatants of dormant T24 and relapsed T24 cells, quantitative proteomic 
and RNA sequencing will allow for elucidation of differences in the cargoes of the two phenotypes 
of the cell line 329-330. Identification of differences in exosomal cargoes will allow for design of 
novel easy to use, test strips that can detect and monitor the progression of the disease. 
 
Future Direction 2 - High-throughput amikagel based microfluidic platforms to 1) identify 
triggers of relapse from tumor dormancy, and 2) rapidly isolate metastatic cancer cell 
fractions  
This dissertation has been instrumental in establishing a novel chemo-mechanically tunable 
hydrogel platform that can capture multiple facets of tumor dormancy and relapse in high-
throughput. A significant advantage of temperature-controlled gelation of Amikagel is the 
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possibility of using it as substrate in microfluidic devices etc. Pre-gel solutions can be easily flown 
into the microfluidic devices followed by T24 bladder cancer cells to form tumor spheroids within 
the microfluidic chambers. Microfluidic devices also allow generation of rapid combinatorial 
assays for high throughput drug screens etc 239, 331. Kim et al. 296 developed a novel microfluidic 
platform for cell based large scale combinatorial drug assays. The microfluidic platform consisted 
of pneumatic valves that allowed accurate fluid control for rapid generation of diverse drug 
gradients. Kim et al. established the use of the technology by demonstrating TRAIL sensitization 
of PC3 prostate cancer cells by sequentially treating cells with anticancer drug doxorubicin. Using 
the microfluidic platform, they could rapidly develop 64 different mixtures of TRAIL and 
doxorubicin to identify the most effective concentration. Microfluidic platform developed for tumor 
dormancy and relapse could have multiple useful applications such as – 
• As described, relapse from tumor dormancy and tumor progression happen due to not 
yet fully understood reasons. Our high throughput platform can allow for elucidation of 
critical factors that can drive a dormant tumor towards relapse and metastases. Utilizing 
our synthetic engineered adhesive amikagel substrates, we have isolated highly dormant 
cancer cell fractions from the heterogeneous mixture of T24 cell populations. A 
microfluidic platform cultured with these dormant cancer cells can allow for exposure of 
multiple triggers such as toxins (nicotine) 332, UV rays 333, stress factors 334, 
chemotherapeutic drugs 335, phthalates 336 etc, that can initiate relapse from tumor 
dormancy. The microfluidic platform can allow for exposure and identification of these 
triggers in high-throughput. Elucidation of bio-physico-chemical triggers that lead to 
relapse from tumor dormancy can allow design and development of strategies to avoid 
the spread of the disease.  
• Identification of strategies to quickly isolate the most metastatic cancer cell fractions help 
in development of targeted drugs against those specific cells. We have shown a synthetic 
engineered adhesivity approach to isolate metastatic cells from a population of 
heterogeneous cancer cells. Exposing the heterogeneous cell spheroid to multiple 
different chemo-mechanical substrates could allow for development of biomaterial 
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strategies to quickly isolate the most metastatic cell types within one microfluidic system. 
Separately, placement of the heterogeneous 3DTM on a hydrogel with chemo-
mechanical gradient can allow for migrational selection of most metastatic cell types, 
leaving behind a truly dormant cell population. 
 
Other Future Directions –  
1. Whole cell RNA sequencing for novel phenotype specific drug discovery   
Whole cell RNA extraction from 2D cells, dormant cells, mother 3D-DTM and relapsed 
cells would allow for sequencing and identification of specific set of genes that are 
upregulated in a each phenotype. Transient phenotype specific RNA expression can lead 
to fundamental biological understanding of underlying phenomena that governs each 
state of the cell. These will likely spur the identification of novel drug targets against 
tumor dormancy and relapse.  
 
2. Conjugation of multiple DNA binding anticancer drugs on Amikabead/Amikalith 
surface for novel pseudoaffinity resins 
Amikabead/Amikalith provide a surface with ample easily conjugable groups such as 
hydroxyls and amines that can be rapidly conjugated to multiple DNA binding ligands. We 
developed an easy to use method to link model drugs mitoxantrone and doxorubicin to 
the surface of Amikabeads and Amikaliths respectively. Similar strategy could be used to 
conjugate multiple other DNA intercalating anticancer drugs such as daunorubicin, 
pixantrone, amonafide etc. Significant amount of research has gone into developing DNA 
binding anticancer drugs with specialized activities such as pure intercalators (flavones, 
ellipticines), groove binders (streptonigrin), mixed groove binders and intercalators 
(amonafide, anthracyclines, mitoxantrone, pixantrone) and covalent intercalators 
(psorospermin) etc 337. Advances made in designing novel DNA binding ligands for anti-
cancer activity can be directly applied to designing novel ligands and ligand combinations 
that can selectively bind and extract desired plasmid DNA from whole bacterial broths. 
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THESIS CONTRIBUTION - This dissertation describes multiple inventions regarding 
design and development of aminoglycoside based hydrogels for applications in high-throughput 
cell culture models of tumor dormancy, relapse (for drug discovery and development) and novel 
chromatographic resins for plasmid DNA biotechnology: 
1. The first demonstration and development of amikacin aminoglycoside based 
hydrogel with tunable chemo-mechanical properties of mechanical stiffness and 
adhesivity. 
2. Aminoglycoside based hydrogels for high-throughput 3D cell culture platforms of 
prostate, bladder, breast and pancreatic cancer cell types.  
3. Novel high-throughput in-vitro platform of tumor dormancy, relapse and 
micrometastases in a 96 well plate format  
4. Identification of chronic ER stress as a novel pathway to induce apoptosis in 
dormant bladder cancer 3DTMs. 
5. Acceleration of chronic ER stress induced apoptosis by exogenous delivery of 
calcium to the cell cytoplasm. 
6. Identification of synthetic material strategies for rapid isolation and separation of 
metastatic cell fractions from a heterogeneous cancer cell population. 
7. Design and development of novel aminoglycoside based microbeads and 
macroporous gels for pDNA binding and recovery. 
 
In addition, this dissertation also describes generation of novel acrylic devices for high-
throughput generation of user desired polymeric scaffolds and micellar mitoxantrone drug delivery 
of TRAIL sensitizer to sensitize multiple cancer cell lines to TRAIL mediated cell death: 
 
8. Micellar delivery of anticancer drug mitoxantrone towards TRAIL sensitization of 
bladder, prostate and breast cancer cell lines in-vitro.  
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9. Design and development of high-throughput acrylic based devices for rapid and 
high-throughput generation of user desired macroporous and non-macroporous 
polymeric scaffolds.  
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